"Active Ingredient (link to Specific Guidance)","URL","Type","Route","Dosage Form","RLD or RS Number","Date Recommended","psg filename"
"Abacavir Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020977.pdf","Draft","Oral","Tablet","020977","10/30/2024","PSG_020977.pdf"
"Abacavir Sulfate; Dolutegravir Sodium; Lamivudine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_205551.pdf","Draft","Oral","Tablet","205551","10/30/2024","PSG_205551.pdf"
"Abacavir Sulfate; Dolutegravir Sodium; Lamivudine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215413.pdf","Draft","Oral","Tablet, For Suspension","215413","10/30/2024","PSG_215413.pdf"
"Abacavir Sulfate; Lamivudine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021652.pdf","Draft","Oral","Tablet","021652","10/30/2024","PSG_021652.pdf"
"Abacavir Sulfate; Lamivudine; Zidovudine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021205.pdf","Draft","Oral","Tablet","021205","10/30/2024","PSG_021205.pdf"
"Abametapir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_206966.pdf","Draft","Topical","Lotion","206966","10/21/2022","PSG_206966.pdf"
"Abemaciclib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208716.pdf","Draft","Oral","Tablet","208716","10/30/2024","PSG_208716.pdf"
"Abiraterone Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210308.pdf","Draft","Oral","Tablet","210308","06/03/2020","PSG_210308.pdf"
"Abiraterone Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Abiraterone acetate_oral tablet_NDA 202379_RV07-18.pdf","Draft","Oral","Tablet","202379","07/20/2018","Abiraterone acetate_oral tablet_NDA 202379_RV07-18.pdf"
"Abrocitinib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213871.pdf","Draft","Oral","Tablet","213871","10/30/2024","PSG_213871.pdf"
"Acalabrutinib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210259.pdf","Draft","Oral","Capsule","210259","10/30/2024","PSG_210259.pdf"
"Acalabrutinib Maleate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_216387.pdf","Draft","Oral","Tablet","216387","11/19/2024","PSG_216387.pdf"
"Acamprosate Calcium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Acamprosate calcium_oral DR tablet_RLD 21431 and 202229_RV03-17.pdf","Draft","Oral","Tablet, Delayed Release","021431","05/16/2017","Acamprosate calcium_oral DR tablet_RLD 21431 and 202229_RV03-17.pdf"
"Acarbose","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020482.pdf","Draft","Oral","Tablet","020482","05/19/2022","PSG_020482.pdf"
"Acetaminophen","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Acetaminophen_ERtab_19872_RC2-11.pdf","Draft","Oral","Tablet, Extended Release","019872","02/23/2011","Acetaminophen_ERtab_19872_RC2-11.pdf"
"Acetaminophen","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018337.pdf","Draft","Rectal","Suppository","018337","05/19/2022","PSG_018337.pdf"
"Acetaminophen; Aspirin; Caffeine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020802.pdf","Draft","Oral","Tablet","020802","10/30/2024","PSG_020802.pdf"
"Acetaminophen; Benzhydrocodone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208653.pdf","Draft","Oral","Tablet","208653","10/30/2024","PSG_208653.pdf"
"Acetaminophen; Butalbital","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Acetaminophen;_Butalbital_cap_88831_88889_RC3-10.pdf","Draft","Oral","Capsule","088831","03/19/2010","Acetaminophen;_Butalbital_cap_88831_88889_RC3-10.pdf"
"Acetaminophen; Butalbital","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Acetaminophen Butalbital Oral Tablet ANDA 89987 RV Feb 2019.pdf","Draft","Oral","Tablet","089987","02/22/2019","Acetaminophen Butalbital Oral Tablet ANDA 89987 RV Feb 2019.pdf"
"Acetaminophen; Butalbital; Caffeine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Acetaminophen;Butalbital;Caffeine_A89007 A0885 A40885_RV Oct 2018.pdf","Draft","Oral","Capsule","040885                                                       089007","11/28/2018","Acetaminophen;Butalbital;Caffeine_A89007 A0885 A40885_RV Oct 2018.pdf"
"Acetaminophen; Butalbital; Caffeine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Acetaminophen; Butalbital; Caffeine_Oraltablet_ANDA 040511_RV Oct 2018.pdf","Draft","Oral","Tablet","040511","11/28/2018","Acetaminophen; Butalbital; Caffeine_Oraltablet_ANDA 040511_RV Oct 2018.pdf"
"Acetaminophen; Butalbital; Caffeine; Codeine Phosphate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020232.pdf","Draft","Oral","Capsule","020232","10/30/2024","PSG_020232.pdf"
"Acetaminophen; Caffeine; Dihydrocodeine Bitartrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Acetaminophen;_Caffeine;_Dihydrocodeine_Bitartrate_tab_40316__40109_RC4-09.pdf","Final","Oral","Tablet","040109","10/28/2011","Acetaminophen;_Caffeine;_Dihydrocodeine_Bitartrate_tab_40316__40109_RC4-09.pdf"
"Acetaminophen; Caffeine; Dihydrocodeine Bitartrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Acetaminophen; Caffeine; Dihydrocodeine Bitartrate Oral Capsule ANDA 204785 RC Feb 2019.pdf","Draft","Oral","Capsule","204785","02/22/2019","Acetaminophen; Caffeine; Dihydrocodeine Bitartrate Oral Capsule ANDA 204785 RC Feb 2019.pdf"
"Acetaminophen; Codeine Phosphate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Acetaminophen; Codeine Phosphate Tablet ANDA 085055 PSG Page RC May 2019.pdf","Draft","Oral","Tablet","085055","05/15/2019","Acetaminophen; Codeine Phosphate Tablet ANDA 085055 PSG Page RC May 2019.pdf"
"Acetaminophen; Hydrocodone Bitartrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Acetaminophen_Hydro_bit 40658; 40556; 40864; 40148; 40099_RV06-16.pdf","Draft","Oral","Tablet","040099                                                       040148                                                       040658                                                       040846","06/16/2016","Acetaminophen_Hydro_bit 40658; 40556; 40864; 40148; 40099_RV06-16.pdf"
"Acetaminophen; Ibuprofen","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211733.pdf","Draft","Oral","Tablet","211733","10/30/2024","PSG_211733.pdf"
"Acetaminophen; Oxycodone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Acetaminophen; Oxycodone HCL_oral ER tablet_RLD 204031_RC 09-16.pdf","Draft","Oral","Tablet, Extended Release","204031","10/04/2016","Acetaminophen; Oxycodone HCL_oral ER tablet_RLD 204031_RC 09-16.pdf"
"Acetaminophen; Oxycodone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Acetaminophen;OxycodoneHCL_Oral tablet_ANDA 40330_RV Oct 2018.pdf","Draft","Oral","Tablet","040330","11/28/2018","Acetaminophen;OxycodoneHCL_Oral tablet_ANDA 40330_RV Oct 2018.pdf"
"Acetaminophen; Propoxyphene Napsylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017122.pdf","Draft","Oral","Tablet","076429","10/30/2024","PSG_017122.pdf"
"Acetaminophen; Tramadol Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021123.pdf","Draft","Oral","Tablet","021123","10/30/2024","PSG_021123.pdf"
"Acetazolamide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Acetazolamide_ERcaps_12945_RC2-10.pdf","Draft","Oral","Capsule, Extended Release","012945","02/25/2010","Acetazolamide_ERcaps_12945_RC2-10.pdf"
"Acetazolamide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_008943.pdf","Draft","Oral","Tablet","008943","10/30/2024","PSG_008943.pdf"
"Acetylcysteine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_207916.pdf","Draft","Oral","Tablet, Effervescent","207916","10/30/2024","PSG_207916.pdf"
"Acitretin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Acitretin_Oral Capsule_RLD19821_Final 08-17.pdf","Final","Oral","Capsule","019821","08/04/2017","Acitretin_Oral Capsule_RLD19821_Final 08-17.pdf"
"Aclidinium Bromide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202450.pdf","Draft","Inhalation","Powder, Metered","202450","02/15/2024","PSG_202450.pdf"
"Aclidinium Bromide; Formoterol Fumarate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210595.pdf","Draft","Inhalation","Powder, Metered","210595","02/15/2024","PSG_210595.pdf"
"Acrivastine; Pseudoephedrine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019806.pdf","Draft","Oral","Capsule","019806","10/30/2024","PSG_019806.pdf"
"Acyclovir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_203791.pdf","Draft","Buccal","Tablet","203791","11/17/2022","PSG_203791.pdf"
"Acyclovir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018828.pdf","Draft","Oral","Capsule","018828","10/30/2024","PSG_018828.pdf"
"Acyclovir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020089.pdf","Draft","Oral","Tablet","020089","10/30/2024","PSG_020089.pdf"
"Acyclovir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021478.pdf","Draft","Topical","Cream","021478","10/21/2022","PSG_021478.pdf"
"Acyclovir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019909.pdf","Draft","Oral","Suspension","019909","10/30/2024","PSG_019909.pdf"
"Acyclovir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018604.pdf","Draft","Topical","Ointment","018604","10/21/2022","PSG_018604.pdf"
"Acyclovir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202408.pdf","Draft","Ophthalmic","Ointment","202408","08/20/2021","PSG_202408.pdf"
"Acyclovir; Hydrocortisone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022436.pdf","Draft","Topical","Cream","022436","10/21/2022","PSG_022436.pdf"
"Adagrasib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_216340.pdf","Draft","Oral","Tablet","216340","10/30/2024","PSG_216340.pdf"
"Adapalene","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022502.pdf","Draft","Topical","Lotion","022502","11/21/2019","PSG_022502.pdf"
"Adapalene","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020748.pdf","Draft","Topical","Cream","020748","11/21/2019","PSG_020748.pdf"
"Adapalene","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020380.pdf","Draft","Topical","Gel","020380","10/21/2022","PSG_020380.pdf"
"Adapalene","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021753.pdf","Draft","Topical","Gel","021753","10/21/2022","PSG_021753.pdf"
"Adapalene; Benzoyl Peroxide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022320.pdf","Draft","Topical","Gel","022320","10/21/2022","PSG_022320.pdf"
"Adapalene; Benzoyl Peroxide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_207917.pdf","Draft","Topical","Gel","207917","10/21/2022","PSG_207917.pdf"
"Adapalene; Benzoyl Peroxide; Clindamycin Phosphate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_216632.pdf","Draft","Topical","Gel","216632","11/19/2024","PSG_216632.pdf"
"Adefovir Dipivoxil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021449.pdf","Draft","Oral","Tablet","021449","10/30/2024","PSG_021449.pdf"
"Afamelanotide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210797.pdf","Draft","Subcutaneous","Implant","210797","02/16/2023","PSG_210797.pdf"
"Afatinib Dimaleate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Afatinib dimaleate_Oral tablet_201292_RC06-15.pdf","Draft","Oral","Tablet","201292","06/24/2015","Afatinib dimaleate_Oral tablet_201292_RC06-15.pdf"
"Air Polymer-Type A","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212279.pdf","Draft","Intrauterine","Foam","212279","08/22/2024","PSG_212279.pdf"
"Albendazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020666.pdf","Draft","Oral","Tablet","020666","06/03/2020","PSG_020666.pdf"
"Albuterol Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020503.pdf","Draft","Inhalation","Aerosol, Metered","020503                                                       020983                                                       021457","08/22/2024","PSG_020503.pdf"
"Albuterol Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_205636.pdf","Draft","Inhalation","Powder, Metered","205636","02/15/2024","PSG_205636.pdf"
"Albuterol Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017853.pdf","Draft","Oral","Tablet","017853","10/30/2024","PSG_017853.pdf"
"Albuterol Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019604.pdf","Draft","Oral","Tablet, Extended Release","019604","03/02/2020","PSG_019604.pdf"
"Albuterol Sulfate; Ipratropium Bromide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021747.pdf","Draft","Inhalation","Spray, Metered","021747","08/22/2024","PSG_021747.pdf"
"Alcaftadine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Alcaftadine_ophthalmic solution_NDA 022134_RC11-17.pdf","Draft","Ophthalmic","Solution/Drops","022134","02/08/2018","Alcaftadine_ophthalmic solution_NDA 022134_RC11-17.pdf"
"Alectinib Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Alectinib HCl_oral capsule_RLD 208434_RC09-16.pdf","Draft","Oral","Capsule","208434","10/04/2016","Alectinib HCl_oral capsule_RLD 208434_RC09-16.pdf"
"Alendronate Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Alendronate sodium_oral effervescent tablet_202344_RC06-15.pdf","Draft","Oral","Tablet, Effervescent","202344","06/24/2015","Alendronate sodium_oral effervescent tablet_202344_RC06-15.pdf"
"Alendronate Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Alendronate__Sodium_tab_20560_RC1-08.pdf","Draft","Oral","Tablet","020560","10/27/2011","Alendronate__Sodium_tab_20560_RC1-08.pdf"
"Alendronate Sodium; Cholecalciferol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Alendronate_Cholecalciferol_tab_21762_RC4-09.pdf","Draft","Oral","Tablet","021762","10/27/2011","Alendronate_Cholecalciferol_tab_21762_RC4-09.pdf"
"Alfuzosin Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Alfuzosin_ERtab_21287_RC7-04.pdf","Draft","Oral","Tablet, Extended Release","021287","11/01/2007","Alfuzosin_ERtab_21287_RC7-04.pdf"
"Aliskiren Hemifumarate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Aliskiren_Hemifumarate_tab_21985_RC8-09.pdf","Draft","Oral","Tablet","021985","08/18/2009","Aliskiren_Hemifumarate_tab_21985_RC8-09.pdf"
"Aliskiren Hemifumarate; Amlodipine Besylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Aliskiren_Hemifumarate; Amlodipine_Besylate_Tab_22545_RC06-12.pdf","Draft","Oral","Tablet","022545","06/14/2012","Aliskiren_Hemifumarate; Amlodipine_Besylate_Tab_22545_RC06-12.pdf"
"Aliskiren Hemifumarate; Hydrochlorothiazide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Aliskiren;_HCTZ_tab_22107_RC8-09.pdf","Draft","Oral","Tablet","022107","08/18/2009","Aliskiren;_HCTZ_tab_22107_RC8-09.pdf"
"Aliskiren Hemifumarate; Valsartan","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Aliskiren_Hemifumarate;_Valsartan_tab_22217_RC03-11.pdf","Draft","Oral","Tablet","022217","03/31/2011","Aliskiren_Hemifumarate;_Valsartan_tab_22217_RC03-11.pdf"
"Allopurinol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_016084.pdf","Draft","Oral","Tablet","016084","11/19/2024","PSG_016084.pdf"
"Allopurinol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_016084-Sus.pdf","Draft","Oral","Suspension","016084","11/19/2024","PSG_016084-Sus.pdf"
"Allopurinol; Lesinurad","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209203.pdf","Draft","Oral","Tablet","209203","10/30/2024","PSG_209203.pdf"
"Almotriptan Malate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021001.pdf","Draft","Oral","Tablet","021001","10/30/2024","PSG_021001.pdf"
"Alogliptin Benzoate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022271.pdf","Draft","Oral","Tablet","022271","10/30/2024","PSG_022271.pdf"
"Alogliptin Benzoate; Metformin Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_203414.pdf","Draft","Oral","Tablet","203414","10/30/2024","PSG_203414.pdf"
"Alogliptin Benzoate; Pioglitazone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022426.pdf","Draft","Oral","Tablet","022426","10/30/2024","PSG_022426.pdf"
"Alosetron Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021107.pdf","Draft","Oral","Tablet","021107","10/30/2024","PSG_021107.pdf"
"Alpelisib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212526.pdf","Draft","Oral","Tablet","212526","08/28/2020","PSG_212526.pdf"
"Alprazolam","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Alprazolam_tab_21434_RC6-04.pdf","Draft","Oral","Tablet, Extended Release","021434","11/01/2007","Alprazolam_tab_21434_RC6-04.pdf"
"Alprazolam","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018276.pdf","Draft","Oral","Tablet","018276","10/30/2024","PSG_018276.pdf"
"Alprazolam","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021726.pdf","Draft","Oral","Tablet, Orally Disintegrating","021726","10/30/2024","PSG_021726.pdf"
"Alprostadil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Alprostadil_urethral suppository_RLD 020700_RC01-16.pdf","Draft","Urethral","Suppository","020700","01/27/2016","Alprostadil_urethral suppository_RLD 020700_RC01-16.pdf"
"Altretamine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Altretamine_caps_19926_RC04-10.pdf","Draft","Oral","Capsule","019926","04/20/2010","Altretamine_caps_19926_RC04-10.pdf"
"Alvimopan","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Alvimopan_Cap_21775_RC06-12 .pdf","Draft","Oral","Capsule","021775","06/14/2012","Alvimopan_Cap_21775_RC06-12 .pdf"
"Amantadine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_016020.pdf","Draft","Oral","Capsule","016020","10/30/2024","PSG_016020.pdf"
"Amantadine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018101.pdf","Draft","Oral","Tablet","018101","10/30/2024","PSG_018101.pdf"
"Amantadine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Amantadine Hydrochloride Oral Extended Release Capsule NDA 208944 RC 09-2018.pdf","Draft","Oral","Capsule, Extended Release","208944","09/13/2018","Amantadine Hydrochloride Oral Extended Release Capsule NDA 208944 RC 09-2018.pdf"
"Amantadine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209410.pdf","Draft","Oral","Tablet, Extended Release","209410","09/16/2019","PSG_209410.pdf"
"Ambrisentan","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022081.pdf","Draft","Oral","Tablet","022081","10/30/2024","PSG_022081.pdf"
"Amcinonide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Amcinonide_topical lotion_RLD 76329_RC 06-16.pdf","Draft","Topical","Lotion","076329","06/16/2016","Amcinonide_topical lotion_RLD 76329_RC 06-16.pdf"
"Amifampridine Phosphate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208078.pdf","Draft","Oral","Tablet","208078","10/30/2024","PSG_208078.pdf"
"Amiloride Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018200.pdf","Draft","Oral","Tablet","018200","10/30/2024","PSG_018200.pdf"
"Amino Acids;Calcium Chloride;Dextrose;Magnesium Sulfate;Potassium Chloride;Sodium Acetate;Sodium Glycerophosphate;Soybean Oil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_200656.pdf","Draft","Intravenous","Emulsion","200656","03/02/2020","PSG_200656.pdf"
"Aminocaproic Acid","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_015197.pdf","Draft","Oral","Tablet","015197","10/30/2024","PSG_015197.pdf"
"Aminosalicylic Acid","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Aminosalicylic_Acid_DRgran_74346_RC7-08.pdf","Draft","Oral","Granule, Delayed Release","074346","07/01/2008","Aminosalicylic_Acid_DRgran_74346_RC7-08.pdf"
"Amiodarone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018972.pdf","Draft","Oral","Tablet","018972","10/30/2024","PSG_018972.pdf"
"Amisulpride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209510.pdf","Draft","Intravenous","Solution","209510","08/20/2021","PSG_209510.pdf"
"Amitriptyline Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_012703.pdf","Draft","Oral","Tablet","085966                                                       085967                                                       085968                                                       085969                                                       085970                                                       085971                                                       012703","10/30/2024","PSG_012703.pdf"
"Amitriptyline Hydrochloride; Chlordiazepoxide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_016949.pdf","Draft","Oral","Tablet","016949","10/30/2024","PSG_016949.pdf"
"Amlodipine Benzoate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211340.pdf","Draft","Oral","Suspension","211340","10/30/2024","PSG_211340.pdf"
"Amlodipine Besylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019787.pdf","Draft","Oral","Tablet","019787","10/30/2024","PSG_019787.pdf"
"Amlodipine Besylate; Atorvastatin Calcium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021540.pdf","Draft","Oral","Tablet","021540","10/30/2024","PSG_021540.pdf"
"Amlodipine Besylate; Benazepril Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020364.pdf","Draft","Oral","Capsule","020364","10/30/2024","PSG_020364.pdf"
"Amlodipine Besylate; Celecoxib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210045.pdf","Draft","Oral","Tablet","210045","10/30/2024","PSG_210045.pdf"
"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_200175.pdf","Draft","Oral","Tablet","200175","10/30/2024","PSG_200175.pdf"
"Amlodipine Besylate; Hydrochlorothiazide; Valsartan","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022314.pdf","Draft","Oral","Tablet","022314","10/30/2024","PSG_022314.pdf"
"Amlodipine Besylate; Olmesartan Medoxomil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022100.pdf","Draft","Oral","Tablet","022100","10/30/2024","PSG_022100.pdf"
"Amlodipine Besylate; Perindopril Arginine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_205003.pdf","Draft","Oral","Tablet","205003","10/30/2024","PSG_205003.pdf"
"Amlodipine Besylate; Telmisartan","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022401.pdf","Draft","Oral","Tablet","022401","08/30/2010","PSG_022401.pdf"
"Amlodipine Besylate; Valsartan","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021990.pdf","Draft","Oral","Tablet","021990","10/30/2024","PSG_021990.pdf"
"Ammonium Lactate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020508.pdf","Draft","Topical","Cream","020508","11/17/2022","PSG_020508.pdf"
"Ammonium Lactate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019155.pdf","Draft","Topical","Lotion","019155","11/17/2022","PSG_019155.pdf"
"Amoxicillin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050542.pdf","Draft","Oral","Tablet, Chewable","050542","10/30/2024","PSG_050542.pdf"
"Amoxicillin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050460.pdf","Draft","Oral","For Suspension","050460","10/30/2024","PSG_050460.pdf"
"Amoxicillin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050760.pdf","Draft","Oral","For Suspension","065119                                                       050760","10/30/2024","PSG_050760.pdf"
"Amoxicillin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Amoxicillin_ERtab_50813_RC04-13.pdf","Draft","Oral","Tablet, Extended Release","050813","04/05/2013","Amoxicillin_ERtab_50813_RC04-13.pdf"
"Amoxicillin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050459.pdf","Draft","Oral","Capsule","050459","10/30/2024","PSG_050459.pdf"
"Amoxicillin; Clarithromycin; Omeprazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050824.pdf","Draft","Oral","Capsule, Tablet, Capsule, Delayed Release","050824","08/28/2020","PSG_050824.pdf"
"Amoxicillin; Clarithromycin; Vonoprazan Fumarate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215152.pdf","Draft","Oral","Capsule; Tablet; Tablet","215152","10/30/2024","PSG_215152.pdf"
"Amoxicillin; Clavulanate Potassium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050785.pdf","Draft","Oral","Tablet, Extended Release","050785","09/16/2019","PSG_050785.pdf"
"Amoxicillin; Clavulanate Potassium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050575.pdf","Draft","Oral","For Suspension","050575","10/30/2024","PSG_050575.pdf"
"Amoxicillin; Clavulanate Potassium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050564.pdf","Draft","Oral","Tablet","050564                                                       050720","10/30/2024","PSG_050564.pdf"
"Amoxicillin; Clavulanate Potassium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050597.pdf","Draft","Oral","Tablet, Chewable","050597","10/30/2024","PSG_050597.pdf"
"Amoxicillin; Clavulanate Potassium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050726.pdf","Draft","Oral","Tablet, Chewable","050726","10/30/2024","PSG_050726.pdf"
"Amoxicillin; Clavulanate Potassium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050725.pdf","Draft","Oral","For Suspension","050725                                                       050755","10/30/2024","PSG_050725.pdf"
"Amoxicillin; Omeprazole Magnesium; Rifabutin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213004.pdf","Draft","Oral","Capsule, Delayed Release","213004","08/28/2020","PSG_213004.pdf"
"Amoxicillin; Vonoprazan Fumarate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215153.pdf","Draft","Oral","Capsule; Tablet","215153","10/30/2024","PSG_215153.pdf"
"Amphetamine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Amphetamine_Oral suspension_NDA 204325_PSG Page RC Nov 2018.pdf","Draft","Oral","Suspension, Extended Release","204325","11/28/2018","Amphetamine_Oral suspension_NDA 204325_PSG Page RC Nov 2018.pdf"
"Amphetamine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Amphetamine_oral ER suspension_RLD 208147_RC12-16.pdf","Draft","Oral","Suspension, Extended Release","208147","12/22/2016","Amphetamine_oral ER suspension_RLD 208147_RC12-16.pdf"
"Amphetamine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Amphetamine_orally disintegrating ER tablet_RLD 204326_RC 03-17.pdf","Draft","Oral","Tablet, Orally Disintegrating, Extended Release","204326","05/16/2017","Amphetamine_orally disintegrating ER tablet_RLD 204326_RC 03-17.pdf"
"Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Amphetamine_Aspartate_21303_RC09-12.pdf","Draft","Oral","Capsule, Extended Release","021303","09/19/2012","Amphetamine_Aspartate_21303_RC09-12.pdf"
"Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_011522.pdf","Draft","Oral","Tablet","011522","10/30/2024","PSG_011522.pdf"
"Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate_draft_Oral cap ER_RLD 022063_RC09-18.pdf","Draft","Oral","Capsule, Extended Release","022063","09/13/2018","Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate_draft_Oral cap ER_RLD 022063_RC09-18.pdf"
"Amphetamine Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Amphetamine sulfate_oral tablet_ANDA 200166_RC11-17.pdf","Draft","Oral","Tablet","200166","02/08/2018","Amphetamine sulfate_oral tablet_ANDA 200166_RC11-17.pdf"
"Amphetamine; Amphetamine Aspartate/Dextroamphetamine Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210526.pdf","Draft","Oral","Tablet, Extended Release","210526","08/02/2022","PSG_210526.pdf"
"Amphotericin B","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050740.pdf","Draft","Injection","Injectable, Liposomal","050740","08/28/2020","PSG_050740.pdf"
"Ampicillin/Ampicillin Trihydrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_064082.pdf","Draft","Oral","Capsule","064082","08/02/2022","PSG_064082.pdf"
"Amprenavir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Amprenavir_cap_21007_RC8-08.pdf","Draft","Oral","Capsule","021007","08/01/2008","Amprenavir_cap_21007_RC8-08.pdf"
"Anagrelide Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020333.pdf","Draft","Oral","Capsule","020333","10/30/2024","PSG_020333.pdf"
"Anastrozole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020541.pdf","Draft","Oral","Tablet","020541","10/30/2024","PSG_020541.pdf"
"Angiotensin II Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/ANGIOTENSIN II ACETATE IV infusion solution NDA 209360 RC Feb 2019.pdf","Draft","Intravenous","Solution","209360","02/22/2019","ANGIOTENSIN II ACETATE IV infusion solution NDA 209360 RC Feb 2019.pdf"
"Apalutamide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210951.pdf","Draft","Oral","Tablet","210951","08/22/2024","PSG_210951.pdf"
"Apixaban","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202155.pdf","Draft","Oral","Tablet","202155","10/30/2024","PSG_202155.pdf"
"Apomorphine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210875.pdf","Draft","Sublingual","Film","210875","02/17/2022","PSG_210875.pdf"
"Apremilast","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_205437.pdf","Draft","Oral","Tablet","205437","10/30/2024","PSG_205437.pdf"
"Aprepitant","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Aprepitant_cap_21549_RC10-05.pdf","Final","Oral","Capsule","021549","05/01/2008","Aprepitant_cap_21549_RC10-05.pdf"
"Aprepitant","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Aprepitan_oral for suspension_RLD 207865_RC03-17.pdf","Draft","Oral","Suspension","207865","05/16/2017","Aprepitan_oral for suspension_RLD 207865_RC03-17.pdf"
"Aprepitant","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209296.pdf","Draft","Intravenous","Emulsion","209296                                                       216457","02/15/2024","PSG_209296.pdf"
"Aripiprazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021436.pdf","Draft","Oral","Tablet","021436","10/30/2024","PSG_021436.pdf"
"Aripiprazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Aripiprazole_ERinjecsusp_202971_RC12-14.pdf","Draft","Intramuscular","For Suspension, Extended Release","202971","12/29/2014","Aripiprazole_ERinjecsusp_202971_RC12-14.pdf"
"Aripiprazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021729.pdf","Draft","Oral","Tablet, Orally Disintegrating","021729","10/30/2024","PSG_021729.pdf"
"Aripiprazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_217006.pdf","Draft","Intramuscular","Suspension, Extended Release","217006","11/19/2024","PSG_217006.pdf"
"Aripiprazole Lauroxil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209830.pdf","Draft","Intramuscular","Suspension, Extended Release","209830","11/19/2024","PSG_209830.pdf"
"Armodafinil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021875.pdf","Draft","Oral","Tablet","021875","10/30/2024","PSG_021875.pdf"
"Arsenic Trioxide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021248.pdf","Draft","Injectable","Injection","021248","05/19/2022","PSG_021248.pdf"
"Artemether;Lumefantrine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Artemether_lumefantrine_tab_22268_RC06-13.pdf","Draft","Oral","Tablet","022268","06/19/2013","Artemether_lumefantrine_tab_22268_RC06-13.pdf"
"Artesunate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213036.pdf","Draft","Intravenous","Powder","213036","11/08/2021","PSG_213036.pdf"
"Asciminib Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215358.pdf","Draft","Oral","Tablet","215358","08/21/2023","PSG_215358.pdf"
"Asenapine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212268.pdf","Draft","Transdermal","System","212268","05/19/2022","PSG_212268.pdf"
"Asenapine Maleate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Asenapine maleate_Sublingual tablet_NDA 022117_RV Oct 2018.pdf","Draft","Sublingual","Tablet","022117","11/28/2018","Asenapine maleate_Sublingual tablet_NDA 022117_RV Oct 2018.pdf"
"Aspirin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_203697.pdf","Draft","Oral","Capsule","203697","10/30/2024","PSG_203697.pdf"
"Aspirin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Aspirin_oral ER capsule_NDA 200671_RC05-17.pdf","Draft","Oral","Capsule, Extended Release","200671","07/13/2017","Aspirin_oral ER capsule_NDA 200671_RC05-17.pdf"
"Aspirin; Butalbital; Caffeine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Aspirin; Butalbital; Caffeine_oral capsule_ RLD 017534_Final 08-17.pdf","Final","Oral","Capsule","017534","08/04/2017","Aspirin; Butalbital; Caffeine_oral capsule_ RLD 017534_Final 08-17.pdf"
"Aspirin; Butalbital; Caffeine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Aspirin;_Butalbital;_Caffeine_tab_86162_RC3-10.pdf","Final","Oral","Tablet","017534","08/04/2017","Aspirin;_Butalbital;_Caffeine_tab_86162_RC3-10.pdf"
"Aspirin; Butalbital; Caffeine; Codeine Phosphate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019429.pdf","Draft","Oral","Capsule","019429","10/30/2024","PSG_019429.pdf"
"Aspirin; Dipyridamole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Aspirin;_Dipyridamole_ERcap_20884_RC3-10.pdf","Draft","Oral","Capsule, Extended Release","020884","03/19/2010","Aspirin;_Dipyridamole_ERcap_20884_RC3-10.pdf"
"Aspirin; Omeprazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Aspirin; Omeprazole_oral DR tablet_NDA 205103_RV11-17.pdf","Draft","Oral","Tablet, Delayed Release","205103","02/08/2018","Aspirin; Omeprazole_oral DR tablet_NDA 205103_RV11-17.pdf"
"Aspirin; Oxycodone Hydrochloride; Aspirin;Oxycodone Terephthalate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Aspirin;_Oxycodone_tab_07337_RC2-10.pdf","Draft","Oral","Tablet","007337","02/25/2010","Aspirin;_Oxycodone_tab_07337_RC2-10.pdf"
"Atazanavir Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021567.pdf","Draft","Oral","Capsule","021567","10/30/2024","PSG_021567.pdf"
"Atazanavir Sulfate; Cobicistat","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_206353.pdf","Draft","Oral","Tablet","206353","10/30/2024","PSG_206353.pdf"
"Atenolol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018240.pdf","Draft","Oral","Tablet","018240","10/30/2024","PSG_018240.pdf"
"Atenolol; Chlorthalidone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018760.pdf","Draft","Oral","Tablet","018760","10/30/2024","PSG_018760.pdf"
"Atogepant","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215206.pdf","Draft","Oral","Tablet","215206","08/21/2023","PSG_215206.pdf"
"Atomoxetine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021411.pdf","Draft","Oral","Capsule","021411","10/30/2024","PSG_021411.pdf"
"Atorvastatin Calcium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020702.pdf","Draft","Oral","Tablet","020702","10/30/2024","PSG_020702.pdf"
"Atorvastatin Calcium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213260.pdf","Draft","Oral","Suspension","213260","10/30/2024","PSG_213260.pdf"
"Atorvastatin Calcium; Ezetimibe","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_200153.pdf","Draft","Oral","Tablet","200153                                                       206084","10/30/2024","PSG_200153.pdf"
"Atovaquone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020500.pdf","Draft","Oral","Suspension","020500","10/30/2024","PSG_020500.pdf"
"Atovaquone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020259.pdf","Draft","Oral","Tablet","020259","10/30/2024","PSG_020259.pdf"
"Atovaquone;Proguanil Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Atovaquone__Proguanil_tab_21078_RC7-08.pdf","Draft","Oral","Tablet","021078","07/01/2008","Atovaquone__Proguanil_tab_21078_RC7-08.pdf"
"Atropine Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213581.pdf","Draft","Ophthalmic","Solution/Drops","213581","08/21/2023","PSG_213581.pdf"
"Atropine Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_206289.pdf","Draft","Ophthalmic","Solution/Drops","206289","02/17/2022","PSG_206289.pdf"
"Atropine Sulfate;Diphenoxylate Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Atropine Sulfate; DiphenoxylateHCl_NDA 012462RC Nov 2018.pdf","Draft","Oral","Tablet","012462","11/28/2018","Atropine Sulfate; DiphenoxylateHCl_NDA 012462RC Nov 2018.pdf"
"Auranofin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018689.pdf","Draft","Oral","Capsule","018689","10/30/2024","PSG_018689.pdf"
"Avacopan","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214487.pdf","Draft","Oral","Capsule","214487","08/21/2023","PSG_214487.pdf"
"Avanafil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202276.pdf","Draft","Oral","Tablet","202276","10/30/2024","PSG_202276.pdf"
"Avapritinib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212608.pdf","Draft","Oral","Tablet","212608","08/20/2021","PSG_212608.pdf"
"Avatrombopag Maleate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210238.pdf","Draft","Oral","Tablet","210238","10/30/2024","PSG_210238.pdf"
"Axitinib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202324.pdf","Draft","Oral","Tablet","202324","10/30/2024","PSG_202324.pdf"
"Azacitidine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214120.pdf","Draft","Oral","Tablet","214120","11/16/2023","PSG_214120.pdf"
"Azacitidine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050794.pdf","Draft","Intravenous, Subcutaneous","Powder","050794","05/19/2021","PSG_050794.pdf"
"Azathioprine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Azathioprine_tabs_16324_RC09-10.pdf","Draft","Oral","Tablet","016324","09/30/2010","Azathioprine_tabs_16324_RC09-10.pdf"
"Azelaic Acid","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020428.pdf","Draft","Topical","Cream","020428","08/22/2024","PSG_020428.pdf"
"Azelaic Acid","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021470.pdf","Draft","Topical","Gel","021470","11/19/2024","PSG_021470.pdf"
"Azelaic Acid","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_207071.pdf","Draft","Topical","Aerosol, Foam","207071","11/18/2020","PSG_207071.pdf"
"Azelastine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213872.pdf","Draft","Nasal","Spray, Metered","213872","08/02/2022","PSG_213872.pdf"
"Azelastine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Azelastine HCl_nasal metered spray_NDA 022203_RC08-17.pdf","Draft","Nasal","Spray, Metered","022203","10/19/2017","Azelastine HCl_nasal metered spray_NDA 022203_RC08-17.pdf"
"Azelastine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020114.pdf","Draft","Nasal","Spray, Metered","020114","08/02/2022","PSG_020114.pdf"
"Azelastine Hydrochloride; Fluticasone Propionate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202236.pdf","Draft","Nasal","Spray, Metered","202236","05/18/2023","PSG_202236.pdf"
"Azilsartan Kamedoxomil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_200796.pdf","Draft","Oral","Tablet","200796","10/30/2024","PSG_200796.pdf"
"Azilsartan Kamedoxomil; Chlorthalidone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202331.pdf","Draft","Oral","Tablet","202331","10/30/2024","PSG_202331.pdf"
"Azithromycin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050693.pdf","Draft","Oral","For Suspension","050693","10/30/2024","PSG_050693.pdf"
"Azithromycin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050710.pdf","Draft","Oral","For Suspension","050710","10/30/2024","PSG_050710.pdf"
"Azithromycin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Azithromycin_ERsusp_50797_RC7-08 .pdf","Draft","Oral","Suspension, Extended Release","050797","07/01/2008","Azithromycin_ERsusp_50797_RC7-08 .pdf"
"Azithromycin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050711.pdf","Draft","Oral","Tablet","050711                                                       050730                                                       050784","10/30/2024","PSG_050711.pdf"
"Bacitracin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Bacitracin_ophthalmic ointment_RLD61212_RV09-16.pdf","Draft","Ophthalmic","Ointment","061212","10/04/2016","Bacitracin_ophthalmic ointment_RLD61212_RV09-16.pdf"
"Baclofen","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021589.pdf","Draft","Oral","Tablet, Orally Disintegrating","021589","10/30/2024","PSG_021589.pdf"
"Baclofen","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017851.pdf","Draft","Oral","Tablet","017851","10/30/2024","PSG_017851.pdf"
"Baclofen","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215602.pdf","Draft","Oral","Suspension","215602","10/30/2024","PSG_215602.pdf"
"Baclofen","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215422.pdf","Draft","Oral","Granules","215422","10/30/2024","PSG_215422.pdf"
"Baloxavir Marboxil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214410.pdf","Draft","Oral","For Suspension","214410","10/30/2024","PSG_214410.pdf"
"Baloxavir Marboxil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210854.pdf","Draft","Oral","Tablet","210854","10/30/2024","PSG_210854.pdf"
"Balsalazide Disodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Balsalazide_disodium_tab_022205_RC06-13.pdf","Draft","Oral","Tablet","022205","06/19/2013","Balsalazide_disodium_tab_022205_RC06-13.pdf"
"Balsalazide Disodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Balsalazide_cap_20610_RC1-08.pdf","Draft","Oral","Capsule","020610","01/01/2008","Balsalazide_cap_20610_RC1-08.pdf"
"Baricitinib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_207924.pdf","Draft","Oral","Tablet","207924","10/30/2024","PSG_207924.pdf"
"Barium Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Barium sulfate_oral paste_NDA 208844_RC08-17.pdf","Draft","Oral","Paste","208844","10/19/2017","Barium sulfate_oral paste_NDA 208844_RC08-17.pdf"
"Barium Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Barium sulfate_oral supension_NDA 208036_RC11-17.pdf","Draft","Oral","Suspension","208036","02/08/2018","Barium sulfate_oral supension_NDA 208036_RC11-17.pdf"
"Barium Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Barium sulfate_oral supension_NDA 208143_RC11-17.pdf","Draft","Oral","Suspension","208143","02/08/2018","Barium sulfate_oral supension_NDA 208143_RC11-17.pdf"
"Beclomethasone Dipropionate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020911.pdf","Draft","Inhalation","Aerosol, Metered","020911","08/21/2023","PSG_020911.pdf"
"Beclomethasone Dipropionate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Beclomethasone dipropionate_draft_Nasal aerosol metered_RLD 202813_RC07-18.pdf","Draft","Nasal","Aerosol, Metered","202813","07/20/2018","Beclomethasone dipropionate_draft_Nasal aerosol metered_RLD 202813_RC07-18.pdf"
"Beclomethasone Dipropionate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_207921.pdf","Draft","Inhalation","Aerosol, Metered","207921","08/21/2023","PSG_207921.pdf"
"Beclomethasone Dipropionate Monohydrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019389.pdf","Draft","Nasal","Spray, Metered","019389","08/21/2023","PSG_019389.pdf"
"Bedaquiline Fumarate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_204384.pdf","Draft","Oral","Tablet","204384","10/30/2024","PSG_204384.pdf"
"Belumosudil Mesylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214783.pdf","Draft","Oral","Tablet","214783","10/30/2024","PSG_214783.pdf"
"Belzutifan","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215383.pdf","Draft","Oral","Tablet","215383","05/18/2023","PSG_215383.pdf"
"Bempedoic Acid","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211616.pdf","Draft","Oral","Tablet","211616","10/30/2024","PSG_211616.pdf"
"Bempedoic Acid; Ezetimibe","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211617.pdf","Draft","Oral","Tablet","211617","10/30/2024","PSG_211617.pdf"
"Benazepril Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019851.pdf","Draft","Oral","Tablet","019851","10/30/2024","PSG_019851.pdf"
"Benazepril Hydrochloride; Hydrochlorothiazide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020033.pdf","Draft","Oral","Tablet","020033","10/30/2024","PSG_020033.pdf"
"Benoxinate hydrochloride; Fluorescein sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Benoxinate hydrochloride; Fluorescein sodium Ophthalmic solution drops 0.25-0.45 NDA 208582 PSG Page RC May 2019.pdf","Draft","Topical","Solution/Drops","208582","05/15/2019","Benoxinate hydrochloride; Fluorescein sodium Ophthalmic solution drops 0.25-0.45 NDA 208582 PSG Page RC May 2019.pdf"
"Benznidazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209570.pdf","Draft","Oral","Tablet","209570","10/30/2024","PSG_209570.pdf"
"Benzonatate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Benzonatate _oral capsule_040749 040627 201209_RV09-15.pdf","Draft","Oral","Capsule","011210","09/18/2015","Benzonatate _oral capsule_040749 040627 201209_RV09-15.pdf"
"Benzoyl Peroxide; Clindamycin Phosphate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050819.pdf","Draft","Topical","Gel","050819","02/16/2023","PSG_050819.pdf"
"Benzoyl Peroxide; Clindamycin Phosphate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050741.pdf","Draft","Topical","Gel","050741","02/16/2023","PSG_050741.pdf"
"Benzoyl Peroxide; Clindamycin Phosphate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050756.pdf","Draft","Topical","Gel","050756","02/16/2023","PSG_050756.pdf"
"Benzoyl Peroxide; Erythromycin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050557.pdf","Draft","Topical","Gel","050557","05/16/2024","PSG_050557.pdf"
"Benzoyl Peroxide; Erythromycin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050769.pdf","Draft","Topical","Gel","050769","05/16/2024","PSG_050769.pdf"
"Benzphetamine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Benzphetamine_HCl_tab_12427_RC5-06.pdf","Final","Oral","Tablet","012427","05/01/2008","Benzphetamine_HCl_tab_12427_RC5-06.pdf"
"Benztropine Mesylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_009193.pdf","Draft","Oral","Tablet","009193","09/16/2019","PSG_009193.pdf"
"Benzyl Alcohol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022129.pdf","Draft","Topical","Lotion","022129","10/21/2022","PSG_022129.pdf"
"Berotralstat Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214094.pdf","Draft","Oral","Capsule","214094","10/30/2024","PSG_214094.pdf"
"Besifloxacin Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022308.pdf","Draft","Ophthalmic","Suspension/Drops","022308","03/02/2020","PSG_022308.pdf"
"Betamethasone Acetate; Betamethasone Sodium Phosphate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_014602.pdf","Draft","Injection","Injectable","014602","11/16/2023","PSG_014602.pdf"
"Betamethasone dipropionate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Betamethasone dipropionate_topical Lotion_NDA 01778_RC08-17.pdf","Draft","Topical","Lotion","017781","10/19/2017","Betamethasone dipropionate_topical Lotion_NDA 01778_RC08-17.pdf"
"Betamethasone dipropionate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Betamethasone Dipropionate_topical cream 0.05_RLD 019137_RC09-16.pdf","Draft","Topical","Cream","019137","10/04/2016","Betamethasone Dipropionate_topical cream 0.05_RLD 019137_RC09-16.pdf"
"Betamethasone dipropionate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Betamethasone dipropionate_ topical augmented cream_RLD 19555_RC04-16.pdf","Draft","Topical","Cream, Augmented","019555","04/14/2016","Betamethasone dipropionate_ topical augmented cream_RLD 19555_RC04-16.pdf"
"Betamethasone dipropionate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Betamethasone dipropionate_topical augmented lotion_RLD 019716_RC01-16.pdf","Draft","Topical","Lotion, Augmented","019716","01/27/2016","Betamethasone dipropionate_topical augmented lotion_RLD 019716_RC01-16.pdf"
"Betamethasone dipropionate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Betamethasone dipropionate_topical augmented ointment_NDA 018741_RC11-17.pdf","Draft","Topical","Ointment, Augmented","018741","02/08/2018","Betamethasone dipropionate_topical augmented ointment_NDA 018741_RC11-17.pdf"
"Betamethasone dipropionate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Betamethasone dipropionate_draft_Topical spray_RLD 208079_RC07-18.pdf","Draft","Topical","Spray","208079","07/20/2018","Betamethasone dipropionate_draft_Topical spray_RLD 208079_RC07-18.pdf"
"Betamethasone Dipropionate; Calcipotriene","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213422.pdf","Draft","Topical","Cream","213422","10/21/2022","PSG_213422.pdf"
"Betamethasone Dipropionate; Calcipotriene","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021852.pdf","Draft","Topical","Ointment","021852","10/21/2022","PSG_021852.pdf"
"Betamethasone Dipropionate; Calcipotriene","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022185.pdf","Draft","Topical","Suspension","022185","10/21/2022","PSG_022185.pdf"
"Betamethasone Dipropionate; Calcipotriene","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_207589.pdf","Draft","Topical","Aerosol, Foam","207589","11/21/2019","PSG_207589.pdf"
"Betamethasone Dipropionate; Clotrimazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020010.pdf","Draft","Topical","Lotion","020010                                                       076493","02/15/2024","PSG_020010.pdf"
"Betamethasone Dipropionate; Clotrimazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018827.pdf","Draft","Topical","Cream","018827                                                       075673","02/15/2024","PSG_018827.pdf"
"Betamethasone Valerate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Betamethasone valerate_topical cream_RLD 018861_RC12-16.pdf","Draft","Topical","Cream","018861","12/22/2016","Betamethasone valerate_topical cream_RLD 018861_RC12-16.pdf"
"Betamethasone Valerate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Betamethasone valerate_topical ointment_RLD 18865_RC10-16.pdf","Draft","Topical","Ointment","018865","10/04/2016","Betamethasone valerate_topical ointment_RLD 18865_RC10-16.pdf"
"Betamethasone Valerate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Betamethasone_valerate_aerofoam_20934_RC12-14.pdf","Draft","Topical","Aerosol, Foam","020934","12/29/2014","Betamethasone_valerate_aerofoam_20934_RC12-14.pdf"
"Betamethasone Valerate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Betamethasone valerate_topical lotion_RLD 018866_RC01-16.pdf","Draft","Topical","Lotion","018866","01/27/2016","Betamethasone valerate_topical lotion_RLD 018866_RC01-16.pdf"
"Betaxolol Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/BETAXOLOL HYDROCHLORIDE ophthalmic suspensiondrops NDA 019845 PSG Page RV May 2019.pdf","Draft","Ophthalmic","Solution/Drops","019845","05/15/2019","BETAXOLOL HYDROCHLORIDE ophthalmic suspensiondrops NDA 019845 PSG Page RV May 2019.pdf"
"Bethanechol Chloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Bethanechol_Chloride_tab_88440_88441_89096_89095_RC9-08.pdf","Draft","Oral","Tablet","006536","09/01/2008","Bethanechol_Chloride_tab_88440_88441_89096_89095_RC9-08.pdf"
"Betrixaban","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Betrixaban_draft_Oral cap_RLD 208383_RC07-18.pdf","Draft","Oral","Capsule","208383","07/20/2018","Betrixaban_draft_Oral cap_RLD 208383_RC07-18.pdf"
"Bexagliflozin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214373.pdf","Draft","Oral","Tablet","214373","10/30/2024","PSG_214373.pdf"
"Bexarotene","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021056.pdf","Draft","Topical","Gel","021056","10/21/2022","PSG_021056.pdf"
"Bexarotene","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021055.pdf","Draft","Oral","Capsule","021055","08/20/2021","PSG_021055.pdf"
"Bicalutamide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020498.pdf","Draft","Oral","Tablet","020498","10/30/2024","PSG_020498.pdf"
"Bictegravir Sodium; Emtricitabine; Tenofovir Alafenamide Fumarate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210251.pdf","Draft","Oral","Tablet","210251","11/19/2024","PSG_210251.pdf"
"Bimatoprost","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211911.pdf","Draft","Ophthalmic","Implant","211911","05/18/2023","PSG_211911.pdf"
"Bimatoprost","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Bimatoprost_ophthalmic solution drops_NDA 021275_RC11-17.pdf","Draft","Ophthalmic","Solution/Drops","021275","02/08/2018","Bimatoprost_ophthalmic solution drops_NDA 021275_RC11-17.pdf"
"Bimatoprost","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Bimatoprost_ophthalmic solution drops_NDA 022184_RC11-17.pdf","Draft","Ophthalmic","Solution/Drops","022184","02/08/2018","Bimatoprost_ophthalmic solution drops_NDA 022184_RC11-17.pdf"
"Bimatoprost","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Bimatoprost_ophthalmic solution drops_NDA 022369_RC11-17.pdf","Draft","Topical","Solution/Drops","022369","02/08/2018","Bimatoprost_ophthalmic solution drops_NDA 022369_RC11-17.pdf"
"Binimetinib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210498.pdf","Draft","Oral","Tablet","210498","10/30/2024","PSG_210498.pdf"
"Bisacodyl; Polyethylene Glycol 3350; Potassium Chloride; Sodium Bicarbonate; Sodium Chloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Bisacodyl; PEG3350_ANDA 202217_RC03-17.pdf","Draft","Oral","For Solution, Tablet, Delayed Release","021551","05/16/2017","Bisacodyl; PEG3350_ANDA 202217_RC03-17.pdf"
"Bismuth Subcitrate Potassium; Metronidazole;Tetracycline Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/BismuthSubcitratePotassiumMetronidazoleTetracyclineHClcap50786RC908.pdf","Draft","Oral","Capsule","050786","09/01/2008","BismuthSubcitratePotassiumMetronidazoleTetracyclineHClcap50786RC908.pdf"
"Bismuth Subsalicylate; Metronidazole; Tetracycline Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050719.pdf","Draft","Oral","Tablet, Chewable, Tablet, Capsule","050719","02/16/2023","PSG_050719.pdf"
"Bisoprolol Fumarate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019982.pdf","Draft","Oral","Tablet","019982","10/30/2024","PSG_019982.pdf"
"Bisoprolol Fumarate; Hydrochlorothiazide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020186.pdf","Draft","Oral","Tablet","020186","10/30/2024","PSG_020186.pdf"
"Boceprevir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202258.pdf","Draft","Oral","Capsule","202258","10/30/2024","PSG_202258.pdf"
"Bortezomib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021602.pdf","Draft","Intravenous, Subcutaneous","Injectable","021602","08/28/2020","PSG_021602.pdf"
"Bosentan","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021290.pdf","Draft","Oral","Tablet","021290","10/30/2024","PSG_021290.pdf"
"Bosentan","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209279.pdf","Draft","Oral","Tablet, For Suspension","209279","10/30/2024","PSG_209279.pdf"
"Bosutinib Monohydrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_203341.pdf","Draft","Oral","Tablet","203341","10/30/2024","PSG_203341.pdf"
"Bremelanotide Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210557.pdf","Draft","Subcutaneous","Solution","210557","03/24/2021","PSG_210557.pdf"
"Brexanolone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211371.pdf","Draft","Intravenous","Solution","211371","06/03/2020","PSG_211371.pdf"
"Brexpiprazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_205422.pdf","Draft","Oral","Tablet","205422","10/30/2024","PSG_205422.pdf"
"Brigatinib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Brigatinib_draft_Oral tab_RLD 208772_RC09-18.pdf","Draft","Oral","Tablet","208772","09/13/2018","Brigatinib_draft_Oral tab_RLD 208772_RC09-18.pdf"
"Brilliant Blue G","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209569.pdf","Draft","Ophthalmic","Solution","209569","12/17/2021","PSG_209569.pdf"
"Brimonidine Tartrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Brimonidine tartrate ophthalmic solution 0.025 NDA 208144 PSG Page RC May 2019.pdf","Draft","Ophthalmic","Solution/Drops","208144","05/15/2019","Brimonidine tartrate ophthalmic solution 0.025 NDA 208144 PSG Page RC May 2019.pdf"
"Brimonidine Tartrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Brimonidine tartrate_ophthalmic solution_NDA 021770_RV08-17.pdf","Draft","Ophthalmic","Solution/Drops  0.1%","021770","10/19/2017","Brimonidine tartrate_ophthalmic solution_NDA 021770_RV08-17.pdf"
"Brimonidine Tartrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Brimonidine tartrate_ophthalmic solution_NDA 020613_RV08-17.pdf","Draft","Ophthalmic","Solution/Drops  0.2%","020613","10/19/2017","Brimonidine tartrate_ophthalmic solution_NDA 020613_RV08-17.pdf"
"Brimonidine Tartrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Brimonidine tartrate_topical gel_204708_RC09-15.pdf","Draft","Topical","Gel","204708","09/18/2015","Brimonidine tartrate_topical gel_204708_RC09-15.pdf"
"Brimonidine Tartrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Brimonidine Tartrate_Ophthalmic Solution_NDA 021262_RV07-17.pdf","Draft","Ophthalmic","Solution/Drops  0.15%","021262","07/13/2017","Brimonidine Tartrate_Ophthalmic Solution_NDA 021262_RV07-17.pdf"
"Brimonidine Tartrate; Brinzolamide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/BRIMONIDINE TARTRATE BRINZOLAMIDE ophthalmic suspension drops NDA 204251 PSG Page RV May 2019.pdf","Draft","Ophthalmic","Suspension/Drops","204251","05/15/2019","BRIMONIDINE TARTRATE BRINZOLAMIDE ophthalmic suspension drops NDA 204251 PSG Page RV May 2019.pdf"
"Brimonidine Tartrate;Timolol Maleate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Brimonidine tartrate Timolol MaleateNDA 021398 RC 09-2018.pdf","Draft","Ophthalmic","Solution/Drops","021398","09/13/2018","Brimonidine tartrate Timolol MaleateNDA 021398 RC 09-2018.pdf"
"Brincidofovir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214460.pdf","Draft","Oral","Suspension","214460","05/18/2023","PSG_214460.pdf"
"Brincidofovir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214461.pdf","Draft","Oral","Tablet","214461","10/30/2024","PSG_214461.pdf"
"Brinzolamide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/BRINZOLAMIDE ophthalmic suspension drops NDA 020816 PSG Page RV May 2019.pdf","Draft","Ophthalmic","Suspension/Drops  1%","020816","05/15/2019","BRINZOLAMIDE ophthalmic suspension drops NDA 020816 PSG Page RV May 2019.pdf"
"Brivaracetam","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_205836.pdf","Draft","Oral","Tablet","205836","10/30/2024","PSG_205836.pdf"
"Bromfenac Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Bromfenac sodium_ophthalmic solution_NDA 021664_RV08-17.pdf","Draft","Ophthalmic","Solution/Drops","021664","10/19/2017","Bromfenac sodium_ophthalmic solution_NDA 021664_RV08-17.pdf"
"Bromocriptine Mesylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Bromocriptine_ Mesylate_cap_17962_RC11-09.pdf","Draft","Oral","Capsule","017962","11/30/2009","Bromocriptine_ Mesylate_cap_17962_RC11-09.pdf"
"Bromocriptine Mesylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Bromocriptine_ Mesylate_tab_17962_RC11-09.pdf","Draft","Oral","Tablet","017962","11/23/2009","Bromocriptine_ Mesylate_tab_17962_RC11-09.pdf"
"Bromocriptine mesylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Bromocriptine Mesylate Tablets NDA20866 RC Feb 2019.pdf","Draft","Oral","Tablet","020866","02/22/2019","Bromocriptine Mesylate Tablets NDA20866 RC Feb 2019.pdf"
"Budesonide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021324.pdf","Draft","Oral","Capsule, Delayed Release","021324","08/20/2021","PSG_021324.pdf"
"Budesonide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021949.pdf","Draft","Inhalation","Powder, Metered","021949","08/22/2024","PSG_021949.pdf"
"Budesonide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Budesonide_Inhalation_Sus_20929_RC_09-12.pdf","Draft","Inhalation","Suspension","020929","09/19/2012","Budesonide_Inhalation_Sus_20929_RC_09-12.pdf"
"Budesonide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Budesonide_ERTab_203634_RC12-14.pdf","Draft","Oral","Tablet, Extended Release","203634","12/10/2014","Budesonide_ERTab_203634_RC12-14.pdf"
"Budesonide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_205613.pdf","Draft","Rectal","Aerosol, Foam","205613","11/18/2020","PSG_205613.pdf"
"Budesonide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020746.pdf","Draft","Nasal","Spray, Metered","020746","08/21/2023","PSG_020746.pdf"
"Budesonide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211929.pdf","Draft","Oral","Capsule, Extended Release","211929","03/02/2020","PSG_211929.pdf"
"Budesonide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215935.pdf","Draft","Oral","Capsule, Delayed Release","215935","11/17/2022","PSG_215935.pdf"
"Budesonide; Formoterol Fumarate Dihydrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021929.pdf","Draft","Inhalation","Aerosol, Metered","021929","11/19/2024","PSG_021929.pdf"
"Budesonide; Formoterol Fumarate; Glycopyrrolate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212122.pdf","Draft","Inhalation","Aerosol, Metered","212122","02/15/2024","PSG_212122.pdf"
"Bumetanide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018225.pdf","Draft","Oral","Tablet","018225","10/30/2024","PSG_018225.pdf"
"Bupivacaine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Bupivacaine_ liposomal injectable injection_NDA 022496_RC11-17.pdf","Draft","Injection","Injectable, Liposomal","022496","02/08/2018","Bupivacaine_ liposomal injectable injection_NDA 022496_RC11-17.pdf"
"Bupivacaine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_204803.pdf","Draft","Infiltration","Solution, Extended Release","204803","05/19/2022","PSG_204803.pdf"
"Buprenorphine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021306.pdf","Draft","Transdermal","Film, Extended Release","021306","06/03/2020","PSG_021306.pdf"
"Buprenorphine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209819.pdf","Draft","Subcutaneous","Solution, Extended Release","209819","06/03/2020","PSG_209819.pdf"
"Buprenorphine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Buprenorphine_hydrochloride_SLtab_78633_RV02-14.pdf","Draft","Sublingual","Tablet","020732","02/01/2014","Buprenorphine_hydrochloride_SLtab_78633_RV02-14.pdf"
"Buprenorphine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Buprenorphine hydrochloride_buccal film_NDA 207932_RC11-17.pdf","Draft","Buccal","Film","207932","02/08/2018","Buprenorphine hydrochloride_buccal film_NDA 207932_RC11-17.pdf"
"Buprenorphine Hydrochloride; Naloxone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Buprenorphine HCL_Naloxone HCL_Buccal Film_205637_RC03-15.pdf","Draft","Buccal","Film","205637","03/06/2015","Buprenorphine HCL_Naloxone HCL_Buccal Film_205637_RC03-15.pdf"
"Buprenorphine Hydrochloride; Naloxone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Buprenorphine HCL; Naloxone HCL_sublingual buccal film_RLD 022410_RV12-16.pdf","Draft","Buccal, Sublingual","Film","022410","12/22/2016","Buprenorphine HCL; Naloxone HCL_sublingual buccal film_RLD 022410_RV12-16.pdf"
"Buprenorphine Hydrochloride; Naloxone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Buprenorphine_HCl;_Naloxone_HCl_subtab_20733_RC5-10.pdf","Draft","Sublingual","Tablet","020733","05/20/2010","Buprenorphine_HCl;_Naloxone_HCl_subtab_20733_RC5-10.pdf"
"Buprenorphine Hydrochloride; Naloxone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Buprenorphine Hcl; Naloxone Hcl_sublingual tablet_RLD 204242_RV12-16.pdf","Draft","Sublingual","Tablet","204242","12/22/2016","Buprenorphine Hcl; Naloxone Hcl_sublingual tablet_RLD 204242_RV12-16.pdf"
"Bupropion Hydrobromide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Bupropion_HBr_ERtab_22108_RV03-13.pdf","Draft","Oral","Tablet, Extended Release","022108","03/29/2013","Bupropion_HBr_ERtab_22108_RV03-13.pdf"
"Bupropion Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Bupropion_HCl_ERtab_22497_RC03-13.pdf","Draft","Oral","Tablet, Extended Release","022497","03/29/2013","Bupropion_HCl_ERtab_22497_RC03-13.pdf"
"Bupropion Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018644.pdf","Draft","Oral","Tablet","018644","10/30/2024","PSG_018644.pdf"
"Bupropion Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Bupropion_HCl_ERtab_21515_RV03-13.pdf","Draft","Oral","Tablet, Extended Release","021515","03/29/2013","Bupropion_HCl_ERtab_21515_RV03-13.pdf"
"Bupropion Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020358.pdf","Draft","Oral","Tablet, Extended Release","020358                                                       020711","08/22/2024","PSG_020358.pdf"
"Bupropion Hydrochloride; Naltrexone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_200063.pdf","Draft","Oral","Tablet, Extended Release","200063","11/18/2020","PSG_200063.pdf"
"Buspirone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018731.pdf","Draft","Oral","Tablet","018731","10/30/2024","PSG_018731.pdf"
"Buspirone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021190.pdf","Draft","Oral","Capsule","021190","11/19/2024","PSG_021190.pdf"
"Busulfan","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Busulfan_tab_09386_RC7-08.pdf","Draft","Oral","Tablet","009386","07/01/2009","Busulfan_tab_09386_RC7-08.pdf"
"Butenafine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020524.pdf","Draft","Topical","Cream","020524","10/21/2022","PSG_020524.pdf"
"Butenafine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021307.pdf","Draft","Topical","Cream","021307","10/21/2022","PSG_021307.pdf"
"Butoconazole Nitrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Butoconazole Nitrate Vaginal Cream ANDA 200923 RV Feb 2019.pdf","Draft","Vaginal","Cream","200923","02/22/2019","Butoconazole Nitrate Vaginal Cream ANDA 200923 RV Feb 2019.pdf"
"Butoconazole Nitrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Butoconazole Nitrate Vaginal Cream NDA 020421 RV Feb 2019.pdf","Draft","Vaginal","Cream","020421","02/22/2019","Butoconazole Nitrate Vaginal Cream NDA 020421 RV Feb 2019.pdf"
"Cabotegravir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215499.pdf","Draft","Intramuscular","Suspension, Extended Release","215499","05/18/2023","PSG_215499.pdf"
"Cabotegravir Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212887.pdf","Draft","Oral","Tablet","212887","10/30/2024","PSG_212887.pdf"
"Cabotegravir; Rilpivirine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212888.pdf","Draft","Intramuscular","Suspension, Extended Release","212888","02/16/2023","PSG_212888.pdf"
"Cabozantinib S-Malate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_203756.pdf","Draft","Oral","Capsule","203756","05/18/2023","PSG_203756.pdf"
"Cabozantinib S-Malate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208692.pdf","Draft","Oral","Tablet","208692","05/18/2023","PSG_208692.pdf"
"Caffeine; Ergotamine Tartrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_086557.pdf","Draft","Rectal","Suppository","086557                                                       009000","02/15/2024","PSG_086557.pdf"
"Calcifediol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208010.pdf","Draft","Oral","Capsule, Extended Release","208010","03/24/2021","PSG_208010.pdf"
"Calcipotriene","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022563.pdf","Draft","Topical","Aerosol, Foam","022563","11/18/2020","PSG_022563.pdf"
"Calcipotriene","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020554.pdf","Draft","Topical","Cream","020554","10/21/2022","PSG_020554.pdf"
"Calcipotriene","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020273.pdf","Draft","Topical","Ointment","020273","10/21/2022","PSG_020273.pdf"
"Calcipotriene","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Calcipotriene_sol_20611_RC08-10.pdf","Draft","Topical","Solution","020611","08/30/2010","Calcipotriene_sol_20611_RC08-10.pdf"
"Calcitonin Salmon","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017769.pdf","Draft","Injection","Injectable","017808","11/17/2022","PSG_017769.pdf"
"Calcitonin Salmon","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020313.pdf","Draft","Nasal","Spray, Metered","020313","03/02/2020","PSG_020313.pdf"
"Calcitriol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Calcitriol_cap _18044_RC7-08.pdf","Draft","Oral","Capsule","018044","09/01/2010","Calcitriol_cap _18044_RC7-08.pdf"
"Calcium Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Calcium acetate_oral tablet_ANDA 078502_RV03-17.pdf","Draft","Oral","Tablet","019976","05/16/2017","Calcium acetate_oral tablet_ANDA 078502_RV03-17.pdf"
"Calcium Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/calcium acetate_oral capsule_RLD 021160_RV03-17.pdf","Draft","Oral","Capsule","021160","05/16/2017","calcium acetate_oral capsule_RLD 021160_RV03-17.pdf"
"Calcium Carbonate; Famotidine; Magnesium Hydroxide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020958.pdf","Draft","Oral","Tablet, Chewable","020958","10/30/2024","PSG_020958.pdf"
"Calcium Carbonate;Risedronate Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Risedronate_Sodium_Calcium_Carbonate_tab_21823_RC10-06.pdf","Final","Oral","Tablet, Tablet","021823","05/12/2008","Risedronate_Sodium_Calcium_Carbonate_tab_21823_RC10-06.pdf"
"Canagliflozin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_204042.pdf","Draft","Oral","Tablet","204042","10/30/2024","PSG_204042.pdf"
"Canagliflozin; Metformin Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Canagliflozin; Metformin HCl_oral ER tablet_NDA 205879_RC08-17.pdf","Draft","Oral","Tablet, Extended Release","205879","10/19/2017","Canagliflozin; Metformin HCl_oral ER tablet_NDA 205879_RC08-17.pdf"
"Canagliflozin; Metformin Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_204353.pdf","Draft","Oral","Tablet","204353","10/30/2024","PSG_204353.pdf"
"Candesartan Cilexetil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020838.pdf","Draft","Oral","Tablet","020838","10/30/2024","PSG_020838.pdf"
"Candesartan Cilexetil; Hydrochlorothiazide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021093.pdf","Draft","Oral","Tablet","021093","10/30/2024","PSG_021093.pdf"
"Cannabidiol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210365.pdf","Draft","Oral","Solution","210365","03/24/2021","PSG_210365.pdf"
"Cantharidin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212905.pdf","Draft","Topical","Solution","212905","11/19/2024","PSG_212905.pdf"
"Capecitabine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Capecitabine_Tabs_20896_RC09-12.pdf","Draft","Oral","Tablet","020896","09/19/2012","Capecitabine_Tabs_20896_RC09-12.pdf"
"Capmatinib Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213591.pdf","Draft","Oral","Tablet","213591","10/30/2024","PSG_213591.pdf"
"Capsaicin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022395.pdf","Draft","Topical","Patch","022395","11/21/2019","PSG_022395.pdf"
"Captopril","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Captopril_oral tablet_RLD 074434_RC09-16.pdf","Draft","Oral","Tablet","018343","10/04/2016","Captopril_oral tablet_RLD 074434_RC09-16.pdf"
"Carbamazepine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Carbamazepine_oral tablet_016608_RV09-15.pdf","Draft","Oral","Tablet","016608","09/18/2015","Carbamazepine_oral tablet_016608_RV09-15.pdf"
"Carbamazepine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Carbamazepine_ER tab_020234_RV03-15.pdf","Draft","Oral","Tablet, Extended Release","020234","03/06/2015","Carbamazepine_ER tab_020234_RV03-15.pdf"
"Carbamazepine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Carbamazepine_Oral ER cap_20712_RV03-15.pdf","Draft","Oral","Capsule, Extended Release","020712                                                       021710","03/06/2015","Carbamazepine_Oral ER cap_20712_RV03-15.pdf"
"Carbamazepine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Carbamazepine_oral suspension_18927_RV03-15.pdf","Draft","Oral","Suspension","018927","03/06/2015","Carbamazepine_oral suspension_18927_RV03-15.pdf"
"Carbamazepine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018281.pdf","Draft","Oral","Tablet, Chewable","018281","08/02/2022","PSG_018281.pdf"
"Carbidopa","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017830.pdf","Draft","Oral","Tablet","017830","10/30/2024","PSG_017830.pdf"
"Carbidopa; Entacapone; Levodopa","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021485.pdf","Draft","Oral","Tablet","021485","10/30/2024","PSG_021485.pdf"
"Carbidopa; Levodopa","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Carbidopa; Levedopa_enteral suspension_RLD 203952_RC03-17.pdf","Draft","Enteral","Suspension","203952","05/16/2017","Carbidopa; Levedopa_enteral suspension_RLD 203952_RC03-17.pdf"
"Carbidopa; Levodopa","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017555.pdf","Draft","Oral","Tablet","017555","10/30/2024","PSG_017555.pdf"
"Carbidopa; Levodopa","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Carbidopa; Levodopa_oral  ER capsule_203312_RC09-15.pdf","Draft","Oral","Capsule, Extended Release","203312","09/18/2015","Carbidopa; Levodopa_oral  ER capsule_203312_RC09-15.pdf"
"Carbidopa; Levodopa","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Carbidopa_Levodopa_ERtab_19856_RC09-12.pdf","Draft","Oral","Tablet, Extended Release","019856","09/19/2012","Carbidopa_Levodopa_ERtab_19856_RC09-12.pdf"
"Carbidopa; Levodopa","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_076699.pdf","Draft","Oral","Tablet, Orally Disintegrating","078690","10/30/2024","PSG_076699.pdf"
"Carbinoxamine Maleate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_008915.pdf","Draft","Oral","Tablet","008915","08/20/2021","PSG_008915.pdf"
"Carbinoxamine Maleate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Carbinoxamine_maleate_oralsusp_22556_RC07-14.pdf","Draft","Oral","Suspension, Extended Release","022556","07/22/2014","Carbinoxamine_maleate_oralsusp_22556_RC07-14.pdf"
"Carglumic Acid","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022562.pdf","Draft","Oral","Tablet, For Suspension","022562","10/30/2024","PSG_022562.pdf"
"Cariprazine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_204370.pdf","Draft","Oral","Capsule","204370","10/30/2024","PSG_204370.pdf"
"Carisoprodol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_011792.pdf","Draft","Oral","Tablet","011792","10/30/2024","PSG_011792.pdf"
"Carvedilol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020297.pdf","Draft","Oral","Tablet","020297","10/30/2024","PSG_020297.pdf"
"Carvedilol Phosphate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022012.pdf","Draft","Oral","Capsule, Extended Release","022012","08/22/2024","PSG_022012.pdf"
"Casimersen","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213026.pdf","Draft","Intravenous","Solution","213026","05/18/2023","PSG_213026.pdf"
"Caspofungin Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021227.pdf","Draft","Intravenous","Powder","021227","08/02/2022","PSG_021227.pdf"
"Cedazuridine; Decitabine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212576.pdf","Draft","Oral","Tablet","212576","05/19/2022","PSG_212576.pdf"
"Cefaclor","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050521.pdf","Draft","Oral","Capsule","050521","10/30/2024","PSG_050521.pdf"
"Cefaclor","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050673.pdf","Draft","Oral","Tablet, Extended Release","050673","11/21/2019","PSG_050673.pdf"
"Cefadroxil; Cefadroxil Hemihydrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050512.pdf","Draft","Oral","Capsule","050512","10/30/2024","PSG_050512.pdf"
"Cefazolin Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211413.pdf","Draft","Intravenous","Powder","211413","11/19/2024","PSG_211413.pdf"
"Cefdinir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050739.pdf","Draft","Oral","Capsule","050739","10/30/2024","PSG_050739.pdf"
"Cefdinir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050749.pdf","Draft","Oral","For Suspension","050749","10/30/2024","PSG_050749.pdf"
"Cefditoren Pivoxil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021222.pdf","Draft","Oral","Tablet","021222","10/30/2024","PSG_021222.pdf"
"Cefiderocol Sulfate Tosylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209445.pdf","Draft","Intravenous","Powder","209445","08/20/2021","PSG_209445.pdf"
"Cefixime","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_065380.pdf","Draft","Oral","Tablet, Chewable","065380","10/30/2024","PSG_065380.pdf"
"Cefixime","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_203195.pdf","Draft","Oral","Capsule","203195","10/30/2024","PSG_203195.pdf"
"Cefixime","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050621.pdf","Draft","Oral","Tablet","050621","10/30/2024","PSG_050621.pdf"
"Cefixime","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050622.pdf","Draft","Oral","For Suspension","202091                                                       050622","10/30/2024","PSG_050622.pdf"
"Cefpodoxime Proxetil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050675.pdf","Draft","Oral","For Suspension","050675","10/30/2024","PSG_050675.pdf"
"Cefpodoxime Proxetil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050674.pdf","Draft","Oral","Tablet","050674","10/30/2024","PSG_050674.pdf"
"Cefprozil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050665.pdf","Draft","Oral","For Suspension","050665","10/30/2024","PSG_050665.pdf"
"Cefprozil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050664.pdf","Draft","Oral","Tablet","050664","10/30/2024","PSG_050664.pdf"
"Cefuroxime Axetil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050605.pdf","Draft","Oral","Tablet","050605","10/30/2024","PSG_050605.pdf"
"Cefuroxime Axetil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050672.pdf","Draft","Oral","For Suspension","050672","10/30/2024","PSG_050672.pdf"
"Celecoxib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Celecoxib_cap_20998_RV11-13.pdf","Draft","Oral","Capsule","020998","11/05/2013","Celecoxib_cap_20998_RV11-13.pdf"
"Celecoxib; Tramadol Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213426.pdf","Draft","Oral","Tablet","213426","10/30/2024","PSG_213426.pdf"
"Cenobamate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212839.pdf","Draft","Oral","Tablet","212839","10/30/2024","PSG_212839.pdf"
"Cephalexin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050406.pdf","Draft","Oral","For Suspension","050406","10/30/2024","PSG_050406.pdf"
"Cephalexin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050405.pdf","Draft","Oral","Capsule","050405","10/30/2024","PSG_050405.pdf"
"Ceritinib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_205755.pdf","Draft","Oral","Capsule","205755","10/30/2024","PSG_205755.pdf"
"Ceritinib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211225.pdf","Draft","Oral","Tablet","211225","10/30/2024","PSG_211225.pdf"
"Cetirizine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021621.pdf","Draft","Oral","Tablet, Chewable","021621","10/30/2024","PSG_021621.pdf"
"Cetirizine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019835.pdf","Draft","Oral","Tablet","019835","10/30/2024","PSG_019835.pdf"
"Cetirizine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022429.pdf","Draft","Oral","Capsule","022429","10/30/2024","PSG_022429.pdf"
"Cetirizine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022578.pdf","Draft","Oral","Tablet, Orally Disintegrating","022578","10/30/2024","PSG_022578.pdf"
"Cetirizine Hydrochloride; Pseudoephedrine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Cetirizine_HCl;_Pseudoephedrine_HCl_ERtab_21150_RC2-08.pdf","Draft","Oral","Tablet, Extended Release","021150","04/06/2008","Cetirizine_HCl;_Pseudoephedrine_HCl_ERtab_21150_RC2-08.pdf"
"Cevimeline Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020989.pdf","Draft","Oral","Capsule","020989","10/30/2024","PSG_020989.pdf"
"Chenodiol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018513.pdf","Draft","Oral","Tablet","018513","10/30/2024","PSG_018513.pdf"
"Chlorambucil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Chlorambucil_tabs_10669_RC07-10.pdf","Draft","Oral","Tablet","010669","07/28/2010","Chlorambucil_tabs_10669_RC07-10.pdf"
"Chlordiazepoxide Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_012249.pdf","Draft","Oral","Capsule","012249                                                       085475                                                       085461                                                       085472","10/30/2024","PSG_012249.pdf"
"Chlordiazepoxide Hydrochloride; Clidinium Bromide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_012750.pdf","Draft","Oral","Capsule","012750","10/30/2024","PSG_012750.pdf"
"Chlorhexidine Gluconate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017768.pdf","Draft","Topical","Solution","017768","11/16/2023","PSG_017768.pdf"
"Chlorhexidine Gluconate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020774.pdf","Draft","Dental","Tablet","020774","05/19/2022","PSG_020774.pdf"
"Chloroprocaine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_216227.pdf","Draft","Ophthalmic","Gel","216227","08/21/2023","PSG_216227.pdf"
"Chloroquine Phosphate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_006002.pdf","Final","Oral","Tablet","006002","04/13/2020","PSG_006002.pdf"
"Chlorothiazide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_011870.pdf","Draft","Oral","Suspension","011870","10/30/2024","PSG_011870.pdf"
"Chlorpheniramine Maleate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_007638.pdf","Draft","Oral","Tablet, Extended Release","007638","09/16/2019","PSG_007638.pdf"
"Chlorpheniramine Maleate; Ibuprofen; Phenylephrine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022113.pdf","Draft","Oral","Tablet","022113","10/30/2024","PSG_022113.pdf"
"Chlorpheniramine Maleate; Ibuprofen; Pseudoephedrine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021441.pdf","Draft","Oral","Tablet","021441","10/30/2024","PSG_021441.pdf"
"Chlorpheniramine Polistirex; Codeine Polistirex","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Chlorpheniramine_polistirex_Codpoli_207768_RC04-16.pdf","Draft","Oral","Suspension, Extended Release","207768","04/14/2016","Chlorpheniramine_polistirex_Codpoli_207768_RC04-16.pdf"
"Chlorpheniramine Polistirex; Hydrocodone Polistirex","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Chlorpheniramine_Polistirex;_Hydrocodone_Polistirex_susp_19111_RC2-10.pdf","Draft","Oral","Suspension, Extended Release","019111","02/25/2010","Chlorpheniramine_Polistirex;_Hydrocodone_Polistirex_susp_19111_RC2-10.pdf"
"Chlorpheniramine Polistirex; Hydrocodone Polistirex","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Chlorpheniramine_Polistirex;_ Hydrocodone_Plistirex_ERcap_77273_RC12-08.pdf","Draft","Oral","Capsule, Extended Release","077273","12/20/2008","Chlorpheniramine_Polistirex;_ Hydrocodone_Plistirex_ERcap_77273_RC12-08.pdf"
"Chlorpromazine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_009149.pdf","Draft","Oral","Tablet","084112                                                       084114","10/30/2024","PSG_009149.pdf"
"Chlorpromazine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_009149-Con.pdf","Draft","Oral","Concentrate","009149","09/16/2019","PSG_009149-Con.pdf"
"Chlorthalidone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019574.pdf","Draft","Oral","Tablet","019574","10/30/2024","PSG_019574.pdf"
"Chlorthalidone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_012283.pdf","Draft","Oral","Tablet","012283","10/30/2024","PSG_012283.pdf"
"Chlorzoxazone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_011300.pdf","Draft","Oral","Tablet","011300","11/21/2019","PSG_011300.pdf"
"Chlorzoxazone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_011529-Tab-500MG.pdf","Draft","Oral","Tablet  500 mg","011529","11/21/2019","PSG_011529-Tab-500MG.pdf"
"Chlorzoxazone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_011529-Tab-750MG.pdf","Draft","Oral","Tablet  750 mg","011529","10/30/2024","PSG_011529-Tab-750MG.pdf"
"Cholestyramine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Cholestyramine_oral powder_74557 and 74558_RV06-15.pdf","Draft","Oral","Powder","016640                                                       019669","06/24/2015","Cholestyramine_oral powder_74557 and 74558_RV06-15.pdf"
"Cholic Acid","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_205750.pdf","Draft","Oral","Capsule","205750","10/30/2024","PSG_205750.pdf"
"Choline Fenofibrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Copy of Choline_Fenofibrate_DRtabs_22224_RC12-10.pdf","Draft","Oral","Capsule, Delayed Release","022224","12/23/2010","Copy of Choline_Fenofibrate_DRtabs_22224_RC12-10.pdf"
"Ciclesonide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Ciclesonide Nasal Aerosol 202129 RC09-12.pdf","Draft","Nasal","Aerosol, Metered","202129","09/19/2012","Ciclesonide Nasal Aerosol 202129 RC09-12.pdf"
"Ciclesonide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022004.pdf","Draft","Nasal","Spray, Metered","022004","08/21/2023","PSG_022004.pdf"
"Ciclesonide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021658.pdf","Draft","Inhalation","Aerosol, Metered","021658","08/21/2023","PSG_021658.pdf"
"Ciclopirox","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Ciclopirox Topical Suspension NDA 019824 RV Feb 2019.pdf","Draft","Topical","Suspension","019824","02/22/2019","Ciclopirox Topical Suspension NDA 019824 RV Feb 2019.pdf"
"Ciclopirox","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Ciclopirox Topical Cream NDA 018748 RV Feb 2019.pdf","Draft","Topical","Cream","018748","02/22/2019","Ciclopirox Topical Cream NDA 018748 RV Feb 2019.pdf"
"Ciclopirox","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Ciclopirox Topical Gel NDA 020519 RV Feb 2019.pdf","Draft","Topical","Gel","020519","02/22/2019","Ciclopirox Topical Gel NDA 020519 RV Feb 2019.pdf"
"Ciclopirox","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Ciclopirox_shmp_21159_RC2-10.pdf","Draft","Topical","Shampoo","021159","02/25/2010","Ciclopirox_shmp_21159_RC2-10.pdf"
"Ciclopirox","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Ciclopirox_soln_21022_ RC2-10.pdf","Draft","Topical","Solution","021022","02/23/2011","Ciclopirox_soln_21022_ RC2-10.pdf"
"Cilastatin Sodium; Imipenem; Relebactam","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212819.pdf","Draft","Intravenous","Powder","212819","07/15/2021","PSG_212819.pdf"
"Cilostazol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Cilostazol_tab_20863_RC10-05.pdf","Final","Oral","Tablet","020863","05/01/2008","Cilostazol_tab_20863_RC10-05.pdf"
"Cimetidine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017920.pdf","Draft","Oral","Tablet","017920","10/30/2024","PSG_017920.pdf"
"Cinacalcet Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021688.pdf","Draft","Oral","Tablet","021688","10/30/2024","PSG_021688.pdf"
"Ciprofloxacin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020780.pdf","Draft","Oral","For Suspension","020780","10/30/2024","PSG_020780.pdf"
"Ciprofloxacin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Ciprofloxacin_draft_Otic susp injec_RLD 207986_RC07-18.pdf","Draft","Otic","Suspension, Injectable","207986","07/20/2018","Ciprofloxacin_draft_Otic susp injec_RLD 207986_RC07-18.pdf"
"Ciprofloxacin hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Ciprofloxacin_HCl_draft_Ophthalmic ointment_RLD_020369_RC09-18.pdf","Draft","Ophthalmic","Ointment","020369","09/13/2018","Ciprofloxacin_HCl_draft_Ophthalmic ointment_RLD_020369_RC09-18.pdf"
"Ciprofloxacin Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Ciprofloxacin hydrochloride_ophthalmic solution_NDA 019992_RV08-17.pdf","Draft","Ophthalmic","Solution/Drops","019992","10/19/2017","Ciprofloxacin hydrochloride_ophthalmic solution_NDA 019992_RV08-17.pdf"
"Ciprofloxacin Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019537.pdf","Draft","Oral","Tablet","019537","10/30/2024","PSG_019537.pdf"
"Ciprofloxacin Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Ciprofloxacin_HCl_ERtab_21744_RC11-07.pdf","Draft","Oral","Tablet, Extended Release","021744","11/01/2007","Ciprofloxacin_HCl_ERtab_21744_RC11-07.pdf"
"Ciprofloxacin Hydrochloride; Hydrocortisone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020805.pdf","Draft","Otic","Suspension/Drops","020805","08/22/2024","PSG_020805.pdf"
"Ciprofloxacin; Ciprofloxacin Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Ciprofloxacin; Ciprofloxacin Hydrochloride_ERtab_21473_RC1-08.pdf","Draft","Oral","Tablet, Extended Release","021473","02/23/2008","Ciprofloxacin; Ciprofloxacin Hydrochloride_ERtab_21473_RC1-08.pdf"
"Ciprofloxacin; Dexamethasone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021537.pdf","Draft","Otic","Suspension/Drops","021537","08/22/2024","PSG_021537.pdf"
"Citalopram Hydrobromide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_077668.pdf","Draft","Oral","Capsule","077668","10/30/2024","PSG_077668.pdf"
"Citalopram Hydrobromide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020822.pdf","Draft","Oral","Tablet","020822","10/30/2024","PSG_020822.pdf"
"Citalopram Hydrobromide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215428.pdf","Draft","Oral","Capsule","215428","10/30/2024","PSG_215428.pdf"
"Citric Acid; Lactic Acid; Potassium Bitartrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208352.pdf","Draft","Vaginal","Gel","208352","05/18/2023","PSG_208352.pdf"
"Cladribine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022561.pdf","Draft","Oral","Tablet","022561","08/22/2024","PSG_022561.pdf"
"Clarithromycin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050662.pdf","Draft","Oral","Tablet","050662","10/30/2024","PSG_050662.pdf"
"Clarithromycin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Clarithromycin_ERtab_50775_RC1-08.pdf","Draft","Oral","Tablet, Extended Release","050775","02/23/2008","Clarithromycin_ERtab_50775_RC1-08.pdf"
"Clarithromycin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050698.pdf","Draft","Oral","For Suspension","050698","10/30/2024","PSG_050698.pdf"
"Clascoterone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213433.pdf","Draft","Topical","Cream","213433","08/21/2023","PSG_213433.pdf"
"Clemastine Fumarate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017661.pdf","Draft","Oral","Tablet","017661","10/30/2024","PSG_017661.pdf"
"Clemastine Fumarate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020925.pdf","Draft","Oral","Tablet","020925","10/30/2024","PSG_020925.pdf"
"Clevidipine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022156.pdf","Draft","Intravenous","Emulsion","022156","03/02/2020","PSG_022156.pdf"
"Clindamycin Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050162.pdf","Draft","Oral","Capsule","050162","10/30/2024","PSG_050162.pdf"
"Clindamycin Phosphate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Clindamycin_Phosphate_crm_50680_RC03-12.pdf","Draft","Vaginal","Cream","050680","03/28/2012","Clindamycin_Phosphate_crm_50680_RC03-12.pdf"
"Clindamycin Phosphate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Clindamycin_Phosphate_crm_50793_RC03-12.pdf","Draft","Vaginal","Cream","050793","03/28/2012","Clindamycin_Phosphate_crm_50793_RC03-12.pdf"
"Clindamycin Phosphate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Clindamycin_Phosphate_supp_50767_RC03-12.pdf","Draft","Vaginal","Suppository","050767","03/28/2012","Clindamycin_Phosphate_supp_50767_RC03-12.pdf"
"Clindamycin Phosphate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050615.pdf","Draft","Topical","Gel","050615","10/21/2022","PSG_050615.pdf"
"Clindamycin Phosphate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050782.pdf","Draft","Topical","Gel","050782","10/21/2022","PSG_050782.pdf"
"Clindamycin Phosphate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050537-Sol.pdf","Draft","Topical","Solution","050537","06/03/2020","PSG_050537-Sol.pdf"
"Clindamycin Phosphate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050537-Swa.pdf","Draft","Topical","Swab","050537","06/03/2020","PSG_050537-Swa.pdf"
"Clindamycin Phosphate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050801.pdf","Draft","Topical","Aerosol, Foam","050801","06/03/2020","PSG_050801.pdf"
"Clindamycin Phosphate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215650.pdf","Draft","Vaginal","Gel","215650","11/17/2022","PSG_215650.pdf"
"Clindamycin Phosphate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050600.pdf","Draft","Topical","Lotion","050600","11/21/2023","PSG_050600.pdf"
"Clindamycin Phosphate; Tretinoin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050802.pdf","Draft","Topical","Gel","050802","10/21/2022","PSG_050802.pdf"
"Clindamycin Phosphate; Tretinoin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050803.pdf","Draft","Topical","Gel","050803","10/21/2022","PSG_050803.pdf"
"Clobazam","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210833.pdf","Draft","Oral","Film","210833","11/18/2020","PSG_210833.pdf"
"Clobazam","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_203993.pdf","Draft","Oral","Suspension","203993","10/30/2024","PSG_203993.pdf"
"Clobazam","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202067.pdf","Draft","Oral","Tablet","202067","10/30/2024","PSG_202067.pdf"
"Clobetasol Propionate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Clobetasol Propionate_Emollient Cream 0.05_RLD 75430_RC09-16.pdf","Draft","Topical","Cream","020340","10/04/2016","Clobetasol Propionate_Emollient Cream 0.05_RLD 75430_RC09-16.pdf"
"Clobetasol Propionate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Clobetasol Propionate_topical gel 0.05_RLD 75368_RC09-16.pdf","Draft","Topical","Gel","020337","10/04/2016","Clobetasol Propionate_topical gel 0.05_RLD 75368_RC09-16.pdf"
"Clobetasol Propionate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Clobetasol propionate_topical cream_RLD 74220_RC04-16.pdf","Draft","Topical","Cream","019322","04/14/2016","Clobetasol propionate_topical cream_RLD 74220_RC04-16.pdf"
"Clobetasol Propionate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Clobetasol propionate_topical lotion_RLD 21535_RC04-16.pdf","Draft","Topical","Lotion","021535","04/14/2016","Clobetasol propionate_topical lotion_RLD 21535_RC04-16.pdf"
"Clobetasol Propionate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Clobetasol_Propionate_fmaerosol_21142_RC2-11.pdf","Draft","Topical","Aerosol, Foam","021142","02/23/2011","Clobetasol_Propionate_fmaerosol_21142_RC2-11.pdf"
"Clobetasol Propionate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Clobetasol_Propionate_shmp_21644_RC2-11.pdf","Draft","Topical","Shampoo","021644","02/23/2011","Clobetasol_Propionate_shmp_21644_RC2-11.pdf"
"Clobetasol Propionate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Clobetasol_Propionate_spray_21835_RC2-11.pdf","Draft","Topical","Spray","021835","02/23/2011","Clobetasol_Propionate_spray_21835_RC2-11.pdf"
"Clobetasol Propionate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Clobetasol_Propionate_sol_19966_RC08-10.pdf","Draft","Topical","Solution","019966","08/30/2010","Clobetasol_Propionate_sol_19966_RC08-10.pdf"
"Clobetasol Propionate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Clobetasol propionate_topical ointment_RLD 019323_RC01-16.pdf","Draft","Topical","Ointment","019323","01/27/2016","Clobetasol propionate_topical ointment_RLD 019323_RC01-16.pdf"
"Clobetasol Propionate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022013.pdf","Draft","Topical","Aerosol, Foam","022013","11/18/2020","PSG_022013.pdf"
"Clobetasol Propionate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213691.pdf","Draft","Topical","Lotion","213691","05/18/2023","PSG_213691.pdf"
"Clocortolone Pivalate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Clocortolone pivalate_topical cream_ NDA 017765_RC05-17.pdf","Draft","Topical","Cream","017765","07/13/2017","Clocortolone pivalate_topical cream_ NDA 017765_RC05-17.pdf"
"Clomiphene Citrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_016131.pdf","Draft","Oral","Tablet","016131","10/30/2024","PSG_016131.pdf"
"Clomipramine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019906.pdf","Draft","Oral","Capsule","019906","10/30/2024","PSG_019906.pdf"
"Clonazepam","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020813.pdf","Draft","Oral","Tablet, Orally Disintegrating","020813","10/30/2024","PSG_020813.pdf"
"Clonazepam","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017533.pdf","Draft","Oral","Tablet","017533","10/30/2024","PSG_017533.pdf"
"Clonazepam","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017533-Sus.pdf","Draft","Oral","Suspension","017533","11/19/2024","PSG_017533-Sus.pdf"
"Clonidine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Clonidine_ERtab_22500_RC08-10.pdf","Draft","Oral","Tablet, Extended Release","022500","08/30/2010","Clonidine_ERtab_22500_RC08-10.pdf"
"Clonidine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018891.pdf","Draft","Transdermal","Film, Extended Release","018891","11/21/2019","PSG_018891.pdf"
"Clonidine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Clonidine hydrochloride_oral tablet_022331_RC09-15.pdf","Draft","Oral","Tablet, Extended Release","022331","09/18/2015","Clonidine hydrochloride_oral tablet_022331_RC09-15.pdf"
"Clonidine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017407.pdf","Draft","Oral","Tablet","017407","10/30/2024","PSG_017407.pdf"
"Clopidogrel Bisulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020839.pdf","Draft","Oral","Tablet","020839","10/30/2024","PSG_020839.pdf"
"Clorazepate Dipotassium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017105.pdf","Draft","Oral","Tablet","017105","10/30/2024","PSG_017105.pdf"
"Clotrimazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Clotrimazole Topical Solution NDA 018181 RV Feb 2019.pdf","Draft","Topical","Solution","018181","02/22/2019","Clotrimazole Topical Solution NDA 018181 RV Feb 2019.pdf"
"Clotrimazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Clotrimazole Topical Cream ANDA 072640 RV Feb 2019.pdf","Draft","Topical","Cream","072640                                                       017619","02/22/2019","Clotrimazole Topical Cream ANDA 072640 RV Feb 2019.pdf"
"Clotrimazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Clotrimazole Vaginal Cream NDA 018052 RV Feb 2019.pdf","Draft","Vaginal","Cream","018052","02/22/2019","Clotrimazole Vaginal Cream NDA 018052 RV Feb 2019.pdf"
"Clotrimazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Clotrimazole Vaginal Cream NDA 020574 RV Feb 2019.pdf","Draft","Vaginal","Cream","020574","02/22/2019","Clotrimazole Vaginal Cream NDA 020574 RV Feb 2019.pdf"
"Clotrimazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Clotrimazole Vaginal Tablet NDA 017717 RV Feb 2019.pdf","Draft","Vaginal","Tablet","017717","02/22/2019","Clotrimazole Vaginal Tablet NDA 017717 RV Feb 2019.pdf"
"Clotrimazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Clotrimazole Vaginal Tablet NDA 020525 RV Feb 2019.pdf","Draft","Vaginal","Tablet","020525","02/22/2019","Clotrimazole Vaginal Tablet NDA 020525 RV Feb 2019.pdf"
"Clotrimazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Clotrimazole_loz_18713_RC9-08.pdf","Draft","Oral","Troche/Lozenge","018713","09/01/2008","Clotrimazole_loz_18713_RC9-08.pdf"
"Clozapine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_203479.pdf","Draft","Oral","Suspension","203479","02/17/2022","PSG_203479.pdf"
"Clozapine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019758.pdf","Draft","Oral","Tablet","019758","02/17/2022","PSG_019758.pdf"
"Clozapine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021590.pdf","Draft","Oral","Tablet, Orally Disintegrating","021590","02/17/2022","PSG_021590.pdf"
"Cobicistat","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_203094.pdf","Draft","Oral","Tablet","203094","10/30/2024","PSG_203094.pdf"
"Cobicistat; Darunavir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Cobicistat; Darunavir ethanolate_oral tablet_RLD 205395_RV12-16.pdf","Draft","Oral","Tablet","205395","12/22/2016","Cobicistat; Darunavir ethanolate_oral tablet_RLD 205395_RV12-16.pdf"
"Cobicistat; Darunavir; Emtricitabine; Tenofovir Alafenamide Fumarate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210455.pdf","Draft","Oral","Tablet","210455","08/02/2022","PSG_210455.pdf"
"Cobicistat; Elvitegravir; Emtricitabine; Tenofovir Alafenamide Fumarate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Cobicistat; ElviteNDA 207561_RV08-17.pdf","Draft","Oral","Tablet","207561","10/19/2017","Cobicistat; ElviteNDA 207561_RV08-17.pdf"
"Cobicistat; Elvitegravir; Emtricitabine; Tenofovir Disoproxil Fumarate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Cobicistat_Elvitegravir..._203100_RC12-14.pdf","Draft","Oral","Tablet","203100","12/29/2014","Cobicistat_Elvitegravir..._203100_RC12-14.pdf"
"Cobimetinib Fumarate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_206192.pdf","Draft","Oral","Tablet","206192","10/30/2024","PSG_206192.pdf"
"Cocaine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209963.pdf","Draft","Nasal","Solution","209963","12/13/2019","PSG_209963.pdf"
"Cocaine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209575.pdf","Draft","Nasal","Solution","209575","05/19/2022","PSG_209575.pdf"
"Colchicine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_204820.pdf","Draft","Oral","Capsule","204820","10/30/2024","PSG_204820.pdf"
"Colchicine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022352.pdf","Draft","Oral","Tablet","022352","10/30/2024","PSG_022352.pdf"
"Colesevelam Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021176.pdf","Draft","Oral","Tablet","021176","11/08/2021","PSG_021176.pdf"
"Colesevelam Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022362.pdf","Draft","Oral","For Suspension","022362","11/08/2021","PSG_022362.pdf"
"Colesevelam Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210895.pdf","Draft","Oral","Bar, Chewable","210895","11/08/2021","PSG_210895.pdf"
"Colestipol Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Colestipol_Hydrochloride_tab_20222_RC07-14.pdf","Draft","Oral","Tablet","020222","07/22/2014","Colestipol_Hydrochloride_tab_20222_RC07-14.pdf"
"Copper","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018680.pdf","Draft","Intrauterine","Intrauterine Device","018680","11/21/2019","PSG_018680.pdf"
"Copper Dotatate Cu-64","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213227.pdf","Draft","Intravenous","Solution","213227","08/20/2021","PSG_213227.pdf"
"Crisaborole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_207695.pdf","Draft","Topical","Ointment","207695","10/21/2022","PSG_207695.pdf"
"Crizotinib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202570.pdf","Draft","Oral","Capsule","202570","10/30/2024","PSG_202570.pdf"
"Crofelemer","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202292.pdf","Draft","Oral","Tablet, Delayed Release","202292","11/18/2020","PSG_202292.pdf"
"Crotamiton","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_006927.pdf","Draft","Topical","Cream","006927","10/21/2022","PSG_006927.pdf"
"Crotamiton","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_009112.pdf","Draft","Topical","Lotion","009112","10/21/2022","PSG_009112.pdf"
"Cyanocobalamin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Cyanocobalamin_nasal metered spray_NDA 021642_RC05-17.pdf","Draft","Nasal","Spray","021642","07/13/2017","Cyanocobalamin_nasal metered spray_NDA 021642_RC05-17.pdf"
"Cyclobenzaprine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017821.pdf","Draft","Oral","Tablet","017821","10/30/2024","PSG_017821.pdf"
"Cyclobenzaprine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Cyclobenzaprine HCl_oral tablet _RLD 17821_final 08-17.pdf","Draft","Oral","Capsule, Extended Release","021777","11/23/2016","Cyclobenzaprine HCl_oral tablet _RLD 17821_final 08-17.pdf"
"Cyclophosphamide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Cyclophosphamide_oral tablet_040032_RV09-15.pdf","Draft","Oral","Tablet","040032","09/18/2015","Cyclophosphamide_oral tablet_040032_RV09-15.pdf"
"Cyclophosphamide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Cyclophosphamide_oral capsule_203856_RC06-15.pdf","Draft","Oral","Capsule","203856","06/24/2015","Cyclophosphamide_oral capsule_203856_RC06-15.pdf"
"Cycloserine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_060593.pdf","Draft","Oral","Capsule","060593","10/30/2024","PSG_060593.pdf"
"Cyclosporine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Cyclosporine_Oral capsule_RLD 050625_RV04-16.pdf","Draft","Oral","Capsule","050625","04/14/2016","Cyclosporine_Oral capsule_RLD 050625_RV04-16.pdf"
"Cyclosporine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Cyclosporine_Oral capsule_RLD 050715_RV04-16.pdf","Draft","Oral","Capsule","050715","04/14/2016","Cyclosporine_Oral capsule_RLD 050715_RV04-16.pdf"
"Cyclosporine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Cyclosporine_ophthalmic emulsion_RLD 050790_RV09-16.pdf","Draft","Ophthalmic","Emulsion","050790","10/04/2016","Cyclosporine_ophthalmic emulsion_RLD 050790_RV09-16.pdf"
"Cyclosporine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_217469.pdf","Draft","Ophthalmic","Solution","217469","11/19/2024","PSG_217469.pdf"
"Cyclosporine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Cyclosporine ophthalmic solution 0.09 NDA 210913 PSG Page RC May 2019.pdf","Draft","Ophthalmic","Solution/Drops","210913","05/15/2019","Cyclosporine ophthalmic solution 0.09 NDA 210913 PSG Page RC May 2019.pdf"
"Cyclosporine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214965.pdf","Draft","Ophthalmic","Emulsion","214965","08/02/2022","PSG_214965.pdf"
"Cyproheptadine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Cyproheptadine hydrochloride_Oral tablet_087056_RC06-15.pdf","Draft","Oral","Tablet","012649","06/24/2015","Cyproheptadine hydrochloride_Oral tablet_087056_RC06-15.pdf"
"Cysteamine Bitartrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Cysteamine bitartrate_oral DR capsule_NDA 203389_RV11-17.pdf","Draft","Oral","Capsule, Delayed Release","203389","02/08/2018","Cysteamine bitartrate_oral DR capsule_NDA 203389_RV11-17.pdf"
"Cysteamine Bitartrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213491.pdf","Draft","Oral","Granule, Delayed Release","213491","03/24/2021","PSG_213491.pdf"
"Cytarabine; Daunorubicin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209401.pdf","Draft","Intravenous","Powder","209401","08/02/2022","PSG_209401.pdf"
"Dabigatran Etexilate Mesylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Dabigatran etexilate mesylate_oral capsule_NDA 022512_RV05-17.pdf","Draft","Oral","Capsule","022512","07/13/2017","Dabigatran etexilate mesylate_oral capsule_NDA 022512_RV05-17.pdf"
"Dabrafenib Mesylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Dabrafenib mesylate_oral capsule_202806_RC06-15.pdf","Draft","Oral","Capsule","202806","06/24/2015","Dabrafenib mesylate_oral capsule_202806_RC06-15.pdf"
"Daclatasvir Dihydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_206843.pdf","Draft","Oral","Tablet","206843","10/30/2024","PSG_206843.pdf"
"Dacomitinib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211288.pdf","Draft","Oral","Tablet","211288","10/30/2024","PSG_211288.pdf"
"Dalfampridine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022250.pdf","Draft","Oral","Tablet, Extended Release","022250","08/22/2024","PSG_022250.pdf"
"Dalteparin Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Dalteparin_Inj_20287_RC09-12.pdf","Draft","Subcutaneous","Injectable","020287","09/19/2012","Dalteparin_Inj_20287_RC09-12.pdf"
"Danazol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Danazol_cap_74582_RC10-05.pdf","Final","Oral","Capsule","074582","05/01/2008","Danazol_cap_74582_RC10-05.pdf"
"Dantrolene Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_205579.pdf","Draft","Intravenous","For Suspension","205579","08/02/2022","PSG_205579.pdf"
"Dantrolene Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017443.pdf","Draft","Oral","Capsule","017443","10/30/2024","PSG_017443.pdf"
"Dapagliflozin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202293.pdf","Draft","Oral","Tablet","202293","10/30/2024","PSG_202293.pdf"
"Dapagliflozin; Metformin Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_205649.pdf","Draft","Oral","Tablet, Extended Release","205649","08/22/2024","PSG_205649.pdf"
"Dapagliflozin; Metformin Hydrochloride; Saxagliptin Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210874.pdf","Draft","Oral","Tablet, Extended Release","210874","03/02/2020","PSG_210874.pdf"
"Dapagliflozin; Saxagliptin Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209091.pdf","Draft","Oral","Tablet","209091","10/30/2024","PSG_209091.pdf"
"Daprodustat","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_216951.pdf","Draft","Oral","Tablet","216951","10/30/2024","PSG_216951.pdf"
"Dapsone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_207154.pdf","Draft","Topical","Gel","207154","02/15/2024","PSG_207154.pdf"
"Dapsone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_086841.pdf","Draft","Oral","Tablet","086841                                                       086842","10/30/2024","PSG_086841.pdf"
"Dapsone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021794.pdf","Draft","Topical","Gel","021794","02/15/2024","PSG_021794.pdf"
"Daptomycin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/DAPTOMYCIN IV infusion powder NDA 209949 & NDA 208385 Page Feb 2019.pdf","Draft","IV Infusion","Powder","209949                                                       208385","02/22/2019","DAPTOMYCIN IV infusion powder NDA 209949 & NDA 208385 Page Feb 2019.pdf"
"Daridorexant Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214985.pdf","Draft","Oral","Tablet","214985","08/21/2023","PSG_214985.pdf"
"Darifenacin Hydrobromide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Darifenacin_HBr_ERtab_21513_RC8-05.pdf","Final","Oral","Tablet, Extended Release","021513","05/12/2008","Darifenacin_HBr_ERtab_21513_RC8-05.pdf"
"Darolutamide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212099.pdf","Draft","Oral","Tablet","212099","10/30/2024","PSG_212099.pdf"
"Darunavir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021976.pdf","Draft","Oral","Tablet","021976","10/30/2024","PSG_021976.pdf"
"Darunavir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202895.pdf","Draft","Oral","Suspension","202895","10/30/2024","PSG_202895.pdf"
"Dasabuvir Sodium; Ombitasvir; Paritaprevir; Ritonavir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/DasabuvirNa; Ombitasvir; Paritaprevir; Ritonavir_RC05-17.pdf","Draft","Oral","Tablet, Extended Release","208624","07/13/2017","DasabuvirNa; Ombitasvir; Paritaprevir; Ritonavir_RC05-17.pdf"
"Dasabuvir Sodium;Ombitasvir;Paritaprevir;Ritonavir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Obitasvir_paritaprevir_ritonavir_dasabuvir_oral tablet_206619_RC09-15.pdf","Draft","Oral","Tablet, Tablet","206619","09/18/2015","Obitasvir_paritaprevir_ritonavir_dasabuvir_oral tablet_206619_RC09-15.pdf"
"Dasatinib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021986.pdf","Draft","Oral","Tablet","021986","10/30/2024","PSG_021986.pdf"
"Dasiglucagon Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214231.pdf","Draft","Subcutaneous","Solution","214231","08/02/2022","PSG_214231.pdf"
"Daunorubicin Citrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050704.pdf","Draft","Injection","Injectable, Liposomal","050704","11/17/2022","PSG_050704.pdf"
"Deferasirox","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Deferasirox_oral tablet_RLD 206910_RC04-16.pdf","Draft","Oral","Tablet","206910","04/14/2016","Deferasirox_oral tablet_RLD 206910_RC04-16.pdf"
"Deferasirox","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Deferasirox_susp_21882_RC5-06.pdf","Final","Oral","Tablet, For Suspension","021882","05/12/2008","Deferasirox_susp_21882_RC5-06.pdf"
"Deferasirox","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Deferasirox_draft_Oral gran_RLD 207968_RC07-18.pdf","Draft","Oral","Granule","207968","07/20/2018","Deferasirox_draft_Oral gran_RLD 207968_RC07-18.pdf"
"Deferiprone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212269.pdf","Draft","Oral","Tablet","212269","11/17/2022","PSG_212269.pdf"
"Deferiprone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021825.pdf","Draft","Oral","Tablet","021825","10/30/2024","PSG_021825.pdf"
"Defibrotide Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208114.pdf","Draft","Intravenous","Solution","208114","05/18/2023","PSG_208114.pdf"
"Deflazacort","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208685.pdf","Draft","Oral","Suspension","208685","10/30/2024","PSG_208685.pdf"
"Deflazacort","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208684.pdf","Draft","Oral","Tablet","208684","10/30/2024","PSG_208684.pdf"
"Degarelix Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022201.pdf","Draft","Subcutaneous","Powder","022201","03/24/2021","PSG_022201.pdf"
"Delafloxacin Meglumine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208610.pdf","Draft","Oral","Tablet","208610","10/30/2024","PSG_208610.pdf"
"Delavirdine Mesylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020705.pdf","Draft","Oral","Tablet","020705","10/30/2024","PSG_020705.pdf"
"Demeclocycline Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Demeclocycline_HCl_tab_50261_RC10-08.pdf","Draft","Oral","Tablet","050261","10/01/2008","Demeclocycline_HCl_tab_50261_RC10-08.pdf"
"Desipramine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_014399.pdf","Draft","Oral","Tablet","014399","10/30/2024","PSG_014399.pdf"
"Desloratadine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021165.pdf","Draft","Oral","Tablet","021165","10/30/2024","PSG_021165.pdf"
"Desloratadine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021312.pdf","Draft","Oral","Tablet, Orally Disintegrating","021312","10/30/2024","PSG_021312.pdf"
"Desloratadine; Pseudoephedrine Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Desloratadine_Pseudoephedrine_Oral_Extended_Release_Tablet_NDA_021313_PSG_Page_RC_May_2019.pdf","Draft","Oral","Tablet, Extended Release","021313","05/15/2019","Desloratadine_Pseudoephedrine_Oral_Extended_Release_Tablet_NDA_021313_PSG_Page_RC_May_2019.pdf"
"Desmopressin Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Desmopressin acetate Sublingual Tablets NDA 022517 PSG Page RC May 2019.pdf","Draft","Sublingual","Tablet","022517","05/15/2019","Desmopressin acetate Sublingual Tablets NDA 022517 PSG Page RC May 2019.pdf"
"Desmopressin Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019955.pdf","Draft","Oral","Tablet","019955","10/30/2024","PSG_019955.pdf"
"Desogestrel; Ethinyl Estradiol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020071.pdf","Draft","Oral","Tablet","020301","10/30/2024","PSG_020071.pdf"
"Desogestrel; Ethinyl Estradiol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021090.pdf","Draft","Oral","Tablet","021090","10/30/2024","PSG_021090.pdf"
"Desogestrel; Ethinyl Estradiol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020713.pdf","Draft","Oral","Tablet","020713","10/30/2024","PSG_020713.pdf"
"Desonide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Desonide_topical ointment_RLD 017426_RC09-16.pdf","Draft","Topical","Ointment","017426","10/04/2016","Desonide_topical ointment_RLD 017426_RC09-16.pdf"
"Desonide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Desonide_topical cream_RLD 017010_RC01-16.pdf","Draft","Topical","Cream","017010","01/27/2016","Desonide_topical cream_RLD 017010_RC01-16.pdf"
"Desonide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Desonide_topical lotion_RLD 072354_RC01-16.pdf","Draft","Topical","Lotion","072354","01/27/2016","Desonide_topical lotion_RLD 072354_RC01-16.pdf"
"Desonide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021978.pdf","Draft","Topical","Aerosol, Foam","021978","11/18/2020","PSG_021978.pdf"
"Desonide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Desonide_draft_Topical gel_RLD 021844_RC09-18.pdf","Draft","Topical","Gel","021844","09/13/2018","Desonide_draft_Topical gel_RLD 021844_RC09-18.pdf"
"Desoximetasone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Desoximetasone_topical spray 0.25_204141_RC03-15.pdf","Draft","Topical","Spray","204141","03/06/2015","Desoximetasone_topical spray 0.25_204141_RC03-15.pdf"
"Desoximetasone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Desoximetasone_cream_073210_073193_RC02-14.pdf","Draft","Topical","Cream","017856                                                       018309","04/01/2014","Desoximetasone_cream_073210_073193_RC02-14.pdf"
"Desoximetasone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Desoximetasone_ointment_18594_74286_RC02-14.pdf","Draft","Topical","Ointment","018594                                                       018763","04/01/2014","Desoximetasone_ointment_18594_74286_RC02-14.pdf"
"Desvenlafaxine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_204150.pdf","Draft","Oral","Tablet, Extended Release","204150","06/03/2020","PSG_204150.pdf"
"Desvenlafaxine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_204683.pdf","Draft","Oral","Tablet, Extended Release","204683","06/03/2020","PSG_204683.pdf"
"Desvenlafaxine Fumarate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_205583.pdf","Draft","Oral","Tablet, Extended Release","205583","06/03/2020","PSG_205583.pdf"
"Desvenlafaxine Succinate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021992.pdf","Draft","Oral","Tablet, Extended Release","021992","06/03/2020","PSG_021992.pdf"
"Deucravacitinib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214958.pdf","Draft","Oral","Tablet","214958","11/16/2023","PSG_214958.pdf"
"Deutetrabenazine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_216354.pdf","Draft","Oral","Tablet, Extended Release","216354","11/16/2023","PSG_216354.pdf"
"Deutetrabenazine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Deutetrabenazine_draft_Oral tab_RLD 208082_RC09-18.pdf","Draft","Oral","Tablet","208082","09/13/2018","Deutetrabenazine_draft_Oral tab_RLD 208082_RC09-18.pdf"
"Dexamethasone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Dexamethasone Oral Concentrate Solution ANDA 088252 RC Feb 2019.pdf","Draft","Oral","Concentrate","088252","02/22/2019","Dexamethasone Oral Concentrate Solution ANDA 088252 RC Feb 2019.pdf"
"Dexamethasone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_011664.pdf","Draft","Oral","Tablet","011664","10/30/2024","PSG_011664.pdf"
"Dexamethasone; Neomycin Sulfate; Polymyxin B Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050023.pdf","Draft","Ophthalmic","Suspension/Drops","050023","02/15/2024","PSG_050023.pdf"
"Dexamethasone; Tobramycin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050616.pdf","Draft","Ophthalmic","Ointment","050616","02/15/2024","PSG_050616.pdf"
"Dexamethasone; Tobramycin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050818.pdf","Draft","Ophthalmic","Suspension/Drops","050818","02/15/2024","PSG_050818.pdf"
"Dexamethasone; Tobramycin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050592.pdf","Draft","Ophthalmic","Suspension/Drops","050592","02/15/2024","PSG_050592.pdf"
"Dexamethsone; Neomycin Sulfate; Polymyxin B Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050065.pdf","Draft","Ophthalmic","Ointment","050065","11/19/2024","PSG_050065.pdf"
"Dexbrompheniramine Maleate; Pseudoephedrine Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Dexbrompheniramine maleate Pseudoephedrine sulfate_078648_RC06-15.pdf","Draft","Oral","Tablet, Extended Release","013483","06/24/2015","Dexbrompheniramine maleate Pseudoephedrine sulfate_078648_RC06-15.pdf"
"Dexlansoprazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Dexlansoprazole_orally disintegrating DR tablet_NDA 208056_RV11-17.pdf","Draft","Oral","Tablet, Orally Disintegrating, Delayed Release","208056","02/08/2018","Dexlansoprazole_orally disintegrating DR tablet_NDA 208056_RV11-17.pdf"
"Dexlansoprazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Dexlansoprazole_oral DR capsule_NDA 022287_RV11-17.pdf","Draft","Oral","Capsule, Delayed Release","022287","02/08/2018","Dexlansoprazole_oral DR capsule_NDA 022287_RV11-17.pdf"
"Dexmethylphenidate Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021278.pdf","Draft","Oral","Tablet","021278","10/30/2024","PSG_021278.pdf"
"Dexmethylphenidate Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Dexmethylphenidate HCL_Oral ER cap_21802_RV03-15.pdf","Draft","Oral","Capsule, Extended Release","021802","03/06/2015","Dexmethylphenidate HCL_Oral ER cap_21802_RV03-15.pdf"
"Dexmethylphenidate Hydrochloride; Serdexmethylphenidate Chloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212994.pdf","Draft","Oral","Capsule","212994","10/30/2024","PSG_212994.pdf"
"Dextroamphetamine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215401.pdf","Draft","Transdermal","System","215401","11/16/2023","PSG_215401.pdf"
"Dextroamphetamine Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Dextroamphetamine Sulfate_Oral ER Cap_017078_RV03-15.pdf","Draft","Oral","Capsule, Extended Release","017078","03/06/2015","Dextroamphetamine Sulfate_Oral ER Cap_017078_RV03-15.pdf"
"Dextroamphetamine Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Dextroamphetamine sulfate_oral tablet_ANDA 040361_RC05-17.pdf","Draft","Oral","Tablet","040361","07/13/2017","Dextroamphetamine sulfate_oral tablet_ANDA 040361_RC05-17.pdf"
"Dextromethorphan Hydrobromide; Guaifenesin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Dextromethorphan_Hydrobromide;_Guaifenesin_ERtab_21620_RC12-08.pdf","Draft","Oral","Tablet, Extended Release","021620","12/20/2008","Dextromethorphan_Hydrobromide;_Guaifenesin_ERtab_21620_RC12-08.pdf"
"Dextromethorphan Hydrobromide; Quinidine Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021879.pdf","Draft","Oral","Capsule","021879","10/30/2024","PSG_021879.pdf"
"Dextromethorphan Polistirex","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Dextromethorphan_Polistirex_ERsusp_18658_RC10-05.pdf","Final","Oral","Suspension, Extended Release","018658","05/12/2008","Dextromethorphan_Polistirex_ERsusp_18658_RC10-05.pdf"
"Diazepam","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Diazepam_Rectal_gel_20648_RC08-10.pdf","Draft","Rectal","Gel","020648","07/28/2010","Diazepam_Rectal_gel_20648_RC08-10.pdf"
"Diazepam","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211635.pdf","Draft","Nasal","Spray","211635","02/15/2024","PSG_211635.pdf"
"Diazepam","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_013263.pdf","Draft","Oral","Tablet","013263","10/30/2024","PSG_013263.pdf"
"Diazoxide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017453.pdf","Draft","Oral","Suspension","017453","10/30/2024","PSG_017453.pdf"
"Dichlorphenamide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_011366.pdf","Draft","Oral","Tablet","011366","10/30/2024","PSG_011366.pdf"
"Diclofenac","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_204592.pdf","Draft","Oral","Capsule","204592","10/30/2024","PSG_204592.pdf"
"Diclofenac Epolamine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021234.pdf","Draft","Topical","System","021234","08/21/2023","PSG_021234.pdf"
"Diclofenac Potassium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022202.pdf","Draft","Oral","Capsule","022202","10/30/2024","PSG_022202.pdf"
"Diclofenac Potassium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020142.pdf","Draft","Oral","Tablet","020142","10/30/2024","PSG_020142.pdf"
"Diclofenac Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Diclofenac sodium_topical solution_NDA 204623_RC05-17.pdf","Draft","Topical","Solution","204623","07/13/2017","Diclofenac sodium_topical solution_NDA 204623_RC05-17.pdf"
"Diclofenac Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Diclofenac_ Sodium_sol_top_20947_RC04-11.pdf","Draft","Topical","Solution","020947","06/30/2011","Diclofenac_ Sodium_sol_top_20947_RC04-11.pdf"
"Diclofenac Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022122.pdf","Draft","Topical","Gel","022122","10/21/2022","PSG_022122.pdf"
"Diclofenac Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021005.pdf","Draft","Topical","Gel","021005","10/21/2022","PSG_021005.pdf"
"Diclofenac Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Diclofenac_Sodium_DRtab_19201_74376_RC10-09.pdf","Draft","Oral","Tablet, Delayed Release","019201","10/01/2009","Diclofenac_Sodium_DRtab_19201_74376_RC10-09.pdf"
"Diclofenac Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Diclofenac_Sodium_ERtab_20254_RC10-09.pdf","Draft","Oral","Tablet, Extended Release","020254","10/01/2009","Diclofenac_Sodium_ERtab_20254_RC10-09.pdf"
"Diclofenac Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Diclofenac sodium_ophthalmic solution_NDA 020037_RV08-17.pdf","Draft","Ophthalmic","Solution/Drops","020037","10/19/2017","Diclofenac sodium_ophthalmic solution_NDA 020037_RV08-17.pdf"
"Diclofenac Sodium; Misoprostol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Diclofenac_Sodium;_Misoprostol_ DRtab_20607_ RC2-02.pdf","Draft","Oral","Tablet, Delayed Release","020607","12/23/2009","Diclofenac_Sodium;_Misoprostol_ DRtab_20607_ RC2-02.pdf"
"Dicloxacillin Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Dicloxacillin_cap_62286_RC6-05.pdf","Final","Oral","Capsule","061454","05/01/2008","Dicloxacillin_cap_62286_RC6-05.pdf"
"Dicyclomine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_007409-Tab.pdf","Draft","Oral","Tablet","007409","10/30/2024","PSG_007409-Tab.pdf"
"Dicyclomine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_007409-Cap.pdf","Draft","Oral","Capsule","007409","10/30/2024","PSG_007409-Cap.pdf"
"Didanosine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Didanosine_tab_for_susp_77275_RV06-13.pdf","Draft","Oral","Tablet, For Suspension","077275","06/19/2013","Didanosine_tab_for_susp_77275_RV06-13.pdf"
"Didanosine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021183.pdf","Draft","Oral","Capsule, Delayed Release Pellets","021183","11/21/2019","PSG_021183.pdf"
"Dienogest;Estradiol Valerate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022252.pdf","Draft","Oral","Tablet","022252","10/30/2024","PSG_022252.pdf"
"Diethylpropion Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Diethylpropion_ERtab_ 12546_RC12-09.pdf","Draft","Oral","Tablet, Extended Release","012546","12/17/2009","Diethylpropion_ERtab_ 12546_RC12-09.pdf"
"Difelikefalin Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214916.pdf","Draft","Intravenous","Solution","214916","05/18/2023","PSG_214916.pdf"
"Diflorasone Diacetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Diflorasone_Ointment_075331_RC07-14.pdf","Draft","Topical","Ointment","019260","07/22/2014","Diflorasone_Ointment_075331_RC07-14.pdf"
"Diflorasone Diacetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Diflorasone diacetate_topical cream_RLD 075508_RC01-16.pdf","Draft","Topical","Cream","075508","01/27/2016","Diflorasone diacetate_topical cream_RLD 075508_RC01-16.pdf"
"Diflorasone Diacetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Diflorasone diacetate_topical cream_RLD 076263_RC01-16.pdf","Draft","Topical","Cream","076263","01/27/2016","Diflorasone diacetate_topical cream_RLD 076263_RC01-16.pdf"
"Diflunisal","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018445.pdf","Draft","Oral","Tablet","018445","10/30/2024","PSG_018445.pdf"
"Difluprednate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Difluprednate_ophthalmic emulsion_RLD 022212_RV02-17.pdf","Draft","Ophthalmic","Emulsion","022212","02/14/2017","Difluprednate_ophthalmic emulsion_RLD 022212_RV02-17.pdf"
"Digoxin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Digoxin_oral tablet_NDA 020405_RV08-17.pdf","Draft","Oral","Tablet","020405","08/29/2017","Digoxin_oral tablet_NDA 020405_RV08-17.pdf"
"Dihydroergotamine Mesylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213436.pdf","Draft","Nasal","Spray, Metered","213436","02/16/2023","PSG_213436.pdf"
"Dihydroergotamine Mesylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020148.pdf","Draft","Nasal","Spray, Metered","020148","06/03/2020","PSG_020148.pdf"
"Diltiazem Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021392.pdf","Draft","Oral","Tablet, Extended Release","021392","06/03/2020","PSG_021392.pdf"
"Diltiazem Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020401.pdf","Draft","Oral","Capsule, Extended Release","020401","06/03/2020","PSG_020401.pdf"
"Diltiazem Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020092.pdf","Draft","Oral","Capsule, Extended Release","020092","06/03/2020","PSG_020092.pdf"
"Diltiazem Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020062.pdf","Draft","Oral","Capsule, Extended Release","020062","06/03/2020","PSG_020062.pdf"
"Diltiazem Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019471.pdf","Draft","Oral","Capsule, Extended Release","019471","06/03/2020","PSG_019471.pdf"
"Diltiazem Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018602.pdf","Draft","Oral","Tablet","018602","03/02/2020","PSG_018602.pdf"
"Dimethyl Fumarate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Dimethyl fumarate_DRcap_204063_RC07-14.pdf","Draft","Oral","Capsule, Delayed Release","204063","07/22/2014","Dimethyl fumarate_DRcap_204063_RC07-14.pdf"
"Dinoprostone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Dinoprostone_Supp_Vag_017810_RC06-12.pdf","Draft","Vaginal","Suppository","017810","06/14/2012","Dinoprostone_Supp_Vag_017810_RC06-12.pdf"
"Dinoprostone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Dinoprostone_insert_vag_ER_20411_RC11-11.pdf","Draft","Vaginal","Insert, Extended Release","020411","11/29/2011","Dinoprostone_insert_vag_ER_20411_RC11-11.pdf"
"Dinoprostone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Dinoprostone_gel_endocx_19617_RC9-11.pdf","Draft","Endocervical","Gel","019617","09/29/2011","Dinoprostone_gel_endocx_19617_RC9-11.pdf"
"Diphenhydramine Citrate; Ibuprofen","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021394.pdf","Draft","Oral","Tablet","021394","10/30/2024","PSG_021394.pdf"
"Diphenhydramine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_005845.pdf","Draft","Oral","Capsule","080738","10/30/2024","PSG_005845.pdf"
"Diphenhydramine Hydrochloride; Ibuprofen","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021393.pdf","Draft","Oral","Capsule","021393","10/30/2024","PSG_021393.pdf"
"Diphenhydramine Hydrochloride; Naproxen Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_205352.pdf","Draft","Oral","Tablet","205352","10/30/2024","PSG_205352.pdf"
"Dipyridamole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_012836.pdf","Draft","Oral","Tablet","012836","10/30/2024","PSG_012836.pdf"
"Diroximel Fumarate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211855.pdf","Draft","Oral","Capsule, Delayed Release","211855","08/28/2020","PSG_211855.pdf"
"Disopyramide Phosphate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017447.pdf","Draft","Oral","Capsule","017447","10/30/2024","PSG_017447.pdf"
"Disopyramide Phosphate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Disopyramide_Phosphate_ERcap_18655_RC10-08.pdf","Draft","Oral","Capsule, Extended Release","018655","10/01/2008","Disopyramide_Phosphate_ERcap_18655_RC10-08.pdf"
"Disulfiram","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_007883.pdf","Draft","Oral","Tablet","007883","10/30/2024","PSG_007883.pdf"
"Divalproex Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Divalproex sodium__oral DR tablet_RLD 018723_RV12-16.pdf","Draft","Oral","Tablet, Delayed Release","018723","12/22/2016","Divalproex sodium__oral DR tablet_RLD 018723_RV12-16.pdf"
"Divalproex Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Divalproex sodium_oral DR pellets capsule_RLD 019680_RV12-16.pdf","Draft","Oral","Capsule, Delayed Release Pellets","019680","12/22/2016","Divalproex sodium_oral DR pellets capsule_RLD 019680_RV12-16.pdf"
"Divalproex Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Divalproex sodium__oral ER tablet_RLD 21168_RV12-16.pdf","Draft","Oral","Tablet, Extended Release","021168","12/22/2016","Divalproex sodium__oral ER tablet_RLD 21168_RV12-16.pdf"
"Docosanol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020941.pdf","Draft","Topical","Cream","020941","10/21/2022","PSG_020941.pdf"
"Dofetilide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020931.pdf","Draft","Oral","Capsule","020931","10/30/2024","PSG_020931.pdf"
"Dolasetron Mesylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020623.pdf","Draft","Oral","Tablet","020623","10/30/2024","PSG_020623.pdf"
"Dolutegravir Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_204790.pdf","Draft","Oral","Tablet","204790","10/30/2024","PSG_204790.pdf"
"Dolutegravir Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213983.pdf","Draft","Oral","Tablet, For Suspension","213983","10/30/2024","PSG_213983.pdf"
"Dolutegravir Sodium; Lamivudine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211994.pdf","Draft","Oral","Tablet","211994","10/30/2024","PSG_211994.pdf"
"Dolutegravir Sodium; Rilpivirine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210192.pdf","Draft","Oral","Tablet","210192","10/30/2024","PSG_210192.pdf"
"Donepezil Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021720.pdf","Draft","Oral","Tablet, Orally Disintegrating","021720","10/30/2024","PSG_021720.pdf"
"Donepezil Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212304.pdf","Draft","Transdermal","System","212304","02/16/2023","PSG_212304.pdf"
"Donepezil Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022568.pdf","Draft","Oral","Tablet","022568","10/30/2024","PSG_022568.pdf"
"Donepezil Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020690.pdf","Draft","Oral","Tablet","020690","10/30/2024","PSG_020690.pdf"
"Donepezil Hydrochloride; Memantine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_206439.pdf","Draft","Oral","Capsule, Extended Release","206439","08/22/2024","PSG_206439.pdf"
"Doravirine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210806.pdf","Draft","Oral","Tablet","210806","03/02/2020","PSG_210806.pdf"
"Doravirine; Lamivudine; Tenofovir Disoproxil Fumarate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210807.pdf","Draft","Oral","Tablet","210807","03/02/2020","PSG_210807.pdf"
"Dorzolamide Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/DORZOLAMIDE HYDROCHLORIDE_ophthalmic solution_NDA 020408_RV07-17.pdf","Draft","Ophthalmic","Solution/Drops","020408","07/13/2017","DORZOLAMIDE HYDROCHLORIDE_ophthalmic solution_NDA 020408_RV07-17.pdf"
"Doxazosin Mesylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019668.pdf","Draft","Oral","Tablet","019668","10/30/2024","PSG_019668.pdf"
"Doxazosin Mesylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Doxazosin_Mesylate_ERtab_21269_RC9-06.pdf","Final","Oral","Tablet, Extended Release","021269","05/12/2008","Doxazosin_Mesylate_ERtab_21269_RC9-06.pdf"
"Doxepin Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022036.pdf","Draft","Oral","Tablet","022036","10/30/2024","PSG_022036.pdf"
"Doxepin Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_016798.pdf","Draft","Oral","Capsule","016798","10/30/2024","PSG_016798.pdf"
"Doxepin Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020126.pdf","Draft","Topical","Cream","020126","10/21/2022","PSG_020126.pdf"
"Doxercalciferol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Doxercalciferol_oral capsule_RLD 20862_Final 08-17.pdf","Final","Oral","Capsule","020862","08/04/2017","Doxercalciferol_oral capsule_RLD 20862_Final 08-17.pdf"
"Doxorubicin Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050718.pdf","Draft","Injection","Injectable, Liposomal","050718","05/19/2022","PSG_050718.pdf"
"Doxycycline","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050641-Cap-100MG.pdf","Draft","Oral","Capsule","050641","10/30/2024","PSG_050641-Cap-100MG.pdf"
"Doxycycline","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050641-Cap-150MG.pdf","Draft","Oral","Capsule","065055","10/30/2024","PSG_050641-Cap-150MG.pdf"
"Doxycycline","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Doxycycline_ DRcap_50805_RC2-08.pdf","Draft","Oral","Capsule","050805","04/06/2008","Doxycycline_ DRcap_50805_RC2-08.pdf"
"Doxycycline","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_065070.pdf","Draft","Oral","Tablet","065070","10/30/2024","PSG_065070.pdf"
"Doxycycline","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050006.pdf","Draft","Oral","For Suspension","050006","10/30/2024","PSG_050006.pdf"
"Doxycycline Calcium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050480.pdf","Draft","Oral","Suspension","050480","10/30/2024","PSG_050480.pdf"
"Doxycycline Hyclate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050751.pdf","Draft","Periodontal","System, Extended Release","050751","08/02/2022","PSG_050751.pdf"
"Doxycycline Hyclate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209844.pdf","Draft","Oral","Tablet","209844","10/30/2024","PSG_209844.pdf"
"Doxycycline Hyclate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050533.pdf","Draft","Oral","Tablet","050533","10/30/2024","PSG_050533.pdf"
"Doxycycline Hyclate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208253.pdf","Draft","Oral","Capsule","208253","10/30/2024","PSG_208253.pdf"
"Doxycycline Hyclate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_205931.pdf","Draft","Oral","Tablet","205931","10/30/2024","PSG_205931.pdf"
"Doxycycline Hyclate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050007.pdf","Draft","Oral","Capsule","050007","10/30/2024","PSG_050007.pdf"
"Doxycycline Hyclate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Doxycycline hyclate_oral DR tablet_NDA 050795_RV03-18.pdf","Draft","Oral","Tablet, Delayed Release","050795","03/28/2018","Doxycycline hyclate_oral DR tablet_NDA 050795_RV03-18.pdf"
"Doxycycline Hyclate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Doxycycline hyclate_oral tablet_NDA 050783_RC11-17.pdf","Draft","Oral","Tablet","050783","02/08/2018","Doxycycline hyclate_oral tablet_NDA 050783_RC11-17.pdf"
"Doxylamine Succinate; Pyridoxine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Doxylamine succinate_Pyridoxine HCl_DRtab_21876_RC07-14.pdf","Draft","Oral","Tablet, Delayed Release","021876","07/22/2014","Doxylamine succinate_Pyridoxine HCl_DRtab_21876_RC07-14.pdf"
"Doxylamine succinate; Pyridoxine hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Doxylamine succinate and pyridoxine hydrochloride oral ER tablet NDA 209661 RC Feb 2019.pdf","Draft","Oral","Capsule, Extended Release","209661","02/22/2019","Doxylamine succinate and pyridoxine hydrochloride oral ER tablet NDA 209661 RC Feb 2019.pdf"
"Dronabinol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Dronabinol_cap_18651_RV02-14.pdf","Draft","Oral","Capsule","018651","02/01/2014","Dronabinol_cap_18651_RV02-14.pdf"
"Dronedarone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022425.pdf","Draft","Oral","Tablet","022425","10/30/2024","PSG_022425.pdf"
"Drospirenone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211367.pdf","Draft","Oral","Tablet","211367","10/30/2024","PSG_211367.pdf"
"Drospirenone; Estetrol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214154.pdf","Draft","Oral","Tablet","214154","10/30/2024","PSG_214154.pdf"
"Drospirenone; Estradiol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021355.pdf","Draft","Oral","Tablet","021355","10/30/2024","PSG_021355.pdf"
"Drospirenone; Ethinyl Estradiol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021676.pdf","Draft","Oral","Tablet","021676","10/30/2024","PSG_021676.pdf"
"Drospirenone; Ethinyl Estradiol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021098.pdf","Draft","Oral","Tablet","021098","10/30/2024","PSG_021098.pdf"
"Drospirenone; Ethinyl Estradiol; Levomefolate Calcium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022532.pdf","Draft","Oral","Tablet","022532                                                       022574","10/30/2024","PSG_022532.pdf"
"Droxidopa","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_203202.pdf","Draft","Oral","Capsule","203202","10/30/2024","PSG_203202.pdf"
"Duloxetine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212516.pdf","Draft","Oral","Capsule, Delayed Release","212516","03/02/2020","PSG_212516.pdf"
"Duloxetine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021427.pdf","Draft","Oral","Capsule, Delayed Release Pellets","021427","09/16/2019","PSG_021427.pdf"
"Durlobactam Sodium; Durlobactam Sodium; Sulbactam Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_216974.pdf","Draft","Intravenous","Powder","216974","02/15/2024","PSG_216974.pdf"
"Dutasteride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Dutasteride_cap_21319_RC7-05.pdf","Final","Oral","Capsule","021319","05/12/2008","Dutasteride_cap_21319_RC7-05.pdf"
"Dutasteride;Tamsulosin Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Dutasteride_tamsulosin_HCl_cap_22460_RV02-14.pdf","Draft","Oral","Capsule","022460","02/01/2014","Dutasteride_tamsulosin_HCl_cap_22460_RV02-14.pdf"
"Duvelisib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211155.pdf","Draft","Oral","Capsule","211155","10/30/2024","PSG_211155.pdf"
"Econazole Nitrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Econazole Nitrate Topical Cream NDA 018751 RV Feb 2019.pdf","Draft","Topical","Cream","018751","02/22/2019","Econazole Nitrate Topical Cream NDA 018751 RV Feb 2019.pdf"
"Edaravone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215446.pdf","Draft","Oral","Suspension","215446","11/16/2023","PSG_215446.pdf"
"Edaravone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209176.pdf","Draft","Intravenous","Solution","209176","03/02/2020","PSG_209176.pdf"
"Edoxaban Tosylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_206316.pdf","Draft","Oral","Tablet","206316","03/02/2020","PSG_206316.pdf"
"Efavirenz","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Efavirenz_cap_20972_RC10-05.pdf","Final","Oral","Capsule","020972","05/12/2008","Efavirenz_cap_20972_RC10-05.pdf"
"Efavirenz","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Efavirenz_tab_21360_RC11-06.pdf","Final","Oral","Tablet","021360","05/12/2008","Efavirenz_tab_21360_RC11-06.pdf"
"Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Efavirenz_ Emtricitabine_Tenofovir_Disoproxil_Fumarate_tab_21937_RC10-08.pdf","Draft","Oral","Tablet","021937","10/01/2008","Efavirenz_ Emtricitabine_Tenofovir_Disoproxil_Fumarate_tab_21937_RC10-08.pdf"
"Efavirenz; Lamivudine; Tenofovir Disoproxil Fumarate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210649.pdf","Draft","Oral","Tablet","210649","06/03/2020","PSG_210649.pdf"
"Efavirenz; Lamivudine; Tenofovir Disoproxil Fumarate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Efavirenz Lamivudine Tenoforvir Dsisoproxile Funarate Tablets NDA208255 PSG Page RC May 2019.pdf","Draft","Oral","Tablet","208255","05/15/2019","Efavirenz Lamivudine Tenoforvir Dsisoproxile Funarate Tablets NDA208255 PSG Page RC May 2019.pdf"
"Efavirenz; Lamivudine; Tenofovir Disoproxil Fumarate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Efavirenz-Lamivudine-Tenofovir Disoproxil Fumarate Oral Tablet NDA 022142 page RC May 2019.pdf","Draft","Oral","Tablet","022142","05/15/2019","Efavirenz-Lamivudine-Tenofovir Disoproxil Fumarate Oral Tablet NDA 022142 page RC May 2019.pdf"
"Efinaconazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Efinaconazole_draft_Topical solution_RLD 203567_RC09-18.pdf","Draft","Topical","Solution","203567","09/13/2018","Efinaconazole_draft_Topical solution_RLD 203567_RC09-18.pdf"
"Elacestrant Dihydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_217639.pdf","Draft","Oral","Tablet","217639","10/30/2024","PSG_217639.pdf"
"Elagolix Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210450.pdf","Draft","Oral","Tablet","210450","03/02/2020","PSG_210450.pdf"
"Elagolix Sodium, Estradiol, Norethindrone Acetate; Elagolix Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213388.pdf","Draft","Oral","Capsule","213388","02/15/2024","PSG_213388.pdf"
"Elbasvir; Grazoprevir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Elbasvir; Grazoprevir_ Oral Tablet_ RLD 208261_ RC09-16.pdf","Draft","Oral","Tablet","208261","10/04/2016","Elbasvir; Grazoprevir_ Oral Tablet_ RLD 208261_ RC09-16.pdf"
"Eletriptan Hydrobromide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021016.pdf","Draft","Oral","Tablet","021016","10/30/2024","PSG_021016.pdf"
"Elexacaftor, Ivacaftor, Tezacaftor; Ivacaftor","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212273.pdf","Draft","Oral","Tablet, Tablet","212273","03/24/2021","PSG_212273.pdf"
"Eliglustat Tartrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_205494.pdf","Draft","Oral","Capsule","205494","10/30/2024","PSG_205494.pdf"
"Eltrombopag Olamine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022291.pdf","Draft","Oral","Tablet","022291","10/30/2024","PSG_022291.pdf"
"Eltrombopag Olamine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_207027.pdf","Draft","Oral","For Suspension","207027","10/30/2024","PSG_207027.pdf"
"Eluxadoline","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_206940.pdf","Draft","Oral","Tablet","206940","10/30/2024","PSG_206940.pdf"
"Elvitegravir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Elvitegravir_oral tablet_RLD203093_RC01-16.pdf","Draft","Oral","Tablet","203093","01/27/2016","Elvitegravir_oral tablet_RLD203093_RC01-16.pdf"
"Empagliflozin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_204629.pdf","Draft","Oral","Tablet","204629","10/30/2024","PSG_204629.pdf"
"Empagliflozin; Linagliptin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_206073.pdf","Draft","Oral","Tablet","206073","10/30/2024","PSG_206073.pdf"
"Empagliflozin; Linagliptin; Metformin Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212614.pdf","Draft","Oral","Tablet, Extended Release","212614","08/28/2020","PSG_212614.pdf"
"Empagliflozin; Metformin Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Empagliflozin; Metformin HCl_oral ER tablet_NDA 208658_RC08-17.pdf","Draft","Oral","Tablet, Extended Release","208658","10/19/2017","Empagliflozin; Metformin HCl_oral ER tablet_NDA 208658_RC08-17.pdf"
"Empagliflozin; Metformin Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_206111.pdf","Draft","Oral","Tablet","206111","10/30/2024","PSG_206111.pdf"
"Emtricitabine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021500.pdf","Draft","Oral","Capsule","021500","10/30/2024","PSG_021500.pdf"
"Emtricitabine; Rilpivirine Hydrochloride; Tenofovir Alafenamide Fumarate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208351.pdf","Draft","Oral","Tablet","208351","10/30/2024","PSG_208351.pdf"
"Emtricitabine; Rilpivirine Hydrochloride; Tenofovir Disoproxil Fumarate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202123.pdf","Draft","Oral","Tablet","202123","10/30/2024","PSG_202123.pdf"
"Emtricitabine; Tenofovir Alafenamide Fumarate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208215.pdf","Draft","Oral","Tablet","208215","10/30/2024","PSG_208215.pdf"
"Emtricitabine; Tenofovir Disoproxil Fumarate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021752.pdf","Draft","Oral","Tablet","021752","10/30/2024","PSG_021752.pdf"
"Enalapril Maleate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018998.pdf","Draft","Oral","Tablet","018998","10/30/2024","PSG_018998.pdf"
"Enasidenib Mesylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209606.pdf","Draft","Oral","Tablet","209606","10/30/2024","PSG_209606.pdf"
"Encorafenib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210496.pdf","Draft","Oral","Capsule","210496","11/21/2019","PSG_210496.pdf"
"Enfuvirtide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021481.pdf","Draft","Subcutaneous","Injectable","021481","11/19/2024","PSG_021481.pdf"
"Enoxaparin Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Enoxaparin_Inj_20164_RC10-11.pdf","Draft","Subcutaneous","Injection","020164","10/28/2011","Enoxaparin_Inj_20164_RC10-11.pdf"
"Entacapone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020796.pdf","Draft","Oral","Tablet","020796","10/30/2024","PSG_020796.pdf"
"Entecavir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Entecavir_tab_21797_RC5-06.pdf","Final","Oral","Tablet","021797","05/12/2008","Entecavir_tab_21797_RC5-06.pdf"
"Entrectinib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212725.pdf","Draft","Oral","Capsule","212725","03/24/2021","PSG_212725.pdf"
"Enzalutamide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_203415.pdf","Draft","Oral","Capsule","203415","02/17/2022","PSG_203415.pdf"
"Enzalutamide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213674.pdf","Draft","Oral","Tablet","213674","11/19/2024","PSG_213674.pdf"
"Epinephrine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_201739.pdf","Draft","Intramuscular, Subcutaneous","Solution","201739","08/21/2023","PSG_201739.pdf"
"Epinephrine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_205920.pdf","Draft","Inhalation","Aerosol, Metered","205920","08/21/2023","PSG_205920.pdf"
"Epinephrine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Epinephrine_draft_Intramuscular subcutaneous solution_RLD 207534_RC07-18.pdf","Draft","Intramuscular, Subcutaneous","Solution","207534","07/20/2018","Epinephrine_draft_Intramuscular subcutaneous solution_RLD 207534_RC07-18.pdf"
"Epinephrine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Epinephrine_intramuscular and subcutaneous injectable_NDA 020800_RC08-17.pdf","Draft","Intramuscular/Subcutaneous","Injectable","020800","10/19/2017","Epinephrine_intramuscular and subcutaneous injectable_NDA 020800_RC08-17.pdf"
"Epinephrine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Epinephrine_intramuscular injection_RLD 19430_RC12-16.pdf","Draft","Intramuscular, Subcutaneous","Injectable","019430","12/22/2016","Epinephrine_intramuscular injection_RLD 19430_RC12-16.pdf"
"Eplerenone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021437.pdf","Draft","Oral","Tablet","021437","10/30/2024","PSG_021437.pdf"
"Eplontersen Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_217388.pdf","Draft","Subcutaneous","Solution","217388","11/19/2024","PSG_217388.pdf"
"Eprosartan Mesylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020738.pdf","Draft","Oral","Tablet","020738","10/30/2024","PSG_020738.pdf"
"Eprosartan Mesylate; Hydrochlorothiazide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021268.pdf","Draft","Oral","Tablet","021268","10/30/2024","PSG_021268.pdf"
"Eravacycline Dihydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/ERAVACYCLINE DIHYDROCHLORIDE POWDER INTRAVENOUS NDA 211109 PSG Page RC May 2019.pdf","Draft","Intravenous","Powder","211109","05/15/2019","ERAVACYCLINE DIHYDROCHLORIDE POWDER INTRAVENOUS NDA 211109 PSG Page RC May 2019.pdf"
"Erdafitinib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212018.pdf","Draft","Oral","Tablet","212018","10/30/2024","PSG_212018.pdf"
"Ergocalciferol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Ergocalciferol_Caps_003444_RV07-14.pdf","Draft","Oral","Capsule","003444","07/22/2014","Ergocalciferol_Caps_003444_RV07-14.pdf"
"Erlotinib Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Erlotinib_HCl_tab_21743_RC1-06.pdf","Final","Oral","Tablet","021743","05/12/2008","Erlotinib_HCl_tab_21743_RC1-06.pdf"
"Ertugliflozin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Ertugliflozin_Oral tablet_NDA 209803_RC Oct 2018.pdf","Draft","Oral","Tablet","209803","11/28/2018","Ertugliflozin_Oral tablet_NDA 209803_RC Oct 2018.pdf"
"Ertugliflozin; Metformin hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209806.pdf","Draft","Oral","Tablet","209806","10/30/2024","PSG_209806.pdf"
"Ertugliflozin; Sitagliptin phosphate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209805.pdf","Draft","Oral","Tablet","209805","10/30/2024","PSG_209805.pdf"
"Erythromycin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050617.pdf","Draft","Topical","Gel","050617","10/21/2022","PSG_050617.pdf"
"Erythromycin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Erythromycin_DRtab_62298_RC02-14.pdf","Draft","Oral","Tablet, Delayed Release","062298","04/01/2014","Erythromycin_DRtab_62298_RC02-14.pdf"
"Erythromycin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Erythromycin_ophthalmic ointment_RLD 062447_RV09-16.pdf","Draft","Ophthalmic","Ointment","062447","10/04/2016","Erythromycin_ophthalmic ointment_RLD 062447_RV09-16.pdf"
"Erythromycin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Erythromycin_SolTopical_ 64187_RC2-10.pdf","Draft","Topical","Solution","064187","02/01/2010","Erythromycin_SolTopical_ 64187_RC2-10.pdf"
"Erythromycin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Erythromycin_swab_64126_RC2-10.pdf","Draft","Topical","Swab","064126","02/01/2010","Erythromycin_swab_64126_RC2-10.pdf"
"Erythromycin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Erythromycin_oral tablet_RLD 061621_RC01-16.pdf","Draft","Oral","Tablet","061621","01/27/2016","Erythromycin_oral tablet_RLD 061621_RC01-16.pdf"
"Erythromycin Ethylsuccinate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_061904.pdf","Draft","Oral","Tablet","061904                                                       061905","10/30/2024","PSG_061904.pdf"
"Erythromycin Ethylsuccinate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050207.pdf","Draft","Oral","Granule","050207","10/30/2024","PSG_050207.pdf"
"Erythromycin Ethylsuccinate; Sulfisoxazole Acetyl","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050529.pdf","Draft","Oral","Granule","050529","10/30/2024","PSG_050529.pdf"
"Escitalopram Oxalate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_077660.pdf","Draft","Oral","Capsule","077660","10/30/2024","PSG_077660.pdf"
"Escitalopram Oxalate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021323.pdf","Draft","Oral","Tablet","021323","10/30/2024","PSG_021323.pdf"
"Esketamine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211243.pdf","Draft","Nasal","Spray","211243","08/28/2020","PSG_211243.pdf"
"Eslicarbazepine Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022416.pdf","Draft","Oral","Tablet","022416","10/30/2024","PSG_022416.pdf"
"Esomeprazole Magnesium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Esomeprazole magnesium_oral DR tablet_NDA 207920_RV08-17.pdf","Draft","Oral","Tablet, Delayed Release","207920","10/19/2017","Esomeprazole magnesium_oral DR tablet_NDA 207920_RV08-17.pdf"
"Esomeprazole Magnesium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Esomeprazole magnesium_oral DR suspension_NDA 021957 and 022101_RV11-17.pdf","Draft","Oral","Powder For Suspension, Delayed Release","021957                                                       022101","02/08/2018","Esomeprazole magnesium_oral DR suspension_NDA 021957 and 022101_RV11-17.pdf"
"Esomeprazole Magnesium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Esomeprazole magnesium_oral DR capsule pellets_NDA 021153_RV11-17.pdf","Draft","Oral","Capsule, Delayed Release Pellets","021153","02/08/2018","Esomeprazole magnesium_oral DR capsule pellets_NDA 021153_RV11-17.pdf"
"Esomeprazole Magnesium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_204655.pdf","Draft","Oral","Capsule, Delayed Release","204655","08/28/2020","PSG_204655.pdf"
"Esomeprazole Magnesium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214278.pdf","Draft","Oral","Tablet, Orally Disintegrating, Delayed Release","214278","08/20/2021","PSG_214278.pdf"
"Esomeprazole Magnesium; Naproxen","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Esomeprazole_Mag;_Naproxen_DRtab_22511_RC03-11.pdf","Draft","Oral","Tablet, Delayed Release","022511","03/01/2011","Esomeprazole_Mag;_Naproxen_DRtab_22511_RC03-11.pdf"
"Esomeprazole Strontium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Esomeprazole Strontium_draft_Oral cap DR_RLD 202342_RC07-18.pdf","Draft","Oral","Capsule, Delayed Release","202342","07/20/2018","Esomeprazole Strontium_draft_Oral cap DR_RLD 202342_RC07-18.pdf"
"Estradiol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_081295.pdf","Draft","Oral","Tablet","084499                                                       084500","10/30/2024","PSG_081295.pdf"
"Estradiol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_203752.pdf","Draft","Transdermal","Film, Extended Release","203752","11/21/2019","PSG_203752.pdf"
"Estradiol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019081.pdf","Draft","Transdermal","Film, Extended Release","019081","11/21/2019","PSG_019081.pdf"
"Estradiol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020375.pdf","Draft","Transdermal","Film, Extended Release","020375                                                       021674","11/21/2019","PSG_020375.pdf"
"Estradiol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020538.pdf","Draft","Transdermal","Film, Extended Release","020538","11/21/2019","PSG_020538.pdf"
"Estradiol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Estradiol_vaginal_crm_86069_RV09-14.pdf","Draft","Vaginal","Cream","086069","09/19/2014","Estradiol_vaginal_crm_86069_RV09-14.pdf"
"Estradiol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Estradiol_vaginal_tablet_20908_ 08-09.pdf","Draft","Vaginal","Tablet","020908","03/31/2011","Estradiol_vaginal_tablet_20908_ 08-09.pdf"
"Estradiol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022038.pdf","Draft","Transdermal","Gel","022038","02/17/2022","PSG_022038.pdf"
"Estradiol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020472.pdf","Draft","Vaginal","Insert, Extended Release","020472","06/03/2020","PSG_020472.pdf"
"Estradiol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021166.pdf","Draft","Transdermal","Gel, Metered","021166","08/20/2021","PSG_021166.pdf"
"Estradiol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021813.pdf","Draft","Transdermal","Gel, Metered","021813","02/17/2022","PSG_021813.pdf"
"Estradiol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022014.pdf","Draft","Transdermal","Spray","022014","02/17/2022","PSG_022014.pdf"
"Estradiol; Levonorgestrel","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021258.pdf","Draft","Transdermal","Film, Extended Release","021258","08/21/2023","PSG_021258.pdf"
"Estradiol; Norethindrone Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020870.pdf","Draft","Transdermal","Film, Extended Release","020870","11/21/2019","PSG_020870.pdf"
"Estradiol; Norethindrone Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020907.pdf","Draft","Oral","Tablet","020907","10/30/2024","PSG_020907.pdf"
"Estramustine Phosphate Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018045.pdf","Draft","Oral","Capsule","018045","04/05/2013","PSG_018045.pdf"
"Estrogens, Conjugated","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Conjugated_estrogens_004782_RC12-14.pdf","Draft","Oral","Tablet","004782","12/29/2014","Conjugated_estrogens_004782_RC12-14.pdf"
"Estrogens, Conjugated","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020216.pdf","Draft","Topical, Vaginal","Cream","020216","11/19/2024","PSG_020216.pdf"
"Estrogens, Esterified","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_083266.pdf","Draft","Oral","Tablet","084948                                                       084949                                                       084950                                                       084951","10/30/2024","PSG_083266.pdf"
"Estrogens; Conjugated Synthetic A","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Estrogens_Conjugated_Synthetic_A_tabs_20992_RC04-10.pdf","Draft","Oral","Tablet","020992","04/20/2010","Estrogens_Conjugated_Synthetic_A_tabs_20992_RC04-10.pdf"
"Eszopiclone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021476.pdf","Draft","Oral","Tablet","021476","10/30/2024","PSG_021476.pdf"
"Etelcalcetide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208325.pdf","Draft","Intravenous","Solution","208325","02/17/2022","PSG_208325.pdf"
"Eteplirsen","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_206488.pdf","Draft","Intravenous","Solution","206488","11/17/2022","PSG_206488.pdf"
"Ethacrynic Acid","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_016092.pdf","Draft","Oral","Tablet","016092","10/30/2024","PSG_016092.pdf"
"Ethambutol Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_016320.pdf","Draft","Oral","Tablet","016320","10/30/2024","PSG_016320.pdf"
"Ethinyl Estradiol; Ethynodiol Diacetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_016927.pdf","Draft","Oral","Tablet","072723                                                       072721","10/30/2024","PSG_016927.pdf"
"Ethinyl Estradiol; Etonogestrel","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Ethinyl_Estradiol_Etonogestrel_vaginal_ring_21187_RC04-13.pdf","Draft","Vaginal","Ring","021187","04/05/2013","Ethinyl_Estradiol_Etonogestrel_vaginal_ring_21187_RC04-13.pdf"
"Ethinyl Estradiol; Levonorgestrel","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019190.pdf","Draft","Oral","Tablet","019190                                                       019192","10/30/2024","PSG_019190.pdf"
"Ethinyl Estradiol; Levonorgestrel","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021864.pdf","Draft","Oral","Tablet","021864","10/30/2024","PSG_021864.pdf"
"Ethinyl Estradiol; Levonorgestrel","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018668.pdf","Draft","Oral","Tablet","018782                                                       018668","10/30/2024","PSG_018668.pdf"
"Ethinyl Estradiol; Levonorgestrel","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020683.pdf","Draft","Oral","Tablet","020683","10/30/2024","PSG_020683.pdf"
"Ethinyl Estradiol; Levonorgestrel","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020860.pdf","Draft","Oral","Tablet","020860","10/30/2024","PSG_020860.pdf"
"Ethinyl Estradiol; Levonorgestrel","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021544.pdf","Draft","Oral","Tablet","021544                                                       021840                                                       204061                                                       022262","10/30/2024","PSG_021544.pdf"
"Ethinyl Estradiol; Levonorgestrel","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_204017.pdf","Draft","Transdermal","System","204017","08/20/2021","PSG_204017.pdf"
"Ethinyl Estradiol; Levonorgestrel","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208612.pdf","Draft","Oral","Tablet","208612","10/30/2024","PSG_208612.pdf"
"Ethinyl Estradiol; Levonorgestrel","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209405.pdf","Draft","Oral","Tablet","209405","03/24/2021","PSG_209405.pdf"
"Ethinyl Estradiol; Norelgestromin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021180.pdf","Draft","Transdermal","Film, Extended Release","200910                                                       021180","11/21/2019","PSG_021180.pdf"
"Ethinyl Estradiol; Norethindrone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022573.pdf","Draft","Oral","Tablet, Chewable","022573","10/30/2024","PSG_022573.pdf"
"Ethinyl Estradiol; Norethindrone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017576.pdf","Draft","Oral","Tablet","017716                                                       200897                                                       203006","10/30/2024","PSG_017576.pdf"
"Ethinyl Estradiol; Norethindrone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018977.pdf","Draft","Oral","Tablet","018977","10/30/2024","PSG_018977.pdf"
"Ethinyl Estradiol; Norethindrone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021490.pdf","Draft","Oral","Tablet","021490                                                       202086","10/30/2024","PSG_021490.pdf"
"Ethinyl Estradiol; Norethindrone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017735.pdf","Draft","Oral","Tablet","017735                                                       017919                                                       018985","10/30/2024","PSG_017735.pdf"
"Ethinyl Estradiol; Norethindrone Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022501.pdf","Draft","Oral","Tablet","022501","10/30/2024","PSG_022501.pdf"
"Ethinyl Estradiol; Norethindrone Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017354.pdf","Draft","Oral","Tablet","017354                                                       017355                                                       021871","10/30/2024","PSG_017354.pdf"
"Ethinyl Estradiol; Norethindrone Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020130.pdf","Draft","Oral","Tablet","020130","10/30/2024","PSG_020130.pdf"
"Ethinyl Estradiol; Norethindrone Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021065.pdf","Draft","Oral","Tablet","021065","10/30/2024","PSG_021065.pdf"
"Ethinyl Estradiol; Norethindrone Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_204654.pdf","Draft","Oral","Tablet, Chewable, Tablet","204654","10/30/2024","PSG_204654.pdf"
"Ethinyl Estradiol; Norethindrone Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_203667.pdf","Draft","Oral","Tablet","203667","10/30/2024","PSG_203667.pdf"
"Ethinyl estradiol; Norethindrone acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Ethinyl estradiol; Norethindrone acetate_draft_Oral cap_RLD 204426_RC07-18.pdf","Draft","Oral","Capsule","204426","07/20/2018","Ethinyl estradiol; Norethindrone acetate_draft_Oral cap_RLD 204426_RC07-18.pdf"
"Ethinyl Estradiol; Norgestimate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019653.pdf","Draft","Oral","Tablet","019653                                                       019697                                                       021241","10/30/2024","PSG_019653.pdf"
"Ethinyl Estradiol; Norgestrel","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_016672.pdf","Draft","Oral","Tablet","017612                                                       017802                                                       016672","10/30/2024","PSG_016672.pdf"
"Ethinyl Estradiol; Segesterone Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209627.pdf","Draft","Vaginal","Ring","209627","05/17/2023","PSG_209627.pdf"
"Ethiodized Oil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Ethiodized Oil_intralymphatic intrauterine oil_RLD 009190_RC12-16.pdf","Draft","Intralymphatic, Intrauterine, Selective Hepatic Intra-arterial","Injectable","009190","12/22/2016","Ethiodized Oil_intralymphatic intrauterine oil_RLD 009190_RC12-16.pdf"
"Ethionamide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_013026.pdf","Draft","Oral","Tablet","013026","10/30/2024","PSG_013026.pdf"
"Ethosuximide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_012380.pdf","Draft","Oral","Capsule","012380","10/30/2024","PSG_012380.pdf"
"Etidronate Disodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Etidronate_Disodium_tab_17831_RC10-05.pdf","Final","Oral","Tablet","017831","05/12/2008","Etidronate_Disodium_tab_17831_RC10-05.pdf"
"Etodolac","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018922-Tab.pdf","Draft","Oral","Tablet","018922","10/30/2024","PSG_018922-Tab.pdf"
"Etodolac","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018922-Cap.pdf","Draft","Oral","Capsule","018922","10/30/2024","PSG_018922-Cap.pdf"
"Etodolac","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Etodolac_ERtabs_75665_RC07-10.pdf","Draft","Oral","Tablet, Extended Release","020584","07/28/2010","Etodolac_ERtabs_75665_RC07-10.pdf"
"Etonogestrel","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021529.pdf","Draft","Implantation","Implant","021529","08/02/2022","PSG_021529.pdf"
"Etoposide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Etoposide_caps_75635_RC08-10.pdf","Draft","Oral","Capsule","075635","08/30/2010","Etoposide_caps_75635_RC08-10.pdf"
"Etravirine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Etravirine_tab_22187_RC09-12.pdf","Draft","Oral","Tablet","022187","09/19/2012","Etravirine_tab_22187_RC09-12.pdf"
"Everolimus","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Everolimus_oral tablet for suspension_NDA 203985_RC08-17.pdf","Draft","Oral","Tablet, For Suspension","203985","10/19/2017","Everolimus_oral tablet for suspension_NDA 203985_RC08-17.pdf"
"Everolimus","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Everolimus_draft_Oral tab_RLD 22334_RC11-18.pdf","Draft","Oral","Tablet","022334","11/28/2018","Everolimus_draft_Oral tab_RLD 22334_RC11-18.pdf"
"Everolimus","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021560.pdf","Draft","Oral","Tablet","021560","06/03/2020","PSG_021560.pdf"
"Exemestane","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020753.pdf","Draft","Oral","Tablet","020753","10/30/2024","PSG_020753.pdf"
"Exenatide Synthetic","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022200.pdf","Draft","Subcutaneous","For Suspension, Extended Release","022200","05/19/2022","PSG_022200.pdf"
"Exenatide Synthetic","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209210.pdf","Draft","Subcutaneous","Suspension, Extended Release","209210","05/19/2022","PSG_209210.pdf"
"Ezetimibe","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021445.pdf","Draft","Oral","Tablet","021445","10/30/2024","PSG_021445.pdf"
"Ezetimibe; Simvastatin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021687.pdf","Draft","Oral","Tablet","021687","10/30/2024","PSG_021687.pdf"
"Ezogabine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022345.pdf","Draft","Oral","Tablet","022345","10/30/2024","PSG_022345.pdf"
"Famciclovir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020363.pdf","Draft","Oral","Tablet","020363","10/30/2024","PSG_020363.pdf"
"Famotidine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019527.pdf","Draft","Oral","For Suspension","019527","10/30/2024","PSG_019527.pdf"
"Famotidine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020752.pdf","Draft","Oral","Tablet, Orally Disintegrating","021712","10/30/2024","PSG_020752.pdf"
"Famotidine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019462.pdf","Draft","Oral","Tablet","019462                                                       020325","10/30/2024","PSG_019462.pdf"
"Famotidine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020801.pdf","Draft","Oral","Tablet, Chewable","020801","10/30/2024","PSG_020801.pdf"
"Famotidine; Ibuprofen","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022519.pdf","Draft","Oral","Tablet","022519","10/30/2024","PSG_022519.pdf"
"Febuxostat","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021856.pdf","Draft","Oral","Tablet","021856","10/30/2024","PSG_021856.pdf"
"Fedratinib Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212327.pdf","Draft","Oral","Capsule","212327","10/30/2024","PSG_212327.pdf"
"Felbamate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Felbamate_oral suspension_NDA 020189_RV11-17.pdf","Draft","Oral","Suspension","020189","02/08/2018","Felbamate_oral suspension_NDA 020189_RV11-17.pdf"
"Felbamate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Felbamate_oral tablet_NDA 020189_RV11-17.pdf","Draft","Oral","Tablet","020189","02/08/2018","Felbamate_oral tablet_NDA 020189_RV11-17.pdf"
"Felodipine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Felodipine_ERtab_78855_RC12-09.pdf","Draft","Oral","Tablet, Extended Release","019834","12/17/2009","Felodipine_ERtab_78855_RC12-09.pdf"
"Fenofibrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Fenofibrate_oral capsule_RLD 021695 (90 and 30 mg)_RC12-16.pdf","Draft","Oral","Capsule","021695","12/22/2016","Fenofibrate_oral capsule_RLD 021695 (90 and 30 mg)_RC12-16.pdf"
"Fenofibrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Fenofibrate_tab_76433_RC03-12.pdf","Draft","Oral","Tablet","021203","03/28/2012","Fenofibrate_tab_76433_RC03-12.pdf"
"Fenofibrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Fenofibrate_cap_75753_RC2-10.pdf","Draft","Oral","Capsule","019304","02/25/2010","Fenofibrate_cap_75753_RC2-10.pdf"
"Fenofibrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Fenofibrate_tab_22118_RC9-08.pdf","Draft","Oral","Tablet","022118","09/01/2008","Fenofibrate_tab_22118_RC9-08.pdf"
"Fenofibrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Fenofibrate_cap_21612_RC2-08.pdf","Draft","Oral","Capsule","021612","04/06/2008","Fenofibrate_cap_21612_RC2-08.pdf"
"Fenofibrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Fenofibrate_cap_21695_RC11-06.pdf","Final","Oral","Capsule","021695","05/12/2008","Fenofibrate_cap_21695_RC11-06.pdf"
"Fenofibrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Fenofibrate_tab_21656_RC3-02.pdf","Final","Oral","Tablet","021656","05/12/2008","Fenofibrate_tab_21656_RC3-02.pdf"
"Fenofibrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Fenofibrate_tab_21350_RC10-08.pdf","Draft","Oral","Tablet","021350","10/01/2008","Fenofibrate_tab_21350_RC10-08.pdf"
"Fenofibric Acid","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022418.pdf","Draft","Oral","Tablet","022418","10/30/2024","PSG_022418.pdf"
"Fenoprofen Calcium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017604.pdf","Draft","Oral","Capsule","017604","10/30/2024","PSG_017604.pdf"
"Fentanyl","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Fentanyl_Sublingual spray_202788_RC06-15.pdf","Draft","Sublingual","Spray","202788","06/24/2015","Fentanyl_Sublingual spray_202788_RC06-15.pdf"
"Fentanyl","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019813.pdf","Draft","Transdermal","Film, Extended Release","019813","11/21/2019","PSG_019813.pdf"
"Fentanyl Citrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022569.pdf","Draft","Nasal","Spray, Metered","022569","08/22/2024","PSG_022569.pdf"
"Fentanyl Citrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Fentanyl_citrate_subltab_22510_RC09-12.pdf","Draft","Sublingual","Tablet","022510","09/19/2012","Fentanyl_citrate_subltab_22510_RC09-12.pdf"
"Fentanyl Citrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Fentanyl_Citrate_TroLoz_20747_RC2-10.pdf","Draft","Transmucosal","Troche/Lozenge","020747","02/25/2010","Fentanyl_Citrate_TroLoz_20747_RC2-10.pdf"
"Fentanyl Citrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Fentanyl_citrate_tablet_buccal_21947_RV06-13.pdf","Draft","Buccal, Sublingual","Tablet","021947","06/19/2013","Fentanyl_citrate_tablet_buccal_21947_RV06-13.pdf"
"Ferric Carboxymaltose","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_203565.pdf","Draft","Intravenous","Solution","203565","11/19/2024","PSG_203565.pdf"
"Ferric Citrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_205874.pdf","Draft","Oral","Tablet","205874","08/22/2024","PSG_205874.pdf"
"Ferric Derisomaltose","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208171.pdf","Draft","Intravenous","Solution","208171","02/15/2024","PSG_208171.pdf"
"Ferric Maltol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212320.pdf","Draft","Oral","Capsule","212320","03/24/2021","PSG_212320.pdf"
"Ferric Oxyhydroxide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017441.pdf","Draft","Injection","Injectable","017441","11/17/2022","PSG_017441.pdf"
"Ferric Oxyhydroxide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020955.pdf","Draft","Injection","Injectable","020955","11/17/2022","PSG_020955.pdf"
"Ferric Oxyhydroxide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_205109.pdf","Draft","Oral","Tablet, Chewable","205109","09/16/2021","PSG_205109.pdf"
"Ferric Oxyhydroxide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021135.pdf","Draft","Intravenous","Injectable","021135","09/16/2021","PSG_021135.pdf"
"Ferric Pyrophosphate Citrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208551.pdf","Draft","Intravenous","Powder","208551","11/16/2023","PSG_208551.pdf"
"Ferric Pyrophosphate Citrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_206317.pdf","Draft","Intravenous","Solution","206317","11/16/2023","PSG_206317.pdf"
"Ferric Pyrophosphate Citrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212860.pdf","Draft","Intravenous","Solution","212860","11/16/2023","PSG_212860.pdf"
"Ferumoxytol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022180.pdf","Draft","Intravenous","Solution","022180","11/19/2024","PSG_022180.pdf"
"Fesoterodine Fumarate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Fesoterodine_Fumarate_ERtab_22030_RC11-10.pdf","Draft","Oral","Tablet, Extended Release","022030","11/26/2010","Fesoterodine_Fumarate_ERtab_22030_RC11-10.pdf"
"Fexinidazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214429.pdf","Draft","Oral","Tablet","214429","02/16/2023","PSG_214429.pdf"
"Fexofenadine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_201373.pdf","Draft","Oral","Suspension","201373","10/30/2024","PSG_201373.pdf"
"Fexofenadine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021963.pdf","Draft","Oral","Suspension","021963","10/30/2024","PSG_021963.pdf"
"Fexofenadine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Fexofenadine_HCl_ODtab_21909_RC8-08.pdf","Draft","Oral","Tablet, Orally Disintegrating","021909","08/01/2008","Fexofenadine_HCl_ODtab_21909_RC8-08.pdf"
"Fexofenadine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020625.pdf","Draft","Oral","Capsule","020625","10/30/2024","PSG_020625.pdf"
"Fexofenadine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020872.pdf","Draft","Oral","Tablet","020872","10/30/2024","PSG_020872.pdf"
"Fexofenadine Hydrochloride; Pseudoephedrine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Fexofenadine;_Pseudoephedrine_ERtab_20786_21704_RC10-09.pdf","Draft","Oral","Tablet, Extended Release","020786                                                       021704","10/01/2009","Fexofenadine;_Pseudoephedrine_ERtab_20786_21704_RC10-09.pdf"
"Fezolinetant","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_216578.pdf","Draft","Oral","Tablet","216578","08/22/2024","PSG_216578.pdf"
"Fidaxomicin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/fidaxomicin_oral tablet_RLD 201699_RC08-16 separate posting.pdf","Draft","Oral","Tablet","201699","08/23/2016","fidaxomicin_oral tablet_RLD 201699_RC08-16 separate posting.pdf"
"Fidaxomicin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213138.pdf","Draft","Oral","For Suspension","213138","11/17/2022","PSG_213138.pdf"
"Finafloxacin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Finafloxacin_otic suspension drops_NDA 206307_RC07-18.pdf","Draft","Otic","Suspension/Drops","206307","07/20/2018","Finafloxacin_otic suspension drops_NDA 206307_RC07-18.pdf"
"Finasteride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020180.pdf","Draft","Oral","Tablet","020180                                                       020788","10/30/2024","PSG_020180.pdf"
"Finasteride; Tadalafil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215423.pdf","Draft","Oral","Capsule","215423","02/15/2024","PSG_215423.pdf"
"Finerenone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215341.pdf","Draft","Oral","Tablet","215341","10/30/2024","PSG_215341.pdf"
"Fingolimod Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022527.pdf","Draft","Oral","Capsule","022527","10/30/2024","PSG_022527.pdf"
"Fingolimod Lauryl Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214962.pdf","Draft","Oral","Tablet, Orally Disintegrating","214962","10/30/2024","PSG_214962.pdf"
"Fish Oil Triglycerides","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210589.pdf","Draft","Intravenous","Emulsion","210589","06/03/2020","PSG_210589.pdf"
"Fish oil; Medium chain triglycerides; Olive oil; Soybean oil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Fish oil; Medium chain triglycerides; Olive oil; Soybean oil NDA 207648 Feb 2019.pdf","Draft","Intravenous","Emulsion","207648","02/22/2019","Fish oil; Medium chain triglycerides; Olive oil; Soybean oil NDA 207648 Feb 2019.pdf"
"Flavoxate Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_016769.pdf","Draft","Oral","Tablet","016769","10/30/2024","PSG_016769.pdf"
"Flecainide Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018830.pdf","Draft","Oral","Tablet","018830","10/30/2024","PSG_018830.pdf"
"Flibanserin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022526.pdf","Draft","Oral","Tablet","022526","10/30/2024","PSG_022526.pdf"
"Flortaucipir F-18","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212123.pdf","Draft","Intravenous","Solution","212123","02/17/2022","PSG_212123.pdf"
"Flotufolastat F-18 Gallium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_216023.pdf","Draft","Intravenous","Solution","216023","02/15/2024","PSG_216023.pdf"
"Fluconazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019949.pdf","Draft","Oral","Tablet","019949","10/30/2024","PSG_019949.pdf"
"Flucytosine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017001.pdf","Draft","Oral","Capsule","017001","10/30/2024","PSG_017001.pdf"
"Fludarabine Phosphate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Fludarabine_tab_22273_RC03-12.pdf","Draft","Oral","Tablet","022273","03/28/2012","Fludarabine_tab_22273_RC03-12.pdf"
"Fludrocortisone Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_010060.pdf","Draft","Oral","Tablet","010060","10/30/2024","PSG_010060.pdf"
"Flunisolide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018148.pdf","Draft","Nasal","Spray, Metered","018148","05/19/2022","PSG_018148.pdf"
"Fluocinolone Acetonide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_012787.pdf","Draft","Topical","Cream","012787","10/21/2022","PSG_012787.pdf"
"Fluocinolone Acetonide; Hydroquinone; Tretinoin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Fluocinolone_Acetonide_Hydroquinone_Tretinoin_crm_21112_RC03-15.pdf","Draft","Topical","Cream","021112","03/06/2015","Fluocinolone_Acetonide_Hydroquinone_Tretinoin_crm_21112_RC03-15.pdf"
"Fluocinonide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Fluocinonide_topical cream_RLD 21758_RC12-16.pdf","Draft","Topical","Cream","021758","12/22/2016","Fluocinonide_topical cream_RLD 21758_RC12-16.pdf"
"Fluocinonide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Fluocinonide_topical gel_RLD 074935_RC06-16.pdf","Draft","Topical","Gel","017373","06/16/2016","Fluocinonide_topical gel_RLD 074935_RC06-16.pdf"
"Fluocinonide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Fluocinonide_topical ointment_RLD 075008_RC 06-16.pdf","Draft","Topical","Ointment","016909","06/16/2016","Fluocinonide_topical ointment_RLD 075008_RC 06-16.pdf"
"Fluocinonide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Fluocinonide_topical cream_NDA 019117_RC11-17.pdf","Draft","Topical","Cream","019117","02/08/2018","Fluocinonide_topical cream_NDA 019117_RC11-17.pdf"
"Fluorodopa F-18","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_200655.pdf","Draft","Intravenous","Solution","200655","11/18/2020","PSG_200655.pdf"
"Fluoroestradiol F-18","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212155.pdf","Draft","Intravenous","Solution","212155","02/17/2022","PSG_212155.pdf"
"Fluorometholone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_016851.pdf","Draft","Ophthalmic","Suspension/Drops","016851","02/15/2024","PSG_016851.pdf"
"Fluorometholone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019216.pdf","Draft","Ophthalmic","Suspension/Drops","019216","06/03/2020","PSG_019216.pdf"
"Fluorometholone Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019079.pdf","Draft","Ophthalmic","Suspension/Drops","019079","09/16/2019","PSG_019079.pdf"
"Fluorouracil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022259.pdf","Draft","Topical","Cream","022259","10/21/2022","PSG_022259.pdf"
"Fluorouracil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_016988.pdf","Draft","Topical","Cream","016988","10/21/2022","PSG_016988.pdf"
"Fluorouracil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Fluorouracil_sol5_16831_RC03-11.pdf","Draft","Topical","Solution  5%","016831","06/30/2011","Fluorouracil_sol5_16831_RC03-11.pdf"
"Fluorouracil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Fluorouracil_sol2_16831_RC03-11.pdf","Draft","Topical","Solution  2%","016831","06/30/2011","Fluorouracil_sol2_16831_RC03-11.pdf"
"Fluorouracil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Fluorouracil Topical Cream NDA 020985 RV Feb 2019.pdf","Draft","Topical","Cream","020985","02/22/2019","Fluorouracil Topical Cream NDA 020985 RV Feb 2019.pdf"
"Fluorouracil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_016831-Cre.pdf","Draft","Topical","Cream","016831","10/21/2022","PSG_016831-Cre.pdf"
"Fluoxetine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202133.pdf","Draft","Oral","Tablet","202133","10/30/2024","PSG_202133.pdf"
"Fluoxetine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021860.pdf","Draft","Oral","Tablet","021860","10/30/2024","PSG_021860.pdf"
"Fluoxetine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020974.pdf","Draft","Oral","Tablet","020974","10/30/2024","PSG_020974.pdf"
"Fluoxetine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Fluoxetine_HCl_DRcap_21235_RC08-10.pdf","Draft","Oral","Capsule, Delayed Release","021235","08/30/2010","Fluoxetine_HCl_DRcap_21235_RC08-10.pdf"
"Fluoxetine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018936.pdf","Draft","Oral","Capsule","018936","10/30/2024","PSG_018936.pdf"
"Fluoxetine Hydrochloride; Olanzapine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021520.pdf","Draft","Oral","Capsule","021520","10/30/2024","PSG_021520.pdf"
"Fluphenazine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_011751.pdf","Draft","Oral","Tablet","011751                                                       089743","10/30/2024","PSG_011751.pdf"
"Flurandrenolide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Flurandrenolide_topical lotion_RLD 013790_RC01-16.pdf","Draft","Topical","Lotion","013790","01/27/2016","Flurandrenolide_topical lotion_RLD 013790_RC01-16.pdf"
"Flutamide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018554.pdf","Draft","Oral","Capsule","018554","10/30/2024","PSG_018554.pdf"
"Fluticasone Furoate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_205625.pdf","Draft","Inhalation","Powder","205625","05/16/2024","PSG_205625.pdf"
"Fluticasone Furoate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022051.pdf","Draft","Nasal","Spray, Metered","022051","05/18/2023","PSG_022051.pdf"
"Fluticasone Furoate; Umeclidinium Bromide; Vilanterol Trifenatate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209482.pdf","Draft","Inhalation","Powder","209482","08/22/2024","PSG_209482.pdf"
"Fluticasone Furoate; Vilanterol Trifenatate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_204275.pdf","Draft","Inhalation","Powder","204275","05/16/2024","PSG_204275.pdf"
"Fluticasone Propionate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021433.pdf","Draft","Inhalation","Aerosol, Metered","021433","08/22/2024","PSG_021433.pdf"
"Fluticasone Propionate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020833.pdf","Draft","Inhalation","Powder","020833","11/19/2024","PSG_020833.pdf"
"Fluticasone Propionate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Fluticasone propionate_topical ointment_RLD 19957_RC09-16.pdf","Draft","Topical","Ointment","019957","10/04/2016","Fluticasone propionate_topical ointment_RLD 19957_RC09-16.pdf"
"Fluticasone Propionate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Fluticasone_Propionate_crm_19958_RC2-11.pdf","Draft","Topical","Cream","019958","02/23/2011","Fluticasone_Propionate_crm_19958_RC2-11.pdf"
"Fluticasone Propionate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_205434.pdf","Draft","Nasal","Spray, Metered","205434","05/19/2021","PSG_205434.pdf"
"Fluticasone Propionate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020121.pdf","Draft","Nasal","Spray, Metered","020121","05/18/2023","PSG_020121.pdf"
"Fluticasone Propionate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208798.pdf","Draft","Inhalation","Powder","208798","08/22/2024","PSG_208798.pdf"
"Fluticasone Propionate; Salmeterol Xinafoate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208799.pdf","Draft","Inhalation","Powder","208799","08/22/2024","PSG_208799.pdf"
"Fluticasone Propionate; Salmeterol Xinafoate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021254.pdf","Draft","Inhalation","Aerosol, Metered","021254","08/22/2024","PSG_021254.pdf"
"Fluticasone Propionate; Salmeterol Xinafoate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021077.pdf","Draft","Inhalation","Powder","021077","11/19/2024","PSG_021077.pdf"
"Fluvastatin Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020261.pdf","Draft","Oral","Capsule","020261","10/30/2024","PSG_020261.pdf"
"Fluvastatin Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Fluvastatin_Sodium_ERtab_21192_RC1-08.pdf","Draft","Oral","Tablet, Extended Release","021192","02/23/2008","Fluvastatin_Sodium_ERtab_21192_RC1-08.pdf"
"Fluvoxamine Maleate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022033.pdf","Draft","Oral","Capsule, Extended Release","022033","08/21/2023","PSG_022033.pdf"
"Formoterol Fumarate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020831.pdf","Draft","Inhalation","Powder","020831","11/19/2024","PSG_020831.pdf"
"Formoterol Fumarate; Glycopyrrolate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208294.pdf","Draft","Inhalation","Aerosol, Metered","208294","02/15/2024","PSG_208294.pdf"
"Formoterol Fumarate; Mometasone Furoate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022518.pdf","Draft","Inhalation","Aerosol, Metered","022518","11/19/2024","PSG_022518.pdf"
"Fosamprenavir Calcium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Fosamprenavir_Calcium_susp_22116_RC11-07.pdf","Draft","Oral","Suspension","022116","11/01/2007","Fosamprenavir_Calcium_susp_22116_RC11-07.pdf"
"Fosamprenavir Calcium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021548.pdf","Draft","Oral","Tablet","021548","10/30/2024","PSG_021548.pdf"
"Fosdenopterin Hydrobromide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214018.pdf","Draft","Intravenous","Powder","214018","11/17/2022","PSG_214018.pdf"
"Fosfomycin Tromethamine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Fosfomycin Tromethamine Oral Solution NDA 050717 PSG Page RV May 2019.pdf","Draft","Oral","For Solution","050717","05/15/2019","Fosfomycin Tromethamine Oral Solution NDA 050717 PSG Page RV May 2019.pdf"
"Fosinopril Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019915.pdf","Draft","Oral","Tablet","019915","10/30/2024","PSG_019915.pdf"
"Fosinopril Sodium; Hydrochlorothiazide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020286.pdf","Draft","Oral","Tablet","020286","10/30/2024","PSG_020286.pdf"
"Fosnetupitant Chloride Hydrochloride; Palonosetron Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Fosnetupitant and Palonosetron Hydrochloride, powder for injection NDA 210493 PSG Page RC May 2019.pdf","Draft","Intravenous","Powder","210493","05/15/2019","Fosnetupitant and Palonosetron Hydrochloride, powder for injection NDA 210493 PSG Page RC May 2019.pdf"
"Fostamatinib Disodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209299.pdf","Draft","Oral","Tablet","209299","09/16/2019","PSG_209299.pdf"
"Fostemsavir Tromethamine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212950.pdf","Draft","Oral","Tablet, Extended Release","212950","08/20/2021","PSG_212950.pdf"
"Frovatriptan Succinate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021006.pdf","Draft","Oral","Tablet","021006","10/30/2024","PSG_021006.pdf"
"Fulvestrant","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021344.pdf","Draft","Intramuscular","Solution","021344","11/16/2023","PSG_021344.pdf"
"Furosemide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_016273.pdf","Draft","Oral","Tablet","016273","10/30/2024","PSG_016273.pdf"
"Furosemide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209988.pdf","Draft","Subcutaneous","Solution","209988","11/16/2023","PSG_209988.pdf"
"Futibatinib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214801.pdf","Draft","Oral","Tablet","214801","10/30/2024","PSG_214801.pdf"
"Gabapentin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022544.pdf","Draft","Oral","Tablet","022544","11/16/2023","PSG_022544.pdf"
"Gabapentin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020235.pdf","Draft","Oral","Capsule","020235","10/30/2024","PSG_020235.pdf"
"Gabapentin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020882.pdf","Draft","Oral","Tablet","020882","10/30/2024","PSG_020882.pdf"
"Gabapentin Enacarbil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Gabapentin_Enacarbil_ERtab_022399_RC06-12.pdf","Draft","Oral","Tablet, Extended Release","022399","06/14/2012","Gabapentin_Enacarbil_ERtab_022399_RC06-12.pdf"
"Gadopiclenol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_216986.pdf","Draft","Intravenous","Solution","216986","05/16/2024","PSG_216986.pdf"
"Galantamine Hydrobromide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021169.pdf","Draft","Oral","Tablet","021169","10/30/2024","PSG_021169.pdf"
"Galantamine Hydrobromide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Galantamine_HBr_ERcap_21615_RC11-051.pdf","Draft","Oral","Capsule, Extended Release","021615","05/01/2007","Galantamine_HBr_ERcap_21615_RC11-051.pdf"
"Gallium DOTATOC Ga 68","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210828.pdf","Draft","Intravenous","Solution","210828","08/28/2020","PSG_210828.pdf"
"Gallium Ga-68 Gozetotide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212642.pdf","Draft","Intravenous","Solution","212642                                                       212643","08/02/2022","PSG_212642.pdf"
"Ganaxolone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215904.pdf","Draft","Oral","Suspension","215904","10/30/2024","PSG_215904.pdf"
"Ganciclovir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022211.pdf","Draft","Ophthalmic","Gel","022211","05/16/2024","PSG_022211.pdf"
"Ganciclovir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020460.pdf","Draft","Oral","Capsule","020460","10/30/2024","PSG_020460.pdf"
"Ganirelix Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021057.pdf","Draft","Injection","Injectable","021057","05/16/2024","PSG_021057.pdf"
"Gatifloxacin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Gatifloxacin_ophthalmic solution drops_NDA 021493_RV11-17.pdf","Draft","Ophthalmic","Solution  0.3%","021493","02/08/2018","Gatifloxacin_ophthalmic solution drops_NDA 021493_RV11-17.pdf"
"Gefitinib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_206995.pdf","Draft","Oral","Tablet","206995","10/30/2024","PSG_206995.pdf"
"Gemfibrozil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Gemfibrozil_ tab_18422_RC12-09.pdf","Draft","Oral","Tablet","018422","12/17/2009","Gemfibrozil_ tab_18422_RC12-09.pdf"
"Gemifloxacin Mesylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021158.pdf","Draft","Oral","Tablet","021158","10/30/2024","PSG_021158.pdf"
"Gentamicin Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_060462.pdf","Draft","Topical","Cream","062307","10/21/2022","PSG_060462.pdf"
"Gentamicin Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_060463.pdf","Draft","Topical","Ointment","062351","10/21/2022","PSG_060463.pdf"
"Gentamicin Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Gentamicin sulfate_ophthalmic solution drops_NDA 050039_RV11-17.pdf","Draft","Ophthalmic","Solution","050039","02/08/2018","Gentamicin sulfate_ophthalmic solution drops_NDA 050039_RV11-17.pdf"
"Gilteritinib Fumarate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211349.pdf","Draft","Oral","Tablet","211349","10/30/2024","PSG_211349.pdf"
"Givosiran Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212194.pdf","Draft","Subcutaneous","Solution","212194","05/18/2023","PSG_212194.pdf"
"Glasdegib Maleate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210656.pdf","Draft","Oral","Tablet","210656","10/30/2024","PSG_210656.pdf"
"Glatiramer Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020622.pdf","Draft","Subcutaneous","Injectable","020622","11/16/2023","PSG_020622.pdf"
"Glecaprevir; Pibrentasvir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Glecaprevir Pibrentasvir Oral Tablet NDA 209394 RC 09-2018.pdf","Draft","Oral","Tablet","209394","09/13/2018","Glecaprevir Pibrentasvir Oral Tablet NDA 209394 RC 09-2018.pdf"
"Glimepiride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020496.pdf","Draft","Oral","Tablet","020496","10/30/2024","PSG_020496.pdf"
"Glimepiride; Pioglitazone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021925.pdf","Draft","Oral","Tablet","021925","10/30/2024","PSG_021925.pdf"
"Glimepiride; Rosiglitazone Maleate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021700.pdf","Draft","Oral","Tablet","021700","10/30/2024","PSG_021700.pdf"
"Glipizide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017783.pdf","Draft","Oral","Tablet","017783","10/30/2024","PSG_017783.pdf"
"Glipizide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Glipizide_ERtab_20329_RC7-08.pdf","Draft","Oral","Tablet, Extended Release","020329","07/01/2008","Glipizide_ERtab_20329_RC7-08.pdf"
"Glipizide; Metformin Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021460.pdf","Draft","Oral","Tablet","021460","10/30/2024","PSG_021460.pdf"
"Glucagon","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212097.pdf","Draft","Subcutaneous","Solution","212097","08/21/2023","PSG_212097.pdf"
"Glucagon","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210134.pdf","Draft","Nasal","Powder","210134","02/16/2023","PSG_210134.pdf"
"Glyburide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020051.pdf","Draft","Oral","Tablet","020051","10/30/2024","PSG_020051.pdf"
"Glyburide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017498.pdf","Draft","Oral","Tablet","017532                                                       017498                                                       074388","10/30/2024","PSG_017498.pdf"
"Glyburide; Metformin Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021178.pdf","Draft","Oral","Tablet","021178","10/30/2024","PSG_021178.pdf"
"Glycopyrrolate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_207923.pdf","Draft","Inhalation","Powder","207923","05/18/2023","PSG_207923.pdf"
"Glycopyrrolate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Glycopyrrolate_tab_12827_RC11-09.pdf","Draft","Oral","Tablet","012827","11/23/2009","Glycopyrrolate_tab_12827_RC11-09.pdf"
"Glycopyrrolate; Indacaterol Maleate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_207930.pdf","Draft","Inhalation","Powder","207930","05/18/2023","PSG_207930.pdf"
"Glycopyrrolate; Neostigmine Methylsulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_216903.pdf","Draft","Intravenous","Solution","216903","11/16/2023","PSG_216903.pdf"
"Glycopyrronium Tosylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210361.pdf","Draft","Topical","Cloth","210361","09/16/2019","PSG_210361.pdf"
"Golodirsen","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211970.pdf","Draft","Intravenous","Solution","211970","02/16/2023","PSG_211970.pdf"
"Goserelin Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019726.pdf","Draft","Implantation","Implant","019726","11/17/2022","PSG_019726.pdf"
"Goserelin Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020578.pdf","Draft","Implantation","Implant","020578","11/17/2022","PSG_020578.pdf"
"Granisetron","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022198.pdf","Draft","Transdermal","Film, Extended Release","022198","11/21/2019","PSG_022198.pdf"
"Granisetron","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022445.pdf","Draft","Subcutaneous","Injection, Extended Release","022445","03/02/2020","PSG_022445.pdf"
"Granisetron Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020305.pdf","Draft","Oral","Tablet","020305","10/30/2024","PSG_020305.pdf"
"Griseofulvin Microsize","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Griseofulvin_Microcrystalline_Susp_62483_RC11-10.pdf","Draft","Oral","Suspension","062483","11/26/2010","Griseofulvin_Microcrystalline_Susp_62483_RC11-10.pdf"
"Griseofulvin Ultramicrosize","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Griseofulvin,_Ultramicrocrystalline_tab_50475_RC10-08.pdf","Draft","Oral","Tablet","050475","10/01/2008","Griseofulvin,_Ultramicrocrystalline_tab_50475_RC10-08.pdf"
"Griseofulvin; Microcrystalline","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_062279.pdf","Draft","Oral","Tablet","062279","10/30/2024","PSG_062279.pdf"
"Guaifenesin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Guaifenesin_ERtab_21282_RC02-14.pdf","Draft","Oral","Tablet, Extended Release","021282","04/01/2014","Guaifenesin_ERtab_21282_RC02-14.pdf"
"Guaifenesin; Pseudoephedrine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Guaifenesin;_Pseudoephedrine_HCl_ERtab_21585_RC12-08.pdf","Draft","Oral","Tablet, Extended Release","021585","12/20/2008","Guaifenesin;_Pseudoephedrine_HCl_ERtab_21585_RC12-08.pdf"
"Guanfacine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Guanfacine hydrochloride_oral ER tablet_022037_RV01-16.pdf","Draft","Oral","Tablet, Extended Release","022037","01/27/2016","Guanfacine hydrochloride_oral ER tablet_022037_RV01-16.pdf"
"Guanfacine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019032.pdf","Draft","Oral","Tablet","019032","10/30/2024","PSG_019032.pdf"
"Halcinonide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Halcinonide_topical cream_RLD 017556_RC12-16.pdf","Draft","Topical","Cream","017556","12/22/2016","Halcinonide_topical cream_RLD 017556_RC12-16.pdf"
"Halcinonide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Halcinonide topical ointment NDA 017824 PSG Page RC May 2019.pdf","Draft","Topical","Ointment","017824","05/15/2019","Halcinonide topical ointment NDA 017824 PSG Page RC May 2019.pdf"
"Halobetasol Propionate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210566.pdf","Draft","Topical","Aerosol, Foam","210566","05/19/2022","PSG_210566.pdf"
"Halobetasol Propionate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209355.pdf","Draft","Topical","Lotion","209355","10/21/2022","PSG_209355.pdf"
"Halobetasol Propionate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Halobetasol_topical lotion_RLD 208183_RC 09-16.pdf","Draft","Topical","Lotion","208183","10/04/2016","Halobetasol_topical lotion_RLD 208183_RC 09-16.pdf"
"Halobetasol Propionate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Halobetasol propionate_topical cream_NDA 19967_RC04-16.pdf","Draft","Topical","Cream","019967","04/14/2016","Halobetasol propionate_topical cream_NDA 19967_RC04-16.pdf"
"Halobetasol Propionate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019968.pdf","Draft","Topical","Ointment","019968","08/22/2024","PSG_019968.pdf"
"Halobetasol Propionate; Tazarotene","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209354.pdf","Draft","Topical","Lotion","209354","11/16/2023","PSG_209354.pdf"
"Haloperidol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_015921.pdf","Draft","Oral","Tablet","015921","10/30/2024","PSG_015921.pdf"
"Heparin Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017029.pdf","Draft","Injection","Injectable","017029                                                       019952                                                       017007                                                       017037                                                       201370                                                       018916                                                       019953                                                       017651                                                       088100","02/17/2022","PSG_017029.pdf"
"Heparin Sodium; Taurolidine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214520.pdf","Draft","","Solution","214520","08/22/2024","PSG_214520.pdf"
"Homatropine Methylbromide; Hydrocodone Bitartrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Homatropine_Methylbromide;_Hydrocodone_Bitartrate_tabs_88508_RC12-09.pdf","Draft","Oral","Tablet","005213","12/01/2009","Homatropine_Methylbromide;_Hydrocodone_Bitartrate_tabs_88508_RC12-09.pdf"
"Hydralazine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Hydralazine_tab_89098_89097_88467_88468_RC7-08.pdf","Draft","Oral","Tablet","008303","07/01/2008","Hydralazine_tab_89098_89097_88467_88468_RC7-08.pdf"
"Hydralazine Hydrochloride; Isosorbide Dinitrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020727.pdf","Draft","Oral","Tablet","020727","10/30/2024","PSG_020727.pdf"
"Hydrochlorothiazide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_011835.pdf","Draft","Oral","Tablet","011835","10/30/2024","PSG_011835.pdf"
"Hydrochlorothiazide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020504.pdf","Draft","Oral","Capsule","020504","10/30/2024","PSG_020504.pdf"
"Hydrochlorothiazide; Lisinopril","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019778.pdf","Draft","Oral","Tablet","019778                                                       019888","10/30/2024","PSG_019778.pdf"
"Hydrochlorothiazide; Losartan Potassium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020387.pdf","Draft","Oral","Tablet","020387","10/30/2024","PSG_020387.pdf"
"Hydrochlorothiazide; Metoprolol Succinate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021956.pdf","Draft","Oral","Tablet, Extended Release","021956","08/22/2024","PSG_021956.pdf"
"Hydrochlorothiazide; Metoprolol Tartrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018303.pdf","Draft","Oral","Tablet","018303","10/30/2024","PSG_018303.pdf"
"Hydrochlorothiazide; Moexipril Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Hydrochlorothiazide_Moexipril_HCl_Tablets_020729_RV07-14.pdf","Draft","Oral","Tablet","020729","07/22/2014","Hydrochlorothiazide_Moexipril_HCl_Tablets_020729_RV07-14.pdf"
"Hydrochlorothiazide; Olmesartan Medoxomil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021532.pdf","Draft","Oral","Tablet","021532","10/30/2024","PSG_021532.pdf"
"Hydrochlorothiazide; Quinapril Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020125.pdf","Draft","Oral","Tablet","020125","10/30/2024","PSG_020125.pdf"
"Hydrochlorothiazide; Spironolactone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_012616.pdf","Draft","Oral","Tablet","012616","10/30/2024","PSG_012616.pdf"
"Hydrochlorothiazide; Telmisartan","https://www.accessdata.fda.gov/drugsatfda_docs/psg/HCTZ_Telmisartan_tab_21162_RC7-08.pdf","Draft","Oral","Tablet","021162","07/01/2008","HCTZ_Telmisartan_tab_21162_RC7-08.pdf"
"Hydrochlorothiazide; Triamterene","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019129.pdf","Draft","Oral","Tablet","019129","10/30/2024","PSG_019129.pdf"
"Hydrochlorothiazide; Triamterene","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_016042.pdf","Draft","Oral","Capsule","016042                                                       073191","10/30/2024","PSG_016042.pdf"
"Hydrochlorothiazide; Valsartan","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020818.pdf","Draft","Oral","Tablet","020818","10/30/2024","PSG_020818.pdf"
"Hydrochlorothiazide;Irbesartan","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020758.pdf","Draft","Oral","Tablet","020758","10/30/2024","PSG_020758.pdf"
"Hydrocodone Bitartrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Hydrocodone bitartrate_oral ER cap_RLD 202880_RC09-16.pdf","Draft","Oral","Capsule, Extended Release","202880","10/04/2016","Hydrocodone bitartrate_oral ER cap_RLD 202880_RC09-16.pdf"
"Hydrocodone Bitartrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Hydrocodone bitartrate_oral ER tablet_NDA 206627_RV07-18.pdf","Draft","Oral","Tablet, Extended Release","206627","07/20/2018","Hydrocodone bitartrate_oral ER tablet_NDA 206627_RV07-18.pdf"
"Hydrocodone Bitartrate; Ibuprofen","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020716.pdf","Draft","Oral","Tablet","020716","10/30/2024","PSG_020716.pdf"
"Hydrocortisone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_009585.pdf","Draft","Topical","Cream","089414","10/21/2022","PSG_009585.pdf"
"Hydrocortisone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Hydrocortisone_topical solution_RLD 81271_RC06-16.pdf","Draft","Topical","Solution","081271","06/16/2016","Hydrocortisone_topical solution_RLD 81271_RC06-16.pdf"
"Hydrocortisone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_008697.pdf","Draft","Oral","Tablet","008697","10/30/2024","PSG_008697.pdf"
"Hydrocortisone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_016199.pdf","Draft","Rectal","Enema","016199","11/17/2022","PSG_016199.pdf"
"Hydrocortisone Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017351.pdf","Draft","Rectal","Aerosol, Metered","017351","11/18/2020","PSG_017351.pdf"
"Hydrocortisone Butyrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Hydrocortisone butyrate_topical lotion_RLD 022076_RC03-17.pdf","Draft","Topical","Lotion","022076","05/16/2017","Hydrocortisone butyrate_topical lotion_RLD 022076_RC03-17.pdf"
"Hydrocortisone Valerate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Hydrocortisone valerate_topical ointment_RLD 070543_RC09-16.pdf","Draft","Topical","Ointment","018726","10/04/2016","Hydrocortisone valerate_topical ointment_RLD 070543_RC09-16.pdf"
"Hydrocortisone Valerate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Hydrocortisone valerate_topical cream_NDA 017950_RC11-17.pdf","Draft","Topical","Cream","017950","02/08/2018","Hydrocortisone valerate_topical cream_NDA 017950_RC11-17.pdf"
"Hydrocortisone; Neomycin Sulfate; Polymyxin B Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_060613.pdf","Draft","Otic","Suspension/Drops","060613","02/15/2024","PSG_060613.pdf"
"Hydrogen Peroxide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209305.pdf","Draft","Topical","Solution","209305","09/16/2019","PSG_209305.pdf"
"Hydromorphone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021217.pdf","Draft","Oral","Tablet, Extended Release","021217","08/22/2024","PSG_021217.pdf"
"Hydromorphone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019892.pdf","Draft","Oral","Tablet","019892","10/30/2024","PSG_019892.pdf"
"Hydroxychloroquine Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_009768.pdf","Draft","Oral","Tablet","009768","10/30/2024","PSG_009768.pdf"
"Hydroxyurea","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208843.pdf","Draft","Oral","Tablet","208843","11/17/2022","PSG_208843.pdf"
"Hydroxyurea","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_016295.pdf","Draft","Oral","Capsule","016295","02/16/2023","PSG_016295.pdf"
"Hydroxyzine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Hydroxyzine_HCl_tabs_88617_88618_88619_RC06-10.pdf","Draft","Oral","Tablet","088617                                                       088618                                                       088619","06/01/2010","Hydroxyzine_HCl_tabs_88617_88618_88619_RC06-10.pdf"
"Hydroxyzine Pamoate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_011459.pdf","Draft","Oral","Capsule","011459","10/30/2024","PSG_011459.pdf"
"Hydroxyzine Pamoate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_011795.pdf","Draft","Oral","Suspension","011795","10/30/2024","PSG_011795.pdf"
"Ibandronate Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Ibandronate_tab_21455_RC11-06.pdf","Final","Oral","Tablet","021455","05/12/2008","Ibandronate_tab_21455_RC11-06.pdf"
"Ibrexafungerp Citrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214900.pdf","Draft","Oral","Tablet","214900","10/30/2024","PSG_214900.pdf"
"Ibrutinib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210563.pdf","Draft","Oral","Tablet","210563","10/30/2024","PSG_210563.pdf"
"Ibrutinib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_205552.pdf","Draft","Oral","Capsule","205552","10/30/2024","PSG_205552.pdf"
"Ibuprofen","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020812.pdf","Draft","Oral","Suspension/Drops","020812","10/30/2024","PSG_020812.pdf"
"Ibuprofen","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020601.pdf","Draft","Oral","Tablet, Chewable","020601","10/30/2024","PSG_020601.pdf"
"Ibuprofen","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019842.pdf","Draft","Oral","Suspension","019842","10/30/2024","PSG_019842.pdf"
"Ibuprofen","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020402.pdf","Draft","Oral","Capsule","020402","10/30/2024","PSG_020402.pdf"
"Ibuprofen","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021472.pdf","Draft","Oral","Capsule","021472","10/30/2024","PSG_021472.pdf"
"Ibuprofen","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017463.pdf","Draft","Oral","Tablet","075682                                                       017463","10/30/2024","PSG_017463.pdf"
"Ibuprofen","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019012.pdf","Draft","Oral","Tablet","019012","10/30/2024","PSG_019012.pdf"
"Ibuprofen","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020516.pdf","Draft","Oral","Suspension","020516","10/30/2024","PSG_020516.pdf"
"Ibuprofen","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Ibuprofen_suspdrp_20603_OTC_RC10-08.pdf","Draft","Oral","Suspension/Drops","020603","10/01/2008","Ibuprofen_suspdrp_20603_OTC_RC10-08.pdf"
"Ibuprofen Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_201803.pdf","Draft","Oral","Tablet","201803","10/30/2024","PSG_201803.pdf"
"Ibuprofen; Phenylephrine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022565.pdf","Draft","Oral","Tablet","022565","10/30/2024","PSG_022565.pdf"
"Ibuprofen; Pseudoephedrine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021374.pdf","Draft","Oral","Capsule","021374","10/30/2024","PSG_021374.pdf"
"Ibuprofen; Pseudoephedrine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021128.pdf","Draft","Oral","Suspension","021128","10/30/2024","PSG_021128.pdf"
"Ibuprofen; Pseudoephedrine hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019771.pdf","Draft","Oral","Tablet","019771","10/30/2024","PSG_019771.pdf"
"Icatibant Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022150.pdf","Draft","Subcutaneous","Injectable","022150","11/19/2024","PSG_022150.pdf"
"Icosapent Ethyl","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202057.pdf","Draft","Oral","Capsule","202057","10/30/2024","PSG_202057.pdf"
"Idelalisib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_205858.pdf","Draft","Oral","Tablet","205858","10/30/2024","PSG_205858.pdf"
"Iloperidone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022192.pdf","Draft","Oral","Tablet","022192","10/30/2024","PSG_022192.pdf"
"Imatinib Mesylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Imatinib_Mesylate_tab_21588_RV07-14.pdf","Draft","Oral","Tablet","021588","07/22/2014","Imatinib_Mesylate_tab_21588_RV07-14.pdf"
"Imipramine Pamoate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017090.pdf","Draft","Oral","Capsule","017090","10/30/2024","PSG_017090.pdf"
"Imiquimod","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Imiquimod Topical Cream 2.5_NDA 022483 RV Feb 2019.pdf","Draft","Topical","Cream  2.5%","022483","02/22/2019","Imiquimod Topical Cream 2.5_NDA 022483 RV Feb 2019.pdf"
"Imiquimod","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Imiquimod Topical Cream 3.75_NDA 022483 RV Feb 2019.pdf","Draft","Topical","Cream  3.75%","022483","02/22/2019","Imiquimod Topical Cream 3.75_NDA 022483 RV Feb 2019.pdf"
"Imiquimod","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Imiquimod Topical Cream NDA 020723 RV Feb 2019.pdf","Draft","Topical","Cream","020723","02/22/2019","Imiquimod Topical Cream NDA 020723 RV Feb 2019.pdf"
"Inclisiran Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214012.pdf","Draft","Subcutaneous","Solution","214012","11/21/2023","PSG_214012.pdf"
"Indacaterol Maleate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022383.pdf","Draft","Inhalation","Powder","022383","05/18/2023","PSG_022383.pdf"
"Indapamide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018538.pdf","Draft","Oral","Tablet","018538","10/30/2024","PSG_018538.pdf"
"Indinavir Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020685.pdf","Draft","Oral","Capsule","020685","10/30/2024","PSG_020685.pdf"
"Indocyanine Green","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211580.pdf","Draft","Intravenous, Interstitial","Powder","211580","11/21/2019","PSG_211580.pdf"
"Indomethacin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_204768.pdf","Draft","Oral","Capsule","204768","10/30/2024","PSG_204768.pdf"
"Indomethacin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_016059.pdf","Draft","Oral","Capsule","016059","10/30/2024","PSG_016059.pdf"
"Indomethacin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Indomethacin_ERcap_74464_RC2-10.pdf","Draft","Oral","Capsule, Extended Release","018185","02/25/2010","Indomethacin_ERcap_74464_RC2-10.pdf"
"Indomethacin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018332.pdf","Draft","Oral","Suspension","018332","10/30/2024","PSG_018332.pdf"
"Indomethacin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017814.pdf","Draft","Rectal","Suppository","017814","08/20/2021","PSG_017814.pdf"
"Infigratinib Phosphate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214622.pdf","Draft","Oral","Capsule","214622","02/16/2023","PSG_214622.pdf"
"Ingenol Mebutate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Ingenol Mebutate Topical Gel 0.05_NDA 202833 RV Feb 2019.pdf","Draft","Topical","Gel  0.050%","202833","02/22/2019","Ingenol Mebutate Topical Gel 0.05_NDA 202833 RV Feb 2019.pdf"
"Ingenol Mebutate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Ingenol Mebutate Topical Gel 0.015_NDA 202833 RV Feb 2019.pdf","Draft","Topical","Gel  0.015%","202833","02/22/2019","Ingenol Mebutate Topical Gel 0.015_NDA 202833 RV Feb 2019.pdf"
"Inotersen Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211172.pdf","Draft","Subcutaneous","Solution","211172","11/17/2022","PSG_211172.pdf"
"Ipratropium Bromide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020393.pdf","Draft","Nasal","Spray, Metered","020393                                                       020394","08/20/2021","PSG_020393.pdf"
"Ipratropium Bromide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021527.pdf","Draft","Inhalation","Aerosol, Metered","021527","08/21/2023","PSG_021527.pdf"
"Irbesartan","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020757.pdf","Draft","Oral","Tablet","020757","10/30/2024","PSG_020757.pdf"
"Irinotecan Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_207793.pdf","Draft","Intravenous","Injectable, Liposomal","207793","02/17/2022","PSG_207793.pdf"
"Isavuconazonium Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_207500.pdf","Draft","Oral","Capsule","207500","10/30/2024","PSG_207500.pdf"
"Isocarboxazid","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_011961.pdf","Draft","Oral","Tablet","011961","10/30/2024","PSG_011961.pdf"
"Isoniazid","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Isoniazid_oral tablet_RLD 08678_RC7-08.pdf","Draft","Oral","Tablet","008678","07/01/2008","Isoniazid_oral tablet_RLD 08678_RC7-08.pdf"
"Isoniazid; Pyrazinamide; Rifampin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050705.pdf","Draft","Oral","Tablet","050705","11/21/2019","PSG_050705.pdf"
"Isosorbide Dinitrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019790.pdf","Draft","Oral","Capsule, Extended Release","019790","11/21/2019","PSG_019790.pdf"
"Isosorbide Dinitrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_012093-Tab-40MG.pdf","Draft","Oral","Tablet","012093","10/30/2024","PSG_012093-Tab-40MG.pdf"
"Isosorbide Dinitrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_012093-Tab-30MG.pdf","Draft","Oral","Tablet","087946","10/30/2024","PSG_012093-Tab-30MG.pdf"
"Isosorbide Mononitrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Isosorbide_Mononitrate_ERtab_20225_RC10-05.pdf","Final","Oral","Tablet, Extended Release","020225","05/01/2008","Isosorbide_Mononitrate_ERtab_20225_RC10-05.pdf"
"Isotretinoin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018662.pdf","Draft","Oral","Capsule","076135                                                       018662","11/18/2020","PSG_018662.pdf"
"Isotretinoin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021951.pdf","Draft","Oral","Capsule","021951","11/18/2020","PSG_021951.pdf"
"Isradipine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019546.pdf","Draft","Oral","Capsule","019546","10/30/2024","PSG_019546.pdf"
"Isradipine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Isradipine_ERtab_20336_RC7-05.pdf","Final","Oral","Tablet, Extended Release","020336","05/12/2008","Isradipine_ERtab_20336_RC7-05.pdf"
"Istradefylline","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022075.pdf","Draft","Oral","Tablet","022075","10/30/2024","PSG_022075.pdf"
"Itraconazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Itraconazole_Tab_22484_RC06-12.pdf","Draft","Oral","Tablet","022484","06/14/2012","Itraconazole_Tab_22484_RC06-12.pdf"
"Itraconazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Itraconazole_cap_20083_RC5-06.pdf","Draft","Oral","Capsule","020083","05/01/2007","Itraconazole_cap_20083_RC5-06.pdf"
"Ivabradine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_206143.pdf","Draft","Oral","Tablet","206143","10/30/2024","PSG_206143.pdf"
"Ivacaftor","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_207925.pdf","Draft","Oral","Granule","207925","05/18/2023","PSG_207925.pdf"
"Ivacaftor","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Ivacaftor_Tablet_203188_RC03-15.pdf","Draft","Oral","Tablet","203188","03/06/2015","Ivacaftor_Tablet_203188_RC03-15.pdf"
"Ivacaftor; Ivacaftor, Tezacaftor","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210491.pdf","Draft","Oral","Tablet, Tablet","210491","03/24/2021","PSG_210491.pdf"
"Ivacaftor; Lumacaftor","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211358.pdf","Draft","Oral","Granule","211358","03/02/2020","PSG_211358.pdf"
"Ivacaftor;Lumacaftor","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Ivacaftor-Lumacaftor Oral Tablet NDA 206038 RV Feb 2019.pdf","Draft","Oral","Tablet","206038","02/22/2019","Ivacaftor-Lumacaftor Oral Tablet NDA 206038 RV Feb 2019.pdf"
"Ivermectin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_206255.pdf","Draft","Topical","Cream","206255","10/21/2022","PSG_206255.pdf"
"Ivermectin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Ivermenctin_tabs_50742_RC03-12.pdf","Draft","Oral","Tablet","050742","03/28/2012","Ivermenctin_tabs_50742_RC03-12.pdf"
"Ivermectin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202736.pdf","Draft","Topical","Lotion","202736","10/21/2022","PSG_202736.pdf"
"Ivosidenib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211192.pdf","Draft","Oral","Tablet","211192","06/03/2020","PSG_211192.pdf"
"Ixazomib Citrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Ixazomibe citrate_oral capsule_NDA 208462_RC11-17.pdf","Draft","Oral","Capsule","208462","02/08/2018","Ixazomibe citrate_oral capsule_NDA 208462_RC11-17.pdf"
"Ketoconazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018533.pdf","Draft","Oral","Tablet","018533","10/30/2024","PSG_018533.pdf"
"Ketoconazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021946.pdf","Draft","Topical","Gel","021946","10/21/2022","PSG_021946.pdf"
"Ketoconazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019084.pdf","Draft","Topical","Cream","019084","10/21/2022","PSG_019084.pdf"
"Ketoconazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Ketoconazole_fmaerosol_ 21738_RV12-14.pdf","Draft","Topical","Aerosol, Foam","021738","12/29/2014","Ketoconazole_fmaerosol_ 21738_RV12-14.pdf"
"Ketoconazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Ketoconazole_sham_1_ 20310_RC09-12.pdf","Draft","Topical, Suspension","Shampoo","020310","09/19/2012","Ketoconazole_sham_1_ 20310_RC09-12.pdf"
"Ketoconazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Ketoconazole_Sham_ 19927_RC7-08.pdf","Draft","Topical","Shampoo","019927","07/01/2008","Ketoconazole_Sham_ 19927_RC7-08.pdf"
"Ketoprofen","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018754.pdf","Draft","Oral","Capsule","018754","10/30/2024","PSG_018754.pdf"
"Ketoprofen","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019816.pdf","Draft","Oral","Capsule, Extended Release","019816","09/16/2019","PSG_019816.pdf"
"Ketorolac Tromethamine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022382.pdf","Draft","Nasal","Spray, Metered","022382","08/28/2020","PSG_022382.pdf"
"Ketorolac Tromethamine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019645.pdf","Draft","Oral","Tablet","019645","10/30/2024","PSG_019645.pdf"
"Ketotifen Fumarate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021066.pdf","Draft","Ophthalmic","Solution/Drops","021066                                                       021996","11/17/2022","PSG_021066.pdf"
"Labetalol Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018687.pdf","Draft","Oral","Tablet","018687                                                       018716","11/19/2024","PSG_018687.pdf"
"Lacosamide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_216185.pdf","Draft","Oral","Capsule, Extended Release","216185","05/16/2024","PSG_216185.pdf"
"Lacosamide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022253.pdf","Draft","Oral","Tablet","022253","10/30/2024","PSG_022253.pdf"
"Lactitol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211281.pdf","Draft","Oral","For Solution","211281","11/08/2021","PSG_211281.pdf"
"Lamivudine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021003.pdf","Draft","Oral","Tablet","021003","10/30/2024","PSG_021003.pdf"
"Lamivudine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020564.pdf","Draft","Oral","Tablet","020564","10/30/2024","PSG_020564.pdf"
"Lamivudine; Tenofovir Disoproxil Fumarate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211284.pdf","Draft","Oral","Tablet","211284","10/30/2024","PSG_211284.pdf"
"Lamivudine; Tenofovir Disoproxil Fumarate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022141.pdf","Draft","Oral","Tablet","022141","10/30/2024","PSG_022141.pdf"
"Lamivudine; Tenofovir Disoproxil Fumarate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022344.pdf","Draft","Oral","Tablet","022344","10/30/2024","PSG_022344.pdf"
"Lamivudine; Zidovudine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020857.pdf","Draft","Oral","Tablet","020857","10/30/2024","PSG_020857.pdf"
"Lamotrigine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Lamotrigine_draft_Oral tab ER_RLD 22115_RC01-16.pdf","Draft","Oral","Tablet, Extended Release","022115","01/27/2016","Lamotrigine_draft_Oral tab ER_RLD 22115_RC01-16.pdf"
"Lamotrigine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020764.pdf","Draft","Oral","Tablet, For Suspension","020764","10/30/2024","PSG_020764.pdf"
"Lamotrigine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020241.pdf","Draft","Oral","Tablet","020241","10/30/2024","PSG_020241.pdf"
"Lamotrigine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022251.pdf","Draft","Oral","Tablet, Orally Disintegrating","022251","10/30/2024","PSG_022251.pdf"
"Lanreotide Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Lanreotide Acetate_draft_Subcutaneous injection_RLD 22074_RC07-14.pdf","Draft","Subcutaneous","Solution","022074","07/22/2014","Lanreotide Acetate_draft_Subcutaneous injection_RLD 22074_RC07-14.pdf"
"Lansoprazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Lansoprazole_draft_Oral cap DR_RLD 20406_RC07-18.pdf","Draft","Oral","Capsule, Delayed Release","020406","07/20/2018","Lansoprazole_draft_Oral cap DR_RLD 20406_RC07-18.pdf"
"Lansoprazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021428.pdf","Draft","Oral","Tablet, Delayed Release, Orally Disintegrating","021428","11/08/2021","PSG_021428.pdf"
"Lanthanum Carbonate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Lanthanum carbonate_draft_Oral powder_RLD 204734_RC06-15.pdf","Draft","Oral","Powder","204734","06/24/2015","Lanthanum carbonate_draft_Oral powder_RLD 204734_RC06-15.pdf"
"Lanthanum Carbonate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021468.pdf","Draft","Oral","Tablet, Chewable","021468","08/02/2022","PSG_021468.pdf"
"Lapatinib Ditosylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022059.pdf","Draft","Oral","Tablet","022059","11/17/2022","PSG_022059.pdf"
"Larotrectinib Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210861.pdf","Draft","Oral","Capsule","210861","10/30/2024","PSG_210861.pdf"
"Lasmiditan Succinate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211280.pdf","Draft","Oral","Tablet","211280","10/30/2024","PSG_211280.pdf"
"Latanoprost","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_216472.pdf","Draft","Ophthalmic","Solution/Drops","216472","11/16/2023","PSG_216472.pdf"
"Latanoprost","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_206185.pdf","Draft","Ophthalmic","Emulsion","206185","06/03/2020","PSG_206185.pdf"
"Latanoprost","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Latanoprost_draft_Ophthalmic solution_RLD 20597_RC07-18.pdf","Draft","Ophthalmic","Solution","020597","07/20/2018","Latanoprost_draft_Ophthalmic solution_RLD 20597_RC07-18.pdf"
"Latanoprost; Netarsudil Dimesylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208259.pdf","Draft","Ophthalmic","Solution/Drops","208259","11/21/2019","PSG_208259.pdf"
"Latanoprostene bunod","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Latanoprostene Bunod_Ophthalmic solution drops_NDA 207795_RC Oct 2018.pdf","Draft","Ophthalmic","Solution/Drops","207795","11/28/2018","Latanoprostene Bunod_Ophthalmic solution drops_NDA 207795_RC Oct 2018.pdf"
"Ledipasvir; Sofosbuvir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_205834.pdf","Draft","Oral","Tablet","205834","05/19/2021","PSG_205834.pdf"
"Ledipasvir; Sofosbuvir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212477.pdf","Draft","Oral","Pellets","212477","03/24/2021","PSG_212477.pdf"
"Lefamulin Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211672.pdf","Draft","Oral","Tablet","211672","11/18/2020","PSG_211672.pdf"
"Lefamulin Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211673.pdf","Draft","Intravenous","Solution","211673","08/28/2020","PSG_211673.pdf"
"Leflunomide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020905.pdf","Draft","Oral","Tablet","020905","10/30/2024","PSG_020905.pdf"
"Lemborexant","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212028.pdf","Draft","Oral","Tablet","212028","10/30/2024","PSG_212028.pdf"
"Lenacapavir Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215974.pdf","Draft","Oral","Tablet","215974","02/15/2024","PSG_215974.pdf"
"Lenacapavir Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215973.pdf","Draft","Subcutaneous","Solution","215973","02/15/2024","PSG_215973.pdf"
"Lenalidomide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021880.pdf","Draft","Oral","Capsule","021880","10/30/2024","PSG_021880.pdf"
"Leniolisib Phosphate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_217759.pdf","Draft","Oral","Tablet","217759","08/22/2024","PSG_217759.pdf"
"Lenvatinib Mesylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_206947.pdf","Draft","Oral","Capsule","206947","11/19/2024","PSG_206947.pdf"
"Lesinurad","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_207988.pdf","Draft","Oral","Tablet","207988","10/30/2024","PSG_207988.pdf"
"Letermovir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Letermovir_IV_infusion_solution_NDA_209940_RC_Oct_2018.pdf","Draft","IV Infusion, Subcutaneous","Solution","209940","11/28/2018","Letermovir_IV_infusion_solution_NDA_209940_RC_Oct_2018.pdf"
"Letermovir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209939.pdf","Draft","Oral","Tablet","209939","10/30/2024","PSG_209939.pdf"
"Letrozole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020726.pdf","Draft","Oral","Tablet","020726","10/30/2024","PSG_020726.pdf"
"Letrozole;Ribociclib Succinate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209935.pdf","Draft","Oral","Tablet","209935","10/30/2024","PSG_209935.pdf"
"Leucovorin Calcium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018342.pdf","Draft","Oral","Tablet","018342","10/30/2024","PSG_018342.pdf"
"Leuprolide Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019732.pdf","Draft","Injection","Injectable","019732                                                       020011                                                       020263","08/20/2021","PSG_019732.pdf"
"Leuprolide Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021343.pdf","Draft","Subcutaneous","Powder","021343","08/20/2021","PSG_021343.pdf"
"Leuprolide Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020517.pdf","Draft","Injection","Injectable","020517                                                       020708","08/20/2021","PSG_020517.pdf"
"Leuprolide Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021379.pdf","Draft","Subcutaneous","Powder","021379                                                       021488","02/17/2022","PSG_021379.pdf"
"Leuprolide Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021731.pdf","Draft","Subcutaneous","Powder","021731                                                       213150","02/17/2022","PSG_021731.pdf"
"Leuprolide Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021088.pdf","Draft","Implantation","Implant","021088","11/08/2021","PSG_021088.pdf"
"Leuprolide Acetate; Norethindrone Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_203696.pdf","Draft","Intramuscular, Oral","Injectable, Tablet","203696","11/08/2021","PSG_203696.pdf"
"Leuprolide Mesylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211488.pdf","Draft","Subcutaneous","Emulsion","211488","02/16/2023","PSG_211488.pdf"
"Levalbuterol Tartrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021730.pdf","Draft","Inhalation","Aerosol, Metered","021730","08/22/2024","PSG_021730.pdf"
"Levetiracetam","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Levetiracetam_draft_Oral tab ER_RLD 22285_RC02-10.pdf","Draft","Oral","Tablet, Extended Release","022285","02/25/2010","Levetiracetam_draft_Oral tab ER_RLD 22285_RC02-10.pdf"
"Levetiracetam","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021035.pdf","Draft","Oral","Tablet","021035","10/30/2024","PSG_021035.pdf"
"Levetiracetam","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_207958.pdf","Draft","Oral","Tablet, For Suspension","207958","10/30/2024","PSG_207958.pdf"
"Levetiracetam","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_204417.pdf","Draft","Oral","Tablet, Extended Release","204417","09/16/2019","PSG_204417.pdf"
"Levocarnitine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018948.pdf","Draft","Oral","Tablet","018948","10/30/2024","PSG_018948.pdf"
"Levocetirizine Dihydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022064.pdf","Draft","Oral","Tablet","022064","10/30/2024","PSG_022064.pdf"
"Levocetirizine Dihydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209089.pdf","Draft","Oral","Tablet","209089","10/30/2024","PSG_209089.pdf"
"Levodopa","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209184.pdf","Draft","Inhalation","Powder","209184","05/16/2024","PSG_209184.pdf"
"Levofloxacin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020634.pdf","Draft","Oral","Tablet","020634","10/30/2024","PSG_020634.pdf"
"Levomilnacipran Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_204168.pdf","Draft","Oral","Capsule, Extended Release","204168","08/22/2024","PSG_204168.pdf"
"Levonorgestrel","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021045.pdf","Draft","Oral","Tablet","021045                                                       021998","10/30/2024","PSG_021045.pdf"
"Levonorgestrel","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_203159.pdf","Draft","Intrauterine","System","203159","11/19/2024","PSG_203159.pdf"
"Levonorgestrel","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021225.pdf","Draft","Intrauterine","Intrauterine Device","021225","01/22/2020","PSG_021225.pdf"
"Levorphanol Tartrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_008720.pdf","Draft","Oral","Tablet","008720","10/30/2024","PSG_008720.pdf"
"Levothyroxine sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Levothyroxine_Sodium capsules_NDA 021924_RC Oct 2018.pdf","Draft","Oral","Capsule","021924","11/28/2018","Levothyroxine_Sodium capsules_NDA 021924_RC Oct 2018.pdf"
"Levothyroxine Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Levothyroxine sodium_draft_Oral tab_RLD 021116              021210              021301              021342              021402_RC12-14.pdf","Draft","Oral","Tablet","021116                                                       021210                                                       021301                                                       021342                                                       021402","12/29/2014","Levothyroxine sodium_draft_Oral tab_RLD 021116              021210              021301              021342              021402_RC12-14.pdf"
"Lidocaine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_008048.pdf","Draft","Topical","Ointment","080198","05/18/2023","PSG_008048.pdf"
"Lidocaine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020612.pdf","Draft","Topical","Patch","020612","11/21/2019","PSG_020612.pdf"
"Lidocaine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_207962.pdf","Draft","Topical","Patch","207962","11/17/2022","PSG_207962.pdf"
"Lidocaine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_008816.pdf","Draft","Topical","Jelly","008816                                                       201094","08/21/2023","PSG_008816.pdf"
"Lidocaine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022221.pdf","Draft","Ophthalmic","Gel","022221","05/16/2024","PSG_022221.pdf"
"Lidocaine; Prilocaine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Lidocaine; Prilocaine_draft_Topical cream_RLD 019941_RC12-14.pdf","Draft","Topical","Cream","019941","12/29/2014","Lidocaine; Prilocaine_draft_Topical cream_RLD 019941_RC12-14.pdf"
"Lifitegrast","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Lifitegrast_Ophthalmic solution drops_NDA 208073_RC Oct 2018.pdf","Draft","Ophthalmic","Solution/Drops","208073","11/28/2018","Lifitegrast_Ophthalmic solution drops_NDA 208073_RC Oct 2018.pdf"
"Linaclotide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202811.pdf","Draft","Oral","Capsule","202811","05/19/2022","PSG_202811.pdf"
"Linagliptin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_201280.pdf","Draft","Oral","Tablet","201280","10/30/2024","PSG_201280.pdf"
"Linagliptin; Metformin Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Linagliptin; Metformin Hydrochloride_draft_Oral tab ER_RLD 208026_RC05-17.pdf","Draft","Oral","Tablet, Extended Release","208026","05/16/2017","Linagliptin; Metformin Hydrochloride_draft_Oral tab ER_RLD 208026_RC05-17.pdf"
"Linagliptin; Metformin Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_201281.pdf","Draft","Oral","Tablet","201281","10/30/2024","PSG_201281.pdf"
"Linezolid","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021132.pdf","Draft","Oral","For Suspension","021132","10/30/2024","PSG_021132.pdf"
"Linezolid","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021130.pdf","Draft","Oral","Tablet","021130","10/30/2024","PSG_021130.pdf"
"Liothyronine Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_010379.pdf","Draft","Oral","Tablet","010379","02/17/2022","PSG_010379.pdf"
"Liraglutide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_206321.pdf","Draft","Subcutaneous","Solution","206321","05/16/2024","PSG_206321.pdf"
"Liraglutide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022341.pdf","Draft","Subcutaneous","Solution","022341","11/19/2024","PSG_022341.pdf"
"Lisdexamfetamine Dimesylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208510.pdf","Draft","Oral","Tablet, Chewable","208510","10/30/2024","PSG_208510.pdf"
"Lisdexamfetamine Dimesylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021977.pdf","Draft","Oral","Capsule","021977","10/30/2024","PSG_021977.pdf"
"Lisinopril","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019777.pdf","Draft","Oral","Tablet","019777","10/30/2024","PSG_019777.pdf"
"Lithium Carbonate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018152.pdf","Draft","Oral","Tablet, Extended Release","076691","05/18/2023","PSG_018152.pdf"
"Lithium Carbonate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018027.pdf","Draft","Oral","Tablet, Extended Release","018027","05/18/2023","PSG_018027.pdf"
"Lithium Carbonate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018558.pdf","Draft","Oral","Tablet","018558","05/18/2023","PSG_018558.pdf"
"Lithium Carbonate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017812.pdf","Draft","Oral","Capsule","017812","05/18/2023","PSG_017812.pdf"
"Lofexidine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209229.pdf","Draft","Oral","Tablet","209229","10/30/2024","PSG_209229.pdf"
"Lomitapide Mesylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_203858.pdf","Draft","Oral","Capsule","203858","11/18/2020","PSG_203858.pdf"
"Lomustine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Lomustine_draft_Oral cap_RLD 017588_RC07-14.pdf","Draft","Oral","Capsule","017588","07/22/2014","Lomustine_draft_Oral cap_RLD 017588_RC07-14.pdf"
"Lonafarnib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213969.pdf","Draft","Oral","Capsule","213969","08/02/2022","PSG_213969.pdf"
"Loperamide Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020448.pdf","Draft","Oral","Tablet, Chewable","020448","10/30/2024","PSG_020448.pdf"
"Loperamide Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021855.pdf","Draft","Oral","Capsule","021855","10/30/2024","PSG_021855.pdf"
"Loperamide Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017694.pdf","Draft","Oral","Capsule","017694","10/30/2024","PSG_017694.pdf"
"Loperamide Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019487.pdf","Draft","Oral","Solution","019487","10/30/2024","PSG_019487.pdf"
"Loperamide Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019860.pdf","Draft","Oral","Tablet","019860","10/30/2024","PSG_019860.pdf"
"Loperamide Hydrochloride; Simethicone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Loperamide Hydrochloride; simethicone_draft_Oral tab_RLD 021140_RC09-15.pdf","Draft","Oral","Tablet","021140","09/18/2015","Loperamide Hydrochloride; simethicone_draft_Oral tab_RLD 021140_RC09-15.pdf"
"Loperamide Hydrochloride; Simethicone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020606.pdf","Draft","Oral","Tablet, Chewable","020606","10/30/2024","PSG_020606.pdf"
"Lopinavir; Ritonavir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Lopinavir; Ritonavir_draft_Oral cap_RLD 21226_RC09-12.pdf","Draft","Oral","Capsule","021226","09/19/2012","Lopinavir; Ritonavir_draft_Oral cap_RLD 21226_RC09-12.pdf"
"Lopinavir; Ritonavir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Lopinavir; Ritonavir_final_Oral tab_RLD 21906_RC09-12.pdf","Final","Oral","Tablet","021906","09/19/2012","Lopinavir; Ritonavir_final_Oral tab_RLD 21906_RC09-12.pdf"
"Loratadine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Loratadine_draft_Oral cap_RLD 021952_RC04-13.pdf","Draft","Oral","Capsule","021952","04/05/2013","Loratadine_draft_Oral cap_RLD 021952_RC04-13.pdf"
"Loratadine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021891.pdf","Draft","Oral","Tablet, Chewable","021891","10/30/2024","PSG_021891.pdf"
"Loratadine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019658.pdf","Draft","Oral","Tablet","019658","10/30/2024","PSG_019658.pdf"
"Loratadine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020704.pdf","Draft","Oral","Tablet, Orally Disintegrating","020704","10/30/2024","PSG_020704.pdf"
"Loratadine; Pseudoephedrine sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Loratadine Pseudoephedrine Oral Extended Release Tablet NDA 020470 RC Feb 2019.pdf","Draft","Oral","Tablet, Extended Release","020470","02/22/2019","Loratadine Pseudoephedrine Oral Extended Release Tablet NDA 020470 RC Feb 2019.pdf"
"Loratadine; Pseudoephedrine Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Loratadine; Pseudoephedrine Sulfate_draft_Oral tab ER_RLD 19670_RC08-10.pdf","Draft","Oral","Tablet, Extended Release","019670","08/30/2010","Loratadine; Pseudoephedrine Sulfate_draft_Oral tab ER_RLD 19670_RC08-10.pdf"
"Lorazepam","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017794.pdf","Draft","Oral","Tablet","017794","10/30/2024","PSG_017794.pdf"
"Lorazepam","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214826.pdf","Draft","Oral","Capsule, Extended Release","214826","05/19/2022","PSG_214826.pdf"
"Lorlatinib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210868.pdf","Draft","Oral","Tablet","210868","11/21/2019","PSG_210868.pdf"
"Losartan Potassium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020386.pdf","Draft","Oral","Tablet","020386","11/19/2024","PSG_020386.pdf"
"Loteprednol Etabonate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020803.pdf","Draft","Ophthalmic","Suspension/Drops","020803","02/15/2024","PSG_020803.pdf"
"Loteprednol Etabonate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210933.pdf","Draft","Ophthalmic","Suspension/Drops","210933","08/02/2022","PSG_210933.pdf"
"Loteprednol Etabonate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202872.pdf","Draft","Ophthalmic","Gel","202872","09/16/2019","PSG_202872.pdf"
"Loteprednol Etabonate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208219.pdf","Draft","Ophthalmic","Gel","208219","08/20/2021","PSG_208219.pdf"
"Loteprednol Etabonate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020583.pdf","Draft","Ophthalmic","Suspension/Drops","020583","02/15/2024","PSG_020583.pdf"
"Loteprednol Etabonate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210565.pdf","Draft","Ophthalmic","Suspension/Drops","210565","09/16/2019","PSG_210565.pdf"
"Loteprednol Etabonate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_200738.pdf","Draft","Ophthalmic","Ointment","200738","02/15/2024","PSG_200738.pdf"
"Loteprednol Etabonate; Tobramycin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050804.pdf","Draft","Ophthalmic","Suspension/Drops","050804","02/15/2024","PSG_050804.pdf"
"Lotilaner","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_217603.pdf","Draft","Ophthalmic","Solution/Drops","217603","05/16/2024","PSG_217603.pdf"
"Lovastatin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021316.pdf","Draft","Oral","Tablet, Extended Release","021316","09/16/2019","PSG_021316.pdf"
"Loxapine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022549.pdf","Draft","Inhalation","Powder","022549","05/18/2023","PSG_022549.pdf"
"Lubiprostone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Lubiprostone_draft_Oral cap_RLD 21908_RC07-15.pdf","Draft","Oral","Capsule","021908","07/17/2015","Lubiprostone_draft_Oral cap_RLD 21908_RC07-15.pdf"
"Luliconazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_204153.pdf","Draft","Topical","Cream","204153","10/21/2022","PSG_204153.pdf"
"Lumasiran Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214103.pdf","Draft","Subcutaneous","Solution","214103","08/21/2023","PSG_214103.pdf"
"Lumateperone Tosylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209500.pdf","Draft","Oral","Capsule","209500","10/30/2024","PSG_209500.pdf"
"Lurasidone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_200603.pdf","Draft","Oral","Tablet","200603","10/30/2024","PSG_200603.pdf"
"Lurbinectedin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213702.pdf","Draft","Intravenous","Powder","213702","11/08/2021","PSG_213702.pdf"
"Lusutrombopag","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210923.pdf","Draft","Oral","Tablet","210923","10/30/2024","PSG_210923.pdf"
"Lutetium Dotatate Lu 177","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208700.pdf","Draft","Intravenous","Solution","208700","11/21/2019","PSG_208700.pdf"
"Lutetium Lu-177 Vipivotide Tetraxetan","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215833.pdf","Draft","Intravenous","Solution","215833","08/21/2023","PSG_215833.pdf"
"Macimorelin acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Macimorelin Acetate_Oral solution_NDA 205598_RC Oct 2018.pdf","Draft","Oral","Solution","205598","11/28/2018","Macimorelin Acetate_Oral solution_NDA 205598_RC Oct 2018.pdf"
"Macitentan","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_204410.pdf","Draft","Oral","Tablet","204410","10/30/2024","PSG_204410.pdf"
"Macitentan; Tadalafil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_218490.pdf","Draft","Oral","Tablet","218490","11/19/2024","PSG_218490.pdf"
"Magnesium Hydroxide;Omeprazole;Sodium Bicarbonate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Omeprazole;_Sodium_Bicarbonate;_Magnesium_Hydroxide_chew_21850_RC2-08.pdf","Draft","Oral","Tablet, Chewable","021850","04/06/2008","Omeprazole;_Sodium_Bicarbonate;_Magnesium_Hydroxide_chew_21850_RC2-08.pdf"
"Magnesium sulfate; Polyethylene glycol 3350; Potassium chloride; Sodium chloride; Sodium sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215344.pdf","Draft","Oral","For Solution","215344","11/19/2024","PSG_215344.pdf"
"Magnesium Sulfate; Potassium Chloride; Sodium Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213135.pdf","Draft","Oral","Tablet","213135","11/17/2022","PSG_213135.pdf"
"Malathion","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Malathion_draft_Topical lotion_RLD 18613_RC06-12.pdf","Draft","Topical","Lotion","018613","06/14/2012","Malathion_draft_Topical lotion_RLD 18613_RC06-12.pdf"
"Mannitol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022368.pdf","Draft","Inhalation","Powder","022368","02/15/2024","PSG_022368.pdf"
"Mannitol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202049.pdf","Draft","Inhalation","Powder","202049","02/15/2024","PSG_202049.pdf"
"Maralixibat Chloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214662.pdf","Draft","Oral","Solution","214662","08/21/2023","PSG_214662.pdf"
"Maraviroc","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022128.pdf","Draft","Oral","Tablet","022128","10/30/2024","PSG_022128.pdf"
"Maribavir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215596.pdf","Draft","Oral","Tablet","215596","10/30/2024","PSG_215596.pdf"
"Mavacamten","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214998.pdf","Draft","Oral","Capsule","214998","10/30/2024","PSG_214998.pdf"
"Mebendazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Mebendazole_draft_Oral tab chewable_RLD 17481_RC02-09.pdf","Draft","Oral","Tablet, Chewable","017481","02/01/2009","Mebendazole_draft_Oral tab chewable_RLD 17481_RC02-09.pdf"
"Mebendazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Mebendazole_draft_Oral tab chewable_RLD 208398_RC02-18.pdf","Draft","Oral","Tablet, Chewable","208398","02/08/2018","Mebendazole_draft_Oral tab chewable_RLD 208398_RC02-18.pdf"
"Mecamylamine hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_010251.pdf","Draft","Oral","Tablet","010251","10/30/2024","PSG_010251.pdf"
"Mechlorethamine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202317.pdf","Draft","Topical","Gel","202317","02/16/2023","PSG_202317.pdf"
"Meclizine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Meclizine Hydrochloride_draft_Oral tab chewable_RLD 10721_RC04-10.pdf","Draft","Oral","Tablet, Chewable","010721","04/20/2010","Meclizine Hydrochloride_draft_Oral tab chewable_RLD 10721_RC04-10.pdf"
"Meclizine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Meclizine_tab_10721_RC12-09.pdf","Draft","Oral","Tablet","010721","12/17/2009","Meclizine_tab_10721_RC12-09.pdf"
"Medroxyprogesterone Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_012541.pdf","Draft","Injection","Injectable","012541","08/02/2022","PSG_012541.pdf"
"Medroxyprogesterone Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020246.pdf","Draft","Injection","Injectable","020246","08/02/2022","PSG_020246.pdf"
"Medroxyprogesterone Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_011839.pdf","Draft","Oral","Tablet","011839","10/30/2024","PSG_011839.pdf"
"Mefenamic Acid","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_015034.pdf","Draft","Oral","Capsule","015034","10/30/2024","PSG_015034.pdf"
"Mefloquine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Mefloquine Hydrochloride_final_Oral tab_RLD 76175_RC05-08.pdf","Final","Oral","Tablet","076175","05/12/2008","Mefloquine Hydrochloride_final_Oral tab_RLD 76175_RC05-08.pdf"
"Megestrol Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020264.pdf","Draft","Oral","Suspension","020264","10/30/2024","PSG_020264.pdf"
"Megestrol Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Megestrol Acetate_draft_Oral susp_RLD 21778_RC02-10.pdf","Draft","Oral","Suspension","021778","02/25/2010","Megestrol Acetate_draft_Oral susp_RLD 21778_RC02-10.pdf"
"Meloxicam","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_207233.pdf","Draft","Oral","Capsule","207233","10/30/2024","PSG_207233.pdf"
"Meloxicam","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021530.pdf","Draft","Oral","Suspension","021530","10/30/2024","PSG_021530.pdf"
"Meloxicam","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020938.pdf","Draft","Oral","Tablet","020938","10/30/2024","PSG_020938.pdf"
"Meloxicam","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211210.pdf","Draft","Oral","Tablet, Orally Disintegrating","211210","10/30/2024","PSG_211210.pdf"
"Meloxicam","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210583.pdf","Draft","Intravenous","Solution","210583","08/02/2022","PSG_210583.pdf"
"Melphalan","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Melphalan_draft_Oral tab_RLD 14691_RC07-09.pdf","Draft","Oral","Tablet","014691","07/01/2009","Melphalan_draft_Oral tab_RLD 14691_RC07-09.pdf"
"Memantine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021487.pdf","Draft","Oral","Tablet","021487","10/30/2024","PSG_021487.pdf"
"Memantine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022525.pdf","Draft","Oral","Capsule, Extended Release","022525","08/22/2024","PSG_022525.pdf"
"Memantine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021487-ODT.pdf","Draft","Oral","Tablet, Orally Disintegrating","021487","11/19/2024","PSG_021487-ODT.pdf"
"Menthol; Methyl Salicylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022029.pdf","Draft","Topical","Patch","022029","11/21/2019","PSG_022029.pdf"
"Meprobamate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Meprobamate_final_Oral tab_RLD 009698_RC10-11.pdf","Final","Oral","Tablet","009698","10/28/2011","Meprobamate_final_Oral tab_RLD 009698_RC10-11.pdf"
"Mercaptopurine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Mercaptopurine_draft_Oral tab_RLD 040528_RC04-11.pdf","Draft","Oral","Tablet","040528","04/01/2011","Mercaptopurine_draft_Oral tab_RLD 040528_RC04-11.pdf"
"Mercaptopurine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Mercaptopurine_draft_Oral susp_RLD 205919_RC01-16.pdf","Draft","Oral","Suspension","205919","01/27/2016","Mercaptopurine_draft_Oral susp_RLD 205919_RC01-16.pdf"
"Mesalamine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Mesalamine_draft_Oral cap DR_RLD 204412_RC06-16.pdf","Draft","Oral","Capsule, Delayed Release","204412","06/16/2016","Mesalamine_draft_Oral cap DR_RLD 204412_RC06-16.pdf"
"Mesalamine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Mesalamine_draft_Oral cap ER_RLD 20049_RC10-17.pdf","Draft","Oral","Capsule, Extended Release","020049","10/19/2017","Mesalamine_draft_Oral cap ER_RLD 20049_RC10-17.pdf"
"Mesalamine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Mesalamine_draft_Oral tab DR_RLD 19651_RC10-16.pdf","Draft","Oral","Tablet, Delayed Release","019651","10/04/2016","Mesalamine_draft_Oral tab DR_RLD 19651_RC10-16.pdf"
"Mesalamine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Mesalamine_draft_Oral tab DR_RLD 21830_RC06-16.pdf","Draft","Oral","Tablet, Delayed Release","021830","06/16/2016","Mesalamine_draft_Oral tab DR_RLD 21830_RC06-16.pdf"
"Mesalamine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Mesalamine_draft_Oral tab DR_RLD 22000_RC06-16.pdf","Draft","Oral","Tablet, Delayed Release","022000","06/16/2016","Mesalamine_draft_Oral tab DR_RLD 22000_RC06-16.pdf"
"Mesalamine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Mesalamine_draft_Rectal enema_RLD 19618_RC01-08.pdf","Draft","Rectal","Enema","019618","02/23/2008","Mesalamine_draft_Rectal enema_RLD 19618_RC01-08.pdf"
"Mesalamine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Mesalamine_draft_Rectal supp_RLD 21252_RC03-13.pdf","Draft","Rectal","Suppository","021252","03/01/2013","Mesalamine_draft_Rectal supp_RLD 21252_RC03-13.pdf"
"Mesalamine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022301.pdf","Draft","Oral","Capsule, Extended Release","022301","09/16/2019","PSG_022301.pdf"
"Mesna","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020855.pdf","Draft","Oral","Tablet","020855","10/30/2024","PSG_020855.pdf"
"Mestranol; Norethindrone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_016659.pdf","Draft","Oral","Tablet","016659","10/30/2024","PSG_016659.pdf"
"Metaxalone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Metaxalone_draft_Oral tab_RLD 13217_RC11-18.pdf","Draft","Oral","Tablet","013217","11/28/2018","Metaxalone_draft_Oral tab_RLD 13217_RC11-18.pdf"
"Metformin Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Metformin_HCl_ERtab_21574_RC3-09.pdf","Draft","Oral","Tablet, Extended Release","021574","02/25/2010","Metformin_HCl_ERtab_21574_RC3-09.pdf"
"Metformin Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Metformin Hydrochloride_draft_Oral tab ER_RLD 21748_RC02-10.pdf","Draft","Oral","Tablet, Extended Release","021748","02/25/2010","Metformin Hydrochloride_draft_Oral tab ER_RLD 21748_RC02-10.pdf"
"Metformin Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020357.pdf","Draft","Oral","Tablet","020357","10/30/2024","PSG_020357.pdf"
"Metformin Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Metformin Hydrochloride_final_Oral tab ER_RLD 21202_RC05-08.pdf","Final","Oral","Tablet, Extended Release","021202","05/12/2008","Metformin Hydrochloride_final_Oral tab ER_RLD 21202_RC05-08.pdf"
"Metformin Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212595.pdf","Draft","Oral","For Suspension, Extended Release","212595","06/03/2020","PSG_212595.pdf"
"Metformin Hydrochloride; Pioglitazone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021842.pdf","Draft","Oral","Tablet","021842","10/30/2024","PSG_021842.pdf"
"Metformin Hydrochloride; Pioglitazone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Metformin Hydrochloride; Pioglitazone Hydrochloride_draft_Oral tab ER_RLD 22024_RC03-10.pdf","Draft","Oral","Tablet, Extended Release","022024","03/19/2010","Metformin Hydrochloride; Pioglitazone Hydrochloride_draft_Oral tab ER_RLD 22024_RC03-10.pdf"
"Metformin Hydrochloride; Repaglinide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022386.pdf","Draft","Oral","Tablet","022386","10/30/2024","PSG_022386.pdf"
"Metformin Hydrochloride; Sitagliptin Phosphate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202270.pdf","Draft","Oral","Tablet, Extended Release","202270","08/22/2024","PSG_202270.pdf"
"Metformin Hydrochloride; Sitagliptin Phosphate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022044.pdf","Draft","Oral","Tablet","022044","10/30/2024","PSG_022044.pdf"
"Metformin Hydrochloride;Saxagliptin Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_200678.pdf","Draft","Oral","Tablet, Extended Release","200678","08/22/2024","PSG_200678.pdf"
"Methadone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Methadone_HCl_tab_06134_17058_RC7-08.pdf","Draft","Oral","Tablet","006134                                                       017058","07/01/2008","Methadone_HCl_tab_06134_17058_RC7-08.pdf"
"Methazolamide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_011721.pdf","Draft","Oral","Tablet","040062                                                       011721","10/30/2024","PSG_011721.pdf"
"Methenamine Hippurate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017681.pdf","Draft","Oral","Tablet","017681","10/30/2024","PSG_017681.pdf"
"Methimazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_007517.pdf","Draft","Oral","Tablet","040350                                                       007517","10/30/2024","PSG_007517.pdf"
"Methocarbamol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Methocarbamol_draft_Oral tab_RLD 11011_RC11-13.pdf","Draft","Oral","Tablet","011011","11/05/2013","Methocarbamol_draft_Oral tab_RLD 11011_RC11-13.pdf"
"Methotrexate Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Methotrexate Sodium_final_Oral tab_RLD 08085_RC10-11.pdf","Final","Oral","Tablet","008085","10/28/2011","Methotrexate Sodium_final_Oral tab_RLD 08085_RC10-11.pdf"
"Methotrexate Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Methotrexate Sodium_final_Oral tab_RLD 40385_RC10-11.pdf","Final","Oral","Tablet","040385","10/28/2011","Methotrexate Sodium_final_Oral tab_RLD 40385_RC10-11.pdf"
"Methoxsalen","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_009048.pdf","Draft","Oral","Capsule","009048","10/30/2024","PSG_009048.pdf"
"Methoxsalen","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019600.pdf","Draft","Oral","Capsule","019600","10/30/2024","PSG_019600.pdf"
"Methscopolamine bromide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Methscopolamine bromide_draft_Oral tab_RLD 040624_RC07-18.pdf","Draft","Oral","Tablet","040624","07/20/2018","Methscopolamine bromide_draft_Oral tab_RLD 040624_RC07-18.pdf"
"Methsuximide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_010596.pdf","Draft","Oral","Capsule","010596","10/30/2024","PSG_010596.pdf"
"Methylergonovine Maleate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_006035.pdf","Draft","Oral","Tablet","006035","10/30/2024","PSG_006035.pdf"
"Methylnaltrexone Bromide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Methylnaltrexone bromide_draft_Oral tab_RLD 208271_RC05-17.pdf","Draft","Oral","Tablet","208271","05/16/2017","Methylnaltrexone bromide_draft_Oral tab_RLD 208271_RC05-17.pdf"
"Methylphenidate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021514.pdf","Draft","Transdermal","Film, Extended Release","021514","11/21/2019","PSG_021514.pdf"
"Methylphenidate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_205489.pdf","Draft","Oral","Tablet, Orally Disintegrating, Extended Release","205489","11/08/2021","PSG_205489.pdf"
"Methylphenidate Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Methylphenidate Hydrochloride_draft_Oral tab ER_RLD 21121_RC07-18.pdf","Draft","Oral","Tablet, Extended Release","021121","07/20/2018","Methylphenidate Hydrochloride_draft_Oral tab ER_RLD 21121_RC07-18.pdf"
"Methylphenidate Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_010187.pdf","Draft","Oral","Tablet","010187","10/30/2024","PSG_010187.pdf"
"Methylphenidate Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021475.pdf","Draft","Oral","Tablet, Chewable","021475","10/30/2024","PSG_021475.pdf"
"Methylphenidate Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Methylphenidate Hydrochloride_draft_Oral suspER_RLD 202100_RC12-14.pdf","Draft","Oral","Suspension, Extended Release","202100","12/23/2014","Methylphenidate Hydrochloride_draft_Oral suspER_RLD 202100_RC12-14.pdf"
"Methylphenidate Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_207960.pdf","Draft","Oral","Tablet, Extended Release, Chewable","207960","11/18/2020","PSG_207960.pdf"
"Methylphenidate Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209311.pdf","Draft","Oral","Capsule, Extended Release","209311","06/03/2020","PSG_209311.pdf"
"Methylphenidate Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212038.pdf","Draft","Oral","Capsule, Extended Release","212038","06/03/2020","PSG_212038.pdf"
"Methylphenidate Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_205831.pdf","Draft","Oral","Capsule, Extended Release","205831","06/03/2020","PSG_205831.pdf"
"Methylphenidate Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021284.pdf","Draft","Oral","Capsule, Extended Release","021284","06/03/2020","PSG_021284.pdf"
"Methylphenidate Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021259.pdf","Draft","Oral","Capsule, Extended Release","021259","06/03/2020","PSG_021259.pdf"
"Methylphenidate Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018029.pdf","Draft","Oral","Tablet, Extended Release","018029","06/03/2020","PSG_018029.pdf"
"Methylprednisolone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_011153.pdf","Draft","Oral","Tablet","011153","10/30/2024","PSG_011153.pdf"
"Methylprednisolone Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_011757.pdf","Draft","Injection","Injectable","011757","02/17/2022","PSG_011757.pdf"
"Methyltestosterone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_083976.pdf","Draft","Oral","Capsule","083976","10/30/2024","PSG_083976.pdf"
"Metoclopramide Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017854.pdf","Draft","Oral","Tablet","017854","10/30/2024","PSG_017854.pdf"
"Metoclopramide Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022246.pdf","Draft","Oral","Tablet, Orally Disintegrating","022246","10/30/2024","PSG_022246.pdf"
"Metoclopramide Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209388.pdf","Draft","Nasal","Spray, Metered","209388","05/19/2021","PSG_209388.pdf"
"Metolazone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017386.pdf","Draft","Oral","Tablet","017386","10/30/2024","PSG_017386.pdf"
"Metoprolol Succinate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019962.pdf","Draft","Oral","Tablet, Extended Release","019962","08/28/2020","PSG_019962.pdf"
"Metoprolol Succinate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210428.pdf","Draft","Oral","Capsule, Extended Release","210428","05/19/2022","PSG_210428.pdf"
"Metoprolol Tartrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017963.pdf","Draft","Oral","Tablet","017963","10/30/2024","PSG_017963.pdf"
"Metronidazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_205223.pdf","Draft","Vaginal","Gel","205223","10/21/2022","PSG_205223.pdf"
"Metronidazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020208.pdf","Draft","Vaginal","Gel","020208                                                       021806","10/21/2022","PSG_020208.pdf"
"Metronidazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Metronidazole_draft_Oral tab_RLD 12623_RC09-10.pdf","Draft","Oral","Tablet","012623","09/30/2010","Metronidazole_draft_Oral tab_RLD 12623_RC09-10.pdf"
"Metronidazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020531.pdf","Draft","Topical","Cream","020531","10/21/2022","PSG_020531.pdf"
"Metronidazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020743.pdf","Draft","Topical","Cream","020743","10/21/2022","PSG_020743.pdf"
"Metronidazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021789.pdf","Draft","Topical","Gel","021789","10/21/2022","PSG_021789.pdf"
"Metronidazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020901.pdf","Draft","Topical","Lotion","020901","10/21/2022","PSG_020901.pdf"
"Metronidazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Metronidazole_draft_Oral cap_RLD 020334_RC01-16.pdf","Draft","Oral","Capsule","020334","01/27/2016","Metronidazole_draft_Oral cap_RLD 020334_RC01-16.pdf"
"Metronidazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019737.pdf","Draft","Topical","Gel","019737","10/21/2022","PSG_019737.pdf"
"Metyrosine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017871.pdf","Draft","Oral","Capsule","017871","10/30/2024","PSG_017871.pdf"
"Mexiletine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018873.pdf","Draft","Oral","Capsule","074377                                                       018873","10/30/2024","PSG_018873.pdf"
"Miconazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Miconazole_Buccal_Tablet_50mg_NDA_22404_RV_Feb_2019.pdf","Draft","Buccal","Tablet","022404","02/22/2019","Miconazole_Buccal_Tablet_50mg_NDA_22404_RV_Feb_2019.pdf"
"Miconazole Nitrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Miconazole_Nitrate_vagcrm2_17450_RC10-09.pdf","Draft","Vaginal","Cream  2%","017450","10/01/2009","Miconazole_Nitrate_vagcrm2_17450_RC10-09.pdf"
"Miconazole Nitrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Miconazole_Nitrate_vagcrm4 _20827_RC10-09.pdf","Draft","Vaginal","Cream  4%","020827","10/01/2009","Miconazole_Nitrate_vagcrm4 _20827_RC10-09.pdf"
"Miconazole Nitrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Miconazole_Nitrate_vagsupp100mg_18520_ RC10-09.pdf","Draft","Vaginal","Suppository  100 mg","018520","10/01/2009","Miconazole_Nitrate_vagsupp100mg_18520_ RC10-09.pdf"
"Miconazole Nitrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Miconazole_Nitrate_vagsupp200mg_18888_ RC10-09.pdf","Draft","Vaginal","Suppository  200 mg","018888","10/01/2009","Miconazole_Nitrate_vagsupp200mg_18888_ RC10-09.pdf"
"Miconazole Nitrate; White Petrolatum; Zinc Oxide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021026.pdf","Draft","Topical","Ointment","021026","11/17/2022","PSG_021026.pdf"
"Midazolam","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211321.pdf","Draft","Nasal","Spray","211321","05/19/2021","PSG_211321.pdf"
"Midazolam Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_216359.pdf","Draft","Intramuscular","Solution","216359","08/21/2023","PSG_216359.pdf"
"Midodrine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019815.pdf","Draft","Oral","Tablet","019815","10/30/2024","PSG_019815.pdf"
"Midostaurin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_207997.pdf","Draft","Oral","Capsule","207997","05/19/2022","PSG_207997.pdf"
"Mifepristone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020687.pdf","Draft","Oral","Tablet","020687","11/21/2019","PSG_020687.pdf"
"Mifepristone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202107.pdf","Draft","Oral","Tablet","202107","11/21/2019","PSG_202107.pdf"
"Migalastat Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208623.pdf","Draft","Oral","Capsule","208623","11/21/2019","PSG_208623.pdf"
"Miglitol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Miglitol_oral tablet_020682_RC06-15.pdf","Draft","Oral","Tablet","020682","06/24/2015","Miglitol_oral tablet_020682_RC06-15.pdf"
"Miglustat","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021348.pdf","Draft","Oral","Capsule","021348","10/30/2024","PSG_021348.pdf"
"Milnacipran Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022256.pdf","Draft","Oral","Tablet","022256","10/30/2024","PSG_022256.pdf"
"Miltefosine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Miltefosine_draft_Oral cap_RLD 204684_RC09-18.pdf","Draft","Oral","Capsule","204684","09/13/2018","Miltefosine_draft_Oral cap_RLD 204684_RC09-18.pdf"
"Minocycline Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Minocycline HCl_Dental ER Powder_50781_ RC03-15.pdf","Draft","Dental","Powder, Extended Release","050781","03/06/2015","Minocycline HCl_Dental ER Powder_50781_ RC03-15.pdf"
"Minocycline Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Minocycline_HCl_ERcap_201922_RC04-13.pdf","Draft","Oral","Capsule, Extended Release","201922","04/05/2013","Minocycline_HCl_ERcap_201922_RC04-13.pdf"
"Minocycline Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050451.pdf","Draft","Oral","Tablet","050451","10/30/2024","PSG_050451.pdf"
"Minocycline Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050649.pdf","Draft","Oral","Capsule","050649                                                       063009","10/30/2024","PSG_050649.pdf"
"Minocycline Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Minocycline hydrochloride_oral ER tablet_050808_RV09-15.pdf","Draft","Oral","Tablet, Extended Release","050808","09/18/2015","Minocycline hydrochloride_oral ER tablet_050808_RV09-15.pdf"
"Minocycline Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212379.pdf","Draft","Topical","Aerosol, Foam","212379","11/08/2021","PSG_212379.pdf"
"Minocycline Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213690.pdf","Draft","Topical","Aerosol, Foam","213690","11/08/2021","PSG_213690.pdf"
"Minocycline Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209269.pdf","Draft","Oral","Tablet, Extended Release","209269","11/08/2021","PSG_209269.pdf"
"Minoxidil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Minoxidil_fmaerosol_OTC_ 21812_RC5-10.pdf","Draft","Topical","Aerosol, Foam","021812","02/23/2011","Minoxidil_fmaerosol_OTC_ 21812_RC5-10.pdf"
"Minoxidil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Minoxidil_sol_ 19501_OTC_RC5-10.pdf","Draft","Topical","Solution","019501","05/20/2010","Minoxidil_sol_ 19501_OTC_RC5-10.pdf"
"Minoxidil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Minoxidil_sol_ 20834_OTC_RC5-10.pdf","Draft","Topical","Solution","020834","05/20/2010","Minoxidil_sol_ 20834_OTC_RC5-10.pdf"
"Minoxidil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018154.pdf","Draft","Oral","Tablet","018154","10/30/2024","PSG_018154.pdf"
"Mirabegron","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202611.pdf","Draft","Oral","Tablet, Extended Release","202611","02/16/2023","PSG_202611.pdf"
"Mirabegron","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213801.pdf","Draft","Oral","For Suspension, Extended Release","213801","02/17/2022","PSG_213801.pdf"
"Mirtazapine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021208.pdf","Draft","Oral","Tablet, Orally Disintegrating","021208","10/30/2024","PSG_021208.pdf"
"Mirtazapine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020415.pdf","Draft","Oral","Tablet","020415","10/30/2024","PSG_020415.pdf"
"Misoprostol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Misoprostol_tab_19268_RC2-10.pdf","Draft","Oral","Tablet","019268","02/25/2010","Misoprostol_tab_19268_RC2-10.pdf"
"Mitapivat Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_216196.pdf","Draft","Oral","Tablet","216196","10/30/2024","PSG_216196.pdf"
"Mitomycin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211728.pdf","Draft","Pyelocalyceal","Powder","211728","11/19/2024","PSG_211728.pdf"
"Mitotane","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Mitotane_Tabs_016885_RC04-13.pdf","Draft","Oral","Tablet","016885","04/05/2013","Mitotane_Tabs_016885_RC04-13.pdf"
"Modafinil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020717.pdf","Draft","Oral","Tablet","020717","10/30/2024","PSG_020717.pdf"
"Moexipril Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Moexipril_HCl_tab_20312_RC5-05.pdf","Final","Oral","Tablet","020312","05/12/2008","Moexipril_HCl_tab_20312_RC5-05.pdf"
"Molindone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017111.pdf","Draft","Oral","Tablet","017111","10/30/2024","PSG_017111.pdf"
"Mometasone Furoate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021067.pdf","Draft","Inhalation","Powder","021067","08/22/2024","PSG_021067.pdf"
"Mometasone Furoate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_205641.pdf","Draft","Inhalation","Aerosol, Metered","205641","11/19/2024","PSG_205641.pdf"
"Mometasone Furoate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Mometasone furoate_topical cream_NDA 019625_RC04-16.pdf","Draft","Topical","Cream","019625","04/14/2016","Mometasone furoate_topical cream_NDA 019625_RC04-16.pdf"
"Mometasone Furoate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Mometasone furoate_topical lotion_RLD 19796_RC04-16.pdf","Draft","Topical","Lotion","019796","04/14/2016","Mometasone furoate_topical lotion_RLD 19796_RC04-16.pdf"
"Mometasone Furoate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Mometasone furoate_ topical ointment_RLD 019543_RC01-16.pdf","Draft","Topical","Ointment","019543","01/27/2016","Mometasone furoate_ topical ointment_RLD 019543_RC01-16.pdf"
"Mometasone Furoate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215712.pdf","Draft","Nasal","Spray, Metered","215712","11/17/2022","PSG_215712.pdf"
"Mometasone Furoate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020762.pdf","Draft","Nasal","Spray, Metered","020762","05/18/2023","PSG_020762.pdf"
"Mometasone Furoate; Olopatadine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211746.pdf","Draft","Nasal","Spray, Metered","211746","08/21/2023","PSG_211746.pdf"
"Monomethyl Fumarate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210296.pdf","Draft","Oral","Capsule, Delayed Release","210296","03/24/2021","PSG_210296.pdf"
"Montelukast Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021409.pdf","Draft","Oral","Granule","021409","10/30/2024","PSG_021409.pdf"
"Montelukast Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020829.pdf","Draft","Oral","Tablet","020829","10/30/2024","PSG_020829.pdf"
"Montelukast Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020830.pdf","Draft","Oral","Tablet, Chewable","020830","10/30/2024","PSG_020830.pdf"
"Morphine Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Morphine sulfate_draft_Oral tab ER_RLD 206544_RC09-18.pdf","Draft","Oral","Tablet, Extended Release","206544","09/13/2018","Morphine sulfate_draft_Oral tab ER_RLD 206544_RC09-18.pdf"
"Morphine Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Morphine sulfate_oral solution_RLD 022195_RC09-16.pdf","Draft","Oral","Solution","022195","10/04/2016","Morphine sulfate_oral solution_RLD 022195_RC09-16.pdf"
"Morphine Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019516.pdf","Draft","Oral","Tablet, Extended Release","019516","08/22/2024","PSG_019516.pdf"
"Morphine Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022207.pdf","Draft","Oral","Tablet","022207","10/30/2024","PSG_022207.pdf"
"Morphine Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021260.pdf","Draft","Oral","Capsule, Extended Release","079040","08/22/2024","PSG_021260.pdf"
"Morphine Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020616.pdf","Draft","Oral","Capsule, Extended Release","020616","08/22/2024","PSG_020616.pdf"
"Morphine sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Morphine sulfate_draft_Oral cap_RLD 208603_RC09-18.pdf","Draft","Oral","Tablet, Extended Release","208603","09/13/2018","Morphine sulfate_draft_Oral cap_RLD 208603_RC09-18.pdf"
"Morphine Sulfate;Naltrexone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Morphine sulfate; Naltrexone HCL_oral ER capsule_NDA 022321_RV07-18.pdf","Draft","Oral","Capsule, Extended Release","022321","07/20/2018","Morphine sulfate; Naltrexone HCL_oral ER capsule_NDA 022321_RV07-18.pdf"
"Moxidectin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210867.pdf","Draft","Oral","Tablet","210867","10/30/2024","PSG_210867.pdf"
"Moxifloxacin Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021085.pdf","Draft","Oral","Tablet","021085","10/30/2024","PSG_021085.pdf"
"Moxifloxacin hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Moxifloxacin hydrochloride_draft_Ophthalmic solution drops_RLD 021598_RC07-18.pdf","Draft","Ophthalmic","Solution/Drops","021598","07/20/2018","Moxifloxacin hydrochloride_draft_Ophthalmic solution drops_RLD 021598_RC07-18.pdf"
"Mupirocin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050591.pdf","Draft","Topical","Ointment","050591","10/21/2022","PSG_050591.pdf"
"Mupirocin Calcium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050746.pdf","Draft","Topical","Cream","050746","10/21/2022","PSG_050746.pdf"
"Mupirocin Calcium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Mupirocin_ Calcium_nasal_oint_50703_RC06-10.pdf","Draft","Nasal","Ointment","050703","06/30/2010","Mupirocin_ Calcium_nasal_oint_50703_RC06-10.pdf"
"Mycophenolate Mofetil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050722.pdf","Draft","Oral","Capsule","050722","10/30/2024","PSG_050722.pdf"
"Mycophenolate Mofetil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050723.pdf","Draft","Oral","Tablet","050723","10/30/2024","PSG_050723.pdf"
"Mycophenolate Mofetil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050759.pdf","Draft","Oral","For Suspension","050759","10/30/2024","PSG_050759.pdf"
"Mycophenolic Acid","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Mycophenolic Acid_draft_Oral tab DR_RLD 50791_RC11-18.pdf","Draft","Oral","Tablet, Delayed Release","050791","11/28/2018","Mycophenolic Acid_draft_Oral tab DR_RLD 50791_RC11-18.pdf"
"Nabilone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Nabilone_cap_18677_RC7-08.pdf","Draft","Oral","Capsule","018677","07/01/2009","Nabilone_cap_18677_RC7-08.pdf"
"Nabumetone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019583.pdf","Draft","Oral","Tablet","019583","10/30/2024","PSG_019583.pdf"
"Nadolol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018063.pdf","Draft","Oral","Tablet","018063","10/30/2024","PSG_018063.pdf"
"Naftifine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Naftifine_HCl_cr_19599_RC03-12.pdf","Draft","Topical","Cream  1%","019599","03/28/2012","Naftifine_HCl_cr_19599_RC03-12.pdf"
"Naftifine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Naftifine_HCl_gel_19356_RC03-12.pdf","Draft","Topical","Gel","019356","03/28/2012","Naftifine_HCl_gel_19356_RC03-12.pdf"
"Naftifine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019599.pdf","Draft","Topical","Cream  2%","019599","01/27/2016","PSG_019599.pdf"
"Naftifine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Naftifine hydrochloride_topical get 2_RLD 204286_RC01-16.pdf","Draft","Topical","Gel","204286","01/27/2016","Naftifine hydrochloride_topical get 2_RLD 204286_RC01-16.pdf"
"Naldemedine Tosylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208854.pdf","Draft","Oral","Tablet","208854","10/30/2024","PSG_208854.pdf"
"Nalmefene Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_217470.pdf","Draft","Nasal","Spray","217470","05/16/2024","PSG_217470.pdf"
"Naloxegol Oxalate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Naloxegol oxalate_oral tablet_NDA 204760_RV11-17.pdf","Draft","Oral","Tablet","204760","02/08/2018","Naloxegol oxalate_oral tablet_NDA 204760_RV11-17.pdf"
"Naloxone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208411.pdf","Draft","Nasal","Spray, Metered","208411","08/22/2024","PSG_208411.pdf"
"Naloxone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212045.pdf","Draft","Nasal","Spray","212045","05/19/2022","PSG_212045.pdf"
"Naloxone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215457.pdf","Draft","Intramuscular, Subcutaneous","Solution","215457","05/18/2023","PSG_215457.pdf"
"Naloxone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208969.pdf","Draft","Nasal","Spray, Metered","208969","02/15/2024","PSG_208969.pdf"
"Naloxone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_217722.pdf","Draft","Nasal","Spray, Metered","217722","08/22/2024","PSG_217722.pdf"
"Naloxone Hydrochloride; Oxycodone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_205777.pdf","Draft","Oral","Tablet, Extended Release","205777","11/18/2020","PSG_205777.pdf"
"Naltrexone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021897.pdf","Draft","Intramuscular","For Suspension, Extended Release","021897","11/16/2023","PSG_021897.pdf"
"Naltrexone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018932.pdf","Draft","Oral","Tablet","018932","10/30/2024","PSG_018932.pdf"
"Naproxen","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Naproxen_DRtab_20067_RC2-10.pdf","Draft","Oral","Tablet, Delayed Release","020067","02/25/2010","Naproxen_DRtab_20067_RC2-10.pdf"
"Naproxen","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017581.pdf","Draft","Oral","Tablet","017581","10/30/2024","PSG_017581.pdf"
"Naproxen","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018965.pdf","Draft","Oral","Suspension","018965","10/30/2024","PSG_018965.pdf"
"Naproxen Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021920.pdf","Draft","Oral","Capsule","021920","10/30/2024","PSG_021920.pdf"
"Naproxen Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020353.pdf","Draft","Oral","Tablet, Extended Release","020353","02/16/2023","PSG_020353.pdf"
"Naproxen Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018164.pdf","Draft","Oral","Tablet","018164","10/30/2024","PSG_018164.pdf"
"Naproxen Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020204.pdf","Draft","Oral","Tablet","020204","10/30/2024","PSG_020204.pdf"
"Naproxen Sodium; Pseudoephedrine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Naproxen sodium; Pseudoephedrine HCl_oral ER tablet_NDA 021076_RC11-17.pdf","Draft","Oral","Tablet, Extended Release","021076","02/08/2018","Naproxen sodium; Pseudoephedrine HCl_oral ER tablet_NDA 021076_RC11-17.pdf"
"Naproxen Sodium; Sumatriptan Succinate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Naproxen_Sodium;_Sumatriptan_Succinate_tab_21926_RC08-10.pdf","Draft","Oral","Tablet","021926","08/30/2010","Naproxen_Sodium;_Sumatriptan_Succinate_tab_21926_RC08-10.pdf"
"Naratriptan Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020763.pdf","Draft","Oral","Tablet","020763","10/30/2024","PSG_020763.pdf"
"Nateglinide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021204.pdf","Draft","Oral","Tablet","021204","10/30/2024","PSG_021204.pdf"
"Nebivolol Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021742.pdf","Draft","Oral","Tablet","021742","10/30/2024","PSG_021742.pdf"
"Nebivolol hydrochloride; Valsartan","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_206302.pdf","Draft","Oral","Tablet","206302","10/30/2024","PSG_206302.pdf"
"Nedosiran Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215842.pdf","Draft","Injection","Solution","215842","08/22/2024","PSG_215842.pdf"
"Nelfinavir Mesylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Nelfinavir Mesylate pwd oral 20778_RC4-06.pdf","Draft","Oral","Suspension","020778","11/01/2007","Nelfinavir Mesylate pwd oral 20778_RC4-06.pdf"
"Nelfinavir Mesylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Nelfinavir_Mesylate_tab_20779_RC4-05.pdf","Final","Oral","Tablet","020779                                                       021503","05/01/2008","Nelfinavir_Mesylate_tab_20779_RC4-05.pdf"
"Nepafenac","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021862.pdf","Draft","Ophthalmic","Suspension/Drops  0.1%","021862","11/19/2024","PSG_021862.pdf"
"Nepafenac","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_203491.pdf","Draft","Ophthalmic","Suspension/Drops  0.3%","203491","11/19/2024","PSG_203491.pdf"
"Neratinib maleate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208051.pdf","Draft","Oral","Tablet","208051","10/30/2024","PSG_208051.pdf"
"Netarsudil dimesylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Netarsudil Dimesylate_Ophthalmic solution drops_NDA 208254_RC Oct 2018.pdf","Draft","Ophthalmic","Solution/Drops","208254","11/28/2018","Netarsudil Dimesylate_Ophthalmic solution drops_NDA 208254_RC Oct 2018.pdf"
"Netupitant; Palonosetron Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_205718.pdf","Draft","Oral","Capsule","205718","10/30/2024","PSG_205718.pdf"
"Nevirapine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Nevirapine_ER_Tablet_201152_RV07-14.pdf","Draft","Oral","Tablet, Extended Release","201152","07/22/2014","Nevirapine_ER_Tablet_201152_RV07-14.pdf"
"Nevirapine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020933.pdf","Draft","Oral","Suspension","020933","10/30/2024","PSG_020933.pdf"
"Nevirapine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020636.pdf","Draft","Oral","Tablet","020636","10/30/2024","PSG_020636.pdf"
"Niacin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Niacin_ER_tab_20381_RC10-09.pdf","Draft","Oral","Tablet, Extended Release","020381","12/23/2009","Niacin_ER_tab_20381_RC10-09.pdf"
"Nicardipine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Nicardipine_HCl_ERcap_20005_RC7-08.pdf","Draft","Oral","Capsule, Extended Release","020005","07/01/2008","Nicardipine_HCl_ERcap_20005_RC7-08.pdf"
"Nicardipine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019488.pdf","Draft","Oral","Capsule","019488","10/30/2024","PSG_019488.pdf"
"Nicotine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020076.pdf","Draft","Transdermal","Film, Extended Release","020076                                                       020165","11/21/2019","PSG_020076.pdf"
"Nicotine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020385.pdf","Draft","Nasal","Spray, Metered","020385","08/02/2022","PSG_020385.pdf"
"Nicotine Polacrilex","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Nicotine Polacrilex Troche Lozenge NDA 21330 RV 09-2018.pdf","Draft","Oral","Troche/Lozenge","021330","09/13/2018","Nicotine Polacrilex Troche Lozenge NDA 21330 RV 09-2018.pdf"
"Nicotine Polacrilex","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Nicotine Polacrilex Buccal Chewing Gum NDA 20066 and NDA 18612 RV 09-2018.pdf","Draft","Buccal","Gum, Chewing","018612                                                       020066","09/13/2018","Nicotine Polacrilex Buccal Chewing Gum NDA 20066 and NDA 18612 RV 09-2018.pdf"
"Nicotine Polacrilex","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Nicotine Polacrilex Troche Lozenge (Mini) NDA 022360 RV 09-2018.pdf","Draft","Oral","Lozenge","022360","09/13/2018","Nicotine Polacrilex Troche Lozenge (Mini) NDA 022360 RV 09-2018.pdf"
"Nifedipine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Nifedipine_ERtab_20198_RC09-12.pdf","Draft","Oral","Tablet, Extended Release","020198","09/01/2012","Nifedipine_ERtab_20198_RC09-12.pdf"
"Nifedipine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Nifedipine_cap_18482_RC06-11.pdf","Draft","Oral","Capsule","018482","06/30/2011","Nifedipine_cap_18482_RC06-11.pdf"
"Nifedipine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Nifedipine_ERtab_19684_RC3-09.pdf","Final","Oral","Tablet, Extended Release","019684","10/28/2011","Nifedipine_ERtab_19684_RC3-09.pdf"
"Nifurtimox","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213464.pdf","Draft","Oral","Tablet","213464","08/02/2022","PSG_213464.pdf"
"Nilotinib Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022068.pdf","Draft","Oral","Capsule","022068","02/15/2024","PSG_022068.pdf"
"Nilutamide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Nilutamide_tab_20169_RC8-09.pdf","Final","Oral","Tablet","020169","10/28/2011","Nilutamide_tab_20169_RC8-09.pdf"
"Nimodipine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018869.pdf","Draft","Oral","Capsule","018869","10/30/2024","PSG_018869.pdf"
"Nintedanib Esylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Nintedanib esylate_oral capsule_205832_RC09-15.pdf","Draft","Oral","Capsule","205832","09/18/2015","Nintedanib esylate_oral capsule_205832_RC09-15.pdf"
"Niraparib Tosylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Niraparib tosylate_oral capsule_NDA 208447_RC11-17.pdf","Draft","Oral","Capsule","208447","02/08/2018","Niraparib tosylate_oral capsule_NDA 208447_RC11-17.pdf"
"Niraparib Tosylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214876.pdf","Draft","Oral","Tablet","214876","02/15/2024","PSG_214876.pdf"
"Nirmatrelvir; Ritonavir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_217188.pdf","Draft","Oral","Tablet; Tablet","217188","08/22/2024","PSG_217188.pdf"
"Nisoldipine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Nisoldipine oral extended release tablet ANDA 079051 RV 09-2018.pdf","Draft","Oral","Tablet, Extended Release","079051","09/13/2018","Nisoldipine oral extended release tablet ANDA 079051 RV 09-2018.pdf"
"Nisoldipine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Nisoldipine_oral ER tablet_NDA 020356_RV07-18.pdf","Draft","Oral","Tablet, Extended Release","020356","07/20/2018","Nisoldipine_oral ER tablet_NDA 020356_RV07-18.pdf"
"Nitazoxanide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021497.pdf","Draft","Oral","Tablet","021497","03/24/2021","PSG_021497.pdf"
"Nitazoxanide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021498.pdf","Draft","Oral","For Suspension","021498","03/24/2021","PSG_021498.pdf"
"Nitisinone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209449.pdf","Draft","Oral","Tablet","209449","10/30/2024","PSG_209449.pdf"
"Nitisinone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Nitisinone_oral capsule_ NDA021232_RC08-17.pdf","Draft","Oral","Capsule","021232","10/19/2017","Nitisinone_oral capsule_ NDA021232_RC08-17.pdf"
"Nitisinone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_206356.pdf","Draft","Oral","Suspension","206356","10/30/2024","PSG_206356.pdf"
"Nitrofurantoin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_009175.pdf","Draft","Oral","Suspension","009175","10/30/2024","PSG_009175.pdf"
"Nitrofurantoin Macrocrystalline","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_016620.pdf","Draft","Oral","Capsule","016620","10/30/2024","PSG_016620.pdf"
"Nitrofurantoin; Nitrofurantoin Macrocrystalline","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020064.pdf","Draft","Oral","Capsule","020064","10/30/2024","PSG_020064.pdf"
"Nitroglycerin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Nitroglycerin_sublingual powder_RLD 208424_RC03-17.pdf","Draft","Sublingual","Powder","208424","05/16/2017","Nitroglycerin_sublingual powder_RLD 208424_RC03-17.pdf"
"Nitroglycerin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Nitroglycerin_transdermal ointment_087355_RC06-15.pdf","Draft","Transdermal","Ointment","087355","06/24/2015","Nitroglycerin_transdermal ointment_087355_RC06-15.pdf"
"Nitroglycerin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Nitroglycerin_Sublingual_AeroSpray_21780_RV02-12.pdf","Draft","Sublingual","Aerosol, Metered","021780","02/10/2012","Nitroglycerin_Sublingual_AeroSpray_21780_RV02-12.pdf"
"Nitroglycerin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Nitroglycerin_sublingual_tab_21134_RC02-11.pdf","Draft","Sublingual","Tablet","021134","02/23/2011","Nitroglycerin_sublingual_tab_21134_RC02-11.pdf"
"Nitroglycerin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Nitroglycerin_Sublingual_Spray_18750_RV02-12.pdf","Draft","Oral/Sublingual","Spray, Metered","018705","02/10/2012","Nitroglycerin_Sublingual_Spray_18750_RV02-12.pdf"
"Nitroglycerin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020145.pdf","Draft","Transdermal","Film, Extended Release","020145","11/21/2019","PSG_020145.pdf"
"Nitroglycerin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020144.pdf","Draft","Transdermal","Film, Extended Release","020144","11/21/2019","PSG_020144.pdf"
"Nitroglycerin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021359.pdf","Draft","Intra-anal","Ointment","021359","11/19/2024","PSG_021359.pdf"
"Norethindrone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017060.pdf","Draft","Oral","Tablet","017060","10/30/2024","PSG_017060.pdf"
"Norethindrone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_016954.pdf","Draft","Oral","Tablet","016954","10/30/2024","PSG_016954.pdf"
"Norethindrone Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018405 .pdf","Draft","Oral","Tablet","018405","10/30/2024","PSG_018405 .pdf"
"Nortriptyline Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018013.pdf","Draft","Oral","Capsule","018013","10/30/2024","PSG_018013.pdf"
"Nusinersen Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209531.pdf","Draft","Intrathecal","Solution","209531","02/17/2022","PSG_209531.pdf"
"Nystatin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_060578.pdf","Draft","Topical","Powder","065203","08/20/2021","PSG_060578.pdf"
"Nystatin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Nystatin_susp_50299_RC11-10.pdf","Draft","Oral","Suspension","062512","11/01/2010","Nystatin_susp_50299_RC11-10.pdf"
"Nystatin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_060575.pdf","Draft","Topical","Cream","064022","10/21/2022","PSG_060575.pdf"
"Nystatin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_060571.pdf","Draft","Topical","Ointment","062124","10/21/2022","PSG_060571.pdf"
"Nystatin; Triamcinolone Acetonide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_060576.pdf","Draft","Topical","Cream","062364","10/21/2022","PSG_060576.pdf"
"Nystatin; Triamcinolone Acetonide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_060572.pdf","Draft","Topical","Ointment","063305","10/21/2022","PSG_060572.pdf"
"Obeticholic Acid","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_207999.pdf","Draft","Oral","Tablet","207999","10/30/2024","PSG_207999.pdf"
"Octreotide Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Octreotide acetate_inj_21008_RV02-14.pdf","Draft","Injection","Injectable","021008","02/01/2014","Octreotide acetate_inj_21008_RV02-14.pdf"
"Octreotide Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208232.pdf","Draft","Oral","Capsule, Delayed Release","208232","03/24/2021","PSG_208232.pdf"
"Octreotide Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213224.pdf","Draft","Subcutaneous","Solution","213224","03/24/2021","PSG_213224.pdf"
"Odevixibat","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215498-Cap.pdf","Draft","Oral","Capsule","215498","05/18/2023","PSG_215498-Cap.pdf"
"Odevixibat","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215498-Cap Pellets.pdf","Draft","Oral","Capsule, Pellets","215498","05/18/2023","PSG_215498-Cap Pellets.pdf"
"Ofloxacin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Ofloxacin_ophthalmic solution drops_NDA 019921_RV08-17.pdf","Draft","Ophthalmic","Solution/Drops","019921","10/19/2017","Ofloxacin_ophthalmic solution drops_NDA 019921_RV08-17.pdf"
"Olanzapine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020592.pdf","Draft","Oral","Tablet","020592","10/30/2024","PSG_020592.pdf"
"Olanzapine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021086.pdf","Draft","Oral","Tablet, Orally Disintegrating","021086","10/30/2024","PSG_021086.pdf"
"Olanzapine Pamoate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Olanzapine_Intramuscular ER suspension_RLD22173_RC01-16.pdf","Draft","Intramuscular","Suspension, Extended Release","022173","01/27/2016","Olanzapine_Intramuscular ER suspension_RLD22173_RC01-16.pdf"
"Olanzapine; Samidorphan L-Malate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213378.pdf","Draft","Oral","Tablet","213378","10/30/2024","PSG_213378.pdf"
"Olaparib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Olaparib_oral capsule_NDA 206162_RC08-17.pdf","Draft","Oral","Capsule","206162","10/19/2017","Olaparib_oral capsule_NDA 206162_RC08-17.pdf"
"Olaparib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208558.pdf","Draft","Oral","Tablet","208558","11/19/2024","PSG_208558.pdf"
"Oliceridine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210730.pdf","Draft","Intravenous","Solution","210730","05/19/2022","PSG_210730.pdf"
"Olive Oil; Soybean Oil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Olive oil; Soybean Oil injectable injection RLD 204508 RC 09-2018.pdf","Draft","Injection","Injectable","204508","09/13/2018","Olive oil; Soybean Oil injectable injection RLD 204508 RC 09-2018.pdf"
"Olmesartan Medoxomil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021286.pdf","Draft","Oral","Tablet","021286","10/30/2024","PSG_021286.pdf"
"Olodaterol Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_203108.pdf","Draft","Inhalation","Spray, Metered","203108","08/22/2024","PSG_203108.pdf"
"Olodaterol Hydrochloride; Tiotropium Bromide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_206756.pdf","Draft","Inhalation","Spray, Metered","206756","08/22/2024","PSG_206756.pdf"
"Olopatadine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Olopatadine HCl_ophthalmic solution_NDA 021545_RV08-17.pdf","Draft","Ophthalmic","Solution/Drops  0.2%","021545","10/19/2017","Olopatadine HCl_ophthalmic solution_NDA 021545_RV08-17.pdf"
"Olopatadine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Olopatadine hydrochloride_ophthalmic solution_NDA 020688_RV08-17.pdf","Draft","Ophthalmic","Solution/Drops  0.1%","020688","10/19/2017","Olopatadine hydrochloride_ophthalmic solution_NDA 020688_RV08-17.pdf"
"Olopatadine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021861.pdf","Draft","Nasal","Spray, Metered","021861","08/02/2022","PSG_021861.pdf"
"Olopatadine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Olopatadine hydrochloride_ophthalmic solution_NDA 206276_RC11-17.pdf","Draft","Ophthalmic","Solution/Drops","206276","02/08/2018","Olopatadine hydrochloride_ophthalmic solution_NDA 206276_RC11-17.pdf"
"Olsalazine Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019715.pdf","Draft","Oral","Capsule","019715","03/02/2020","PSG_019715.pdf"
"Olutasidenib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215814.pdf","Draft","Oral","Capsule","215814","02/15/2024","PSG_215814.pdf"
"Omadacycline Tosylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209816.pdf","Draft","Oral","Tablet","209816","11/21/2019","PSG_209816.pdf"
"Omadacycline Tosylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209817.pdf","Draft","Intravenous","Powder","209817","11/21/2019","PSG_209817.pdf"
"Omaveloxolone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_216718.pdf","Draft","Oral","Capsule","216718","10/30/2024","PSG_216718.pdf"
"Ombitasvir; Paritaprevir; Ritonavir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Ombitasvir_Paritaprevir_Ritonavir_oral tablet_RLD 207931_RC06-16.pdf","Draft","Oral","Tablet","207931","06/16/2016","Ombitasvir_Paritaprevir_Ritonavir_oral tablet_RLD 207931_RC06-16.pdf"
"Omega 3 Acid Ethyl Esters","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021654.pdf","Draft","Oral","Capsule","021654","08/28/2020","PSG_021654.pdf"
"Omega-3-Acid Ethyl Esters Type A","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_204977.pdf","Draft","Oral","Capsule","204977","10/30/2024","PSG_204977.pdf"
"Omega3 Carboxylic Acids","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Omega-3 Carboxylic Acids_oral capsule_RLD 205060_RV12-16.pdf","Draft","Oral","Capsule","205060","12/22/2016","Omega-3 Carboxylic Acids_oral capsule_RLD 205060_RV12-16.pdf"
"Omeprazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Omeprazole_DRtab_022032_RC09-12.pdf","Draft","Oral","Tablet, Delayed Release","022032","09/19/2012","Omeprazole_DRtab_022032_RC09-12.pdf"
"Omeprazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Omeprazole_DRcap_19810_RC5-06.pdf","Draft","Oral","Capsule, Delayed Release","019810","11/26/2010","Omeprazole_DRcap_19810_RC5-06.pdf"
"Omeprazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Omeprazole_orally disintegrating DR tablet_NDA 209400_RC07-18.pdf","Draft","Oral","Tablet, Orally Disintegrating, Delayed Release","209400","07/20/2018","Omeprazole_orally disintegrating DR tablet_NDA 209400_RC07-18.pdf"
"Omeprazole Magnesium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_078878.pdf","Draft","Oral","Capsule, Delayed Release","078878","11/17/2022","PSG_078878.pdf"
"Omeprazole Magnesium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Omeprazole_Magnesium_DRtabOTC_21229_RC4-06.pdf","Final","Oral","Tablet, Delayed Release","021229","05/12/2008","Omeprazole_Magnesium_DRtabOTC_21229_RC4-06.pdf"
"Omeprazole Magnesium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Omeprazole magnesium oral delayed release suspension NDA 022056 PSG Page RC May 2019.pdf","Draft","Oral","For Suspension, Delayed Release","022056","05/15/2019","Omeprazole magnesium oral delayed release suspension NDA 022056 PSG Page RC May 2019.pdf"
"Omeprazole; Sodium Bicarbonate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Omeprazole_Sodium bicarbonate_Oral suspension_022283_RC06-15.pdf","Draft","Oral","Suspension, Powder","022283","06/24/2015","Omeprazole_Sodium bicarbonate_Oral suspension_022283_RC06-15.pdf"
"Omeprazole; Sodium Bicarbonate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Omeprazole;_Sodium Bicarbonate_cap_21849_RC7-08.pdf","Draft","Oral","Capsule","021849","07/01/2008","Omeprazole;_Sodium Bicarbonate_cap_21849_RC7-08.pdf"
"Omeprazole; Sodium Bicarbonate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Omeprazole_susp_21636_R5-05.pdf","Draft","Oral","Suspension","021636","07/01/2009","Omeprazole_susp_21636_R5-05.pdf"
"Omidenepag Isopropyl","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215092.pdf","Draft","Ophthalmic","Solution","215092","11/16/2023","PSG_215092.pdf"
"Ondansetron","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020781.pdf","Draft","Oral","Tablet, Orally Disintegrating","020781","10/30/2024","PSG_020781.pdf"
"Ondansetron","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Ondansetron_oral_film_22524_RC03-12.pdf","Draft","Oral","Film","022524","03/28/2012","Ondansetron_oral_film_22524_RC03-12.pdf"
"Ondansetron Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020103.pdf","Draft","Oral","Tablet","020103","10/30/2024","PSG_020103.pdf"
"Opicapone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212489.pdf","Draft","Oral","Capsule","212489","11/08/2021","PSG_212489.pdf"
"Orlistat","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020766.pdf","Draft","Oral","Capsule","020766                                                       021887","08/20/2021","PSG_020766.pdf"
"Orphenadrine Citrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Orphenadrine_ Citrate_ERtabs_40327_RC04-10.pdf","Draft","Oral","Tablet, Extended Release","012157","04/20/2010","Orphenadrine_ Citrate_ERtabs_40327_RC04-10.pdf"
"Oseltamivir Phosphate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021087.pdf","Draft","Oral","Capsule","021087","10/30/2024","PSG_021087.pdf"
"Oseltamivir Phosphate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021246.pdf","Draft","Oral","For Suspension","021246","10/30/2024","PSG_021246.pdf"
"Osilodrostat Phosphate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212801.pdf","Draft","Oral","Tablet","212801","10/30/2024","PSG_212801.pdf"
"Osimertinib Mesylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208065.pdf","Draft","Oral","Tablet","208065","10/30/2024","PSG_208065.pdf"
"Ospemifene","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_203505.pdf","Draft","Oral","Tablet","203505","10/30/2024","PSG_203505.pdf"
"Oteseconazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215888.pdf","Draft","Oral","Capsule","215888","10/30/2024","PSG_215888.pdf"
"Oxaprozin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018841.pdf","Draft","Oral","Tablet","018841","10/30/2024","PSG_018841.pdf"
"Oxazepam","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_015539-Cap.pdf","Draft","Oral","Capsule","015539                                                       072253","10/30/2024","PSG_015539-Cap.pdf"
"Oxcarbazepine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202810.pdf","Draft","Oral","Tablet, Extended Release","202810","08/22/2024","PSG_202810.pdf"
"Oxcarbazepine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021285.pdf","Draft","Oral","Suspension","021285","10/30/2024","PSG_021285.pdf"
"Oxcarbazepine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021014.pdf","Draft","Oral","Tablet","021014","10/30/2024","PSG_021014.pdf"
"Oxiconazole Nitrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Oxiconazole Nitrate Cream NDA 019828 RV Feb 2019.pdf","Draft","Topical","Cream","019828","02/22/2019","Oxiconazole Nitrate Cream NDA 019828 RV Feb 2019.pdf"
"Oxiconazole Nitrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Oxiconazole Nitrate Lotion NDA 020209 RV Feb 2019.pdf","Draft","Topical","Lotion","020209","02/22/2019","Oxiconazole Nitrate Lotion NDA 020209 RV Feb 2019.pdf"
"Oxybutynin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202211.pdf","Draft","Transdermal","Film, Extended Release","202211","11/21/2019","PSG_202211.pdf"
"Oxybutynin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Oxybutynin_ Transdermal metered gel_202513_RC06-15.pdf","Draft","Transdermal","Gel, Metered","202513","06/24/2015","Oxybutynin_ Transdermal metered gel_202513_RC06-15.pdf"
"Oxybutynin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021351.pdf","Draft","Transdermal","Film, Extended Release","021351","11/21/2019","PSG_021351.pdf"
"Oxybutynin Chloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Oxybutynin chloride_transdermal gel 10_RLD 22204_RC04-16.pdf","Draft","Transdermal","Gel","022204","04/14/2016","Oxybutynin chloride_transdermal gel 10_RLD 22204_RC04-16.pdf"
"Oxybutynin Chloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017577.pdf","Draft","Oral","Tablet","075079                                                       017577","10/30/2024","PSG_017577.pdf"
"Oxybutynin Chloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Oxybutynin_ERtabs_ 20897_RV11-13.pdf","Draft","Oral","Tablet, Extended Release","020897","11/05/2013","Oxybutynin_ERtabs_ 20897_RV11-13.pdf"
"Oxycodone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208090.pdf","Draft","Oral","Capsule, Extended Release","208090","11/17/2022","PSG_208090.pdf"
"Oxycodone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_200534.pdf","Draft","Oral","Capsule","200534","10/30/2024","PSG_200534.pdf"
"Oxycodone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Oxycodone hydrochloride_oral ER tablet_NDA 022272_RV07-18.pdf","Draft","Oral","Tablet, Extended Release","022272","07/20/2018","Oxycodone hydrochloride_oral ER tablet_NDA 022272_RV07-18.pdf"
"Oxycodone hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Oxycodone hydrochloride oral tablet NDA 209777 RC 09-2018.pdf","Draft","Oral","Tablet","209777","09/13/2018","Oxycodone hydrochloride oral tablet NDA 209777 RC 09-2018.pdf"
"Oxycodone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021011.pdf","Draft","Oral","Tablet","021011","10/30/2024","PSG_021011.pdf"
"Oxymetazoline Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212520.pdf","Draft","Ophthalmic","Solution/Drops","212520","04/02/2024","PSG_212520.pdf"
"Oxymetazoline Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208552.pdf","Draft","Topical","Cream","208552","10/21/2022","PSG_208552.pdf"
"Oxymetazoline Hydrochloride; Tetracaine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208032.pdf","Draft","Nasal","Spray, Metered","208032","08/02/2022","PSG_208032.pdf"
"Oxymetholone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_016848.pdf","Draft","Oral","Tablet","016848","10/30/2024","PSG_016848.pdf"
"Oxymorphone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Oxymorphone_HCl_tab_21611_RC1-08.pdf","Draft","Oral","Tablet","021611","02/23/2008","Oxymorphone_HCl_tab_21611_RC1-08.pdf"
"Oxymorphone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021610.pdf","Draft","Oral","Tablet, Extended Release","021610","08/22/2024","PSG_021610.pdf"
"Ozanimod Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209899.pdf","Draft","Oral","Capsule","209899","10/30/2024","PSG_209899.pdf"
"Ozenoxacin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208945.pdf","Draft","Topical","Cream","208945","10/21/2022","PSG_208945.pdf"
"Paclitaxel","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021660.pdf","Draft","IV Infusion","For Suspension","021660","08/20/2021","PSG_021660.pdf"
"Paclitaxel","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_216338.pdf","Draft","Intravenous","Powder","216338","11/19/2024","PSG_216338.pdf"
"Pacritinib Citrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208712.pdf","Draft","Oral","Capsule","208712","10/30/2024","PSG_208712.pdf"
"Pafolacianine Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214907.pdf","Draft","Intravenous","Solution","214907","08/02/2022","PSG_214907.pdf"
"Palbociclib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212436.pdf","Draft","Oral","Tablet","212436","05/19/2022","PSG_212436.pdf"
"Palbociclib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_207103.pdf","Draft","Oral","Capsule","207103","10/30/2024","PSG_207103.pdf"
"Paliperidone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Paliperidone_oral_ERtab_021999_RV03-15.pdf","Draft","Oral","Tablet, Extended Release","021999","03/06/2015","Paliperidone_oral_ERtab_021999_RV03-15.pdf"
"Paliperidone Palmitate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022264.pdf","Draft","Intramuscular","Suspension, Extended Release","022264","05/18/2023","PSG_022264.pdf"
"Paliperidone Palmitate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_207946.pdf","Draft","Intramuscular","Suspension, Extended Release","207946","08/20/2021","PSG_207946.pdf"
"Palonosetron Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022233.pdf","Draft","Oral","Capsule","022233","10/30/2024","PSG_022233.pdf"
"Palovarotene","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215559.pdf","Draft","Oral","Capsule","215559","11/19/2024","PSG_215559.pdf"
"Panobinostat Lactate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_205353.pdf","Draft","Oral","Capsule","205353","10/30/2024","PSG_205353.pdf"
"Pantoprazole Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Pantoprazole_Sodium_DRtab_20987_RC7-06.pdf","Final","Oral","Tablet, Delayed Release","020987","05/12/2008","Pantoprazole_Sodium_DRtab_20987_RC7-06.pdf"
"Pantoprazole Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Pantoprazole sodium_oral DR suspension_NDA 022020_RV11-17.pdf","Draft","Oral","Powder For Suspension, Delayed Release","022020","02/08/2018","Pantoprazole sodium_oral DR suspension_NDA 022020_RV11-17.pdf"
"Paricalcitol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Paricalcitol_cap_21606_RC11-07.pdf","Draft","Oral","Capsule","021606","11/01/2007","Paricalcitol_cap_21606_RC11-07.pdf"
"Paroxetine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Paroxetine_oral ER tablet_RLD 020936_RV06-16.pdf","Draft","Oral","Tablet, Extended Release","020936","06/16/2016","Paroxetine_oral ER tablet_RLD 020936_RV06-16.pdf"
"Paroxetine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020031.pdf","Draft","Oral","Tablet","020031","10/30/2024","PSG_020031.pdf"
"Paroxetine Mesylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_204516.pdf","Draft","Oral","Capsule","204516","10/30/2024","PSG_204516.pdf"
"Paroxetine mesylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021299.pdf","Draft","Oral","Tablet","021299","10/30/2024","PSG_021299.pdf"
"Patisiran Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210922.pdf","Draft","Intravenous","Solution","210922","11/17/2022","PSG_210922.pdf"
"Pazopanib Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022465.pdf","Draft","Oral","Tablet","022465","03/24/2021","PSG_022465.pdf"
"Pegcetacoplan","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_217171.pdf","Draft","Intravitreal","Solution","217171","08/22/2024","PSG_217171.pdf"
"Pegcetacoplan","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215014.pdf","Draft","Subcutaneous","Solution","215014","05/16/2024","PSG_215014.pdf"
"Pemetrexed Disodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215179.pdf","Draft","Intravenous","Solution","215179","11/19/2024","PSG_215179.pdf"
"Pemigatinib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213736.pdf","Draft","Oral","Tablet","213736","10/30/2024","PSG_213736.pdf"
"Penbutolol Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018976.pdf","Draft","Oral","Tablet","018976","10/30/2024","PSG_018976.pdf"
"Penciclovir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020629.pdf","Draft","Topical","Cream","020629","10/21/2022","PSG_020629.pdf"
"Penicillamine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Penicillamine_Oral Tablet_NDA 19854_RC Oct 2018.pdf","Draft","Oral","Tablet","019854","11/28/2018","Penicillamine_Oral Tablet_NDA 19854_RC Oct 2018.pdf"
"Penicillamine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Penicillamine_cap_19853_RC8-08.pdf","Draft","Oral","Capsule","019853","08/01/2008","Penicillamine_cap_19853_RC8-08.pdf"
"Penicillin G Benzathine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050141.pdf","Draft","Injection","Injectable","050141","03/24/2021","PSG_050141.pdf"
"Penicillin V Potassium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_060003.pdf","Draft","Oral","Tablet","065435","10/30/2024","PSG_060003.pdf"
"Pentosan Polysulfate Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020193.pdf","Draft","Oral","Capsule","020193","05/19/2021","PSG_020193.pdf"
"Pentoxifylline","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018631.pdf","Draft","Oral","Tablet, Extended Release","018631","05/18/2023","PSG_018631.pdf"
"Perampanel","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208277.pdf","Draft","Oral","Suspension","208277","10/30/2024","PSG_208277.pdf"
"Perampanel","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202834.pdf","Draft","Oral","Tablet","202834","10/30/2024","PSG_202834.pdf"
"Perfluorohexyloctane","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_216675.pdf","Draft","Ophthalmic","Solution/Drops","216675","05/16/2024","PSG_216675.pdf"
"Perflutren","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Perflutren Liposomal Injection RLD 021064 RC 09-2018 .pdf","Draft","Intravenous","Injectable","021064","09/13/2018","Perflutren Liposomal Injection RLD 021064 RC 09-2018 .pdf"
"Perindopril Erbumine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020184.pdf","Draft","Oral","Tablet","020184","10/30/2024","PSG_020184.pdf"
"Permethrin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Permethrin_topical cream_RLD 019855_RC08-17.pdf","Draft","Topical","Cream","019855","10/19/2017","Permethrin_topical cream_RLD 019855_RC08-17.pdf"
"Perphenazine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_010775.pdf","Draft","Oral","Tablet","010775","10/30/2024","PSG_010775.pdf"
"Pexidartinib Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211810.pdf","Draft","Oral","Capsule","211810","05/19/2021","PSG_211810.pdf"
"Phendimetrazine Tartrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Phendimetrazine_tartrate_ERcap_18074_RC8-09.pdf","Final","Oral","Capsule, Extended Release","018074","10/28/2011","Phendimetrazine_tartrate_ERcap_18074_RC8-09.pdf"
"Phendimetrazine Tartrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Phendimetrazine_tartrate_tab_85272_RC8-09.pdf","Final","Oral","Tablet","085272","10/28/2011","Phendimetrazine_tartrate_tab_85272_RC8-09.pdf"
"Phenelzine Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_011909.pdf","Draft","Oral","Tablet","011909","10/30/2024","PSG_011909.pdf"
"Phenoxybenzamine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Phenoxybenzamine_HCl_cap_08708_RV12-12.pdf","Draft","Oral","Capsule","008708","12/14/2012","Phenoxybenzamine_HCl_cap_08708_RV12-12.pdf"
"Phentermine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202088.pdf","Draft","Oral","Tablet, Orally Disintegrating","202088","10/30/2024","PSG_202088.pdf"
"Phentermine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Phentermine_HCl_cap_88023_87190_RC5-09.pdf","Final","Oral","Capsule","087190                                                       088023","10/28/2011","Phentermine_HCl_cap_88023_87190_RC5-09.pdf"
"Phentermine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Phentermine_HCl_tab_85128_88605_RC5-09.pdf","Final","Oral","Tablet","085128                                                       088605","10/28/2011","Phentermine_HCl_tab_85128_88605_RC5-09.pdf"
"Phentermine Hydrochloride;Topiramate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022580.pdf","Draft","Oral","Capsule, Extended Release","022580","08/22/2024","PSG_022580.pdf"
"Phentolamine Mesylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_217064.pdf","Draft","Ophthalmic","Solution","217064","11/19/2024","PSG_217064.pdf"
"Phenytoin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Phenytoin_oral  chewable tablet_ANDA 084427_RV03-17.pdf","Draft","Oral","Tablet, Chewable","084427","05/16/2017","Phenytoin_oral  chewable tablet_ANDA 084427_RV03-17.pdf"
"Phenytoin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Phenytoin_oral suspension_RLD 008762_RV03-17.pdf","Draft","Oral","Suspension","008762","05/16/2017","Phenytoin_oral suspension_RLD 008762_RV03-17.pdf"
"Phenytoin Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Phenytoin_sodium_ERcap_040298_RV12-14.pdf","Draft","Oral","Capsule, Extended Release","040298","12/29/2014","Phenytoin_sodium_ERcap_040298_RV12-14.pdf"
"Phenytoin Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Phenytoin_sodium_ERcap_084349_RV12-14.pdf","Draft","Oral","Capsule, Extended Release","084349","12/29/2014","Phenytoin_sodium_ERcap_084349_RV12-14.pdf"
"Phytonadione","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_010104.pdf","Draft","Oral","Tablet","010104","11/19/2024","PSG_010104.pdf"
"Phytonadione","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_011745.pdf","Draft","Injectable","Injection","012223","11/19/2024","PSG_011745.pdf"
"Phytonadione","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_083722.pdf","Draft","Injection","Injectable","083722","11/19/2024","PSG_083722.pdf"
"Phytonadione","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_087954.pdf","Draft","Injection","Injectable","087954                                                       087955","11/19/2024","PSG_087954.pdf"
"Piflufolastat F-18","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214793.pdf","Draft","Intravenous","Solution","214793","05/18/2023","PSG_214793.pdf"
"Pilocarpine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214028.pdf","Draft","Ophthalmic","Solution","214028","08/21/2023","PSG_214028.pdf"
"Pilocarpine hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PILOCARPINE HYDROCHLORIDE ophthalmic solution NDA 200890 RC 09-2018.pdf","Draft","Ophthalmic","Solution","200890","09/13/2018","PILOCARPINE HYDROCHLORIDE ophthalmic solution NDA 200890 RC 09-2018.pdf"
"Pilocarpine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020237.pdf","Draft","Oral","Tablet","020237","10/30/2024","PSG_020237.pdf"
"Pimavanserin Tartrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_207318.pdf","Draft","Oral","Tablet","207318","10/30/2024","PSG_207318.pdf"
"Pimavanserin Tartrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210793.pdf","Draft","Oral","Capsule","210793","10/30/2024","PSG_210793.pdf"
"Pimecrolimus","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021302.pdf","Draft","Topical","Cream","021302","10/21/2022","PSG_021302.pdf"
"Pimozide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017473.pdf","Draft","Oral","Tablet","017473","10/30/2024","PSG_017473.pdf"
"Pindolol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018285.pdf","Draft","Oral","Tablet","018285","10/30/2024","PSG_018285.pdf"
"Pioglitazone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021073.pdf","Draft","Oral","Tablet","021073","10/30/2024","PSG_021073.pdf"
"Pirfenidone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208780.pdf","Draft","Oral","Tablet","208780","10/30/2024","PSG_208780.pdf"
"Pirfenidone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022535.pdf","Draft","Oral","Capsule","022535","10/30/2024","PSG_022535.pdf"
"Piroxicam","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018147.pdf","Draft","Oral","Capsule","018147","10/30/2024","PSG_018147.pdf"
"Pirtobrutinib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_216059.pdf","Draft","Oral","Tablet","216059","05/16/2024","PSG_216059.pdf"
"Pitavastatin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022363.pdf","Draft","Oral","Tablet","022363","10/30/2024","PSG_022363.pdf"
"Pitavastatin Magnesium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208379.pdf","Draft","Oral","Tablet","208379","10/30/2024","PSG_208379.pdf"
"Pitavastatin sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209875.pdf","Draft","Oral","Tablet","209875","10/30/2024","PSG_209875.pdf"
"Pitolisant Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211150.pdf","Draft","Oral","Tablet","211150","10/30/2024","PSG_211150.pdf"
"Plazomicin Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210303.pdf","Draft","Intravenous","Solution","210303","09/16/2019","PSG_210303.pdf"
"Plecanatide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208745.pdf","Draft","Oral","Tablet","208745","09/16/2019","PSG_208745.pdf"
"Podofilox","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020529.pdf","Draft","Topical","Gel","020529","10/21/2022","PSG_020529.pdf"
"Podofilox","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Podofilox_sol_19795_2_RC08-11.pdf","Draft","Topical","Solution","019795","08/31/2011","Podofilox_sol_19795_2_RC08-11.pdf"
"Pomalidomide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_204026.pdf","Draft","Oral","Capsule","204026","10/30/2024","PSG_204026.pdf"
"Ponatinib Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Ponatinib hydrochloride_oral tablet_203469_RC09-15.pdf","Draft","Oral","Tablet","203469","09/18/2015","Ponatinib hydrochloride_oral tablet_203469_RC09-15.pdf"
"Ponesimod","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213498.pdf","Draft","Oral","Tablet","213498","10/30/2024","PSG_213498.pdf"
"Posaconazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214770.pdf","Draft","Oral","For Suspension, Delayed Release","214770","02/17/2022","PSG_214770.pdf"
"Posaconazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Posaconazole_Susp_22003_RC11-07.pdf","Draft","Oral","Suspension","022003","11/01/2007","Posaconazole_Susp_22003_RC11-07.pdf"
"Posaconazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_205053.pdf","Draft","Oral","Tablet, Delayed Release","205053","08/22/2024","PSG_205053.pdf"
"Potassium Chloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Potassium_chloride_ERtab_018279_RC03-15.pdf","Draft","Oral","Tablet, Extended Release","018279","03/06/2015","Potassium_chloride_ERtab_018279_RC03-15.pdf"
"Potassium Chloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Potassium_Chloride_ERtabs_19123_RC10-11.pdf","Draft","Oral","Tablet, Extended Release","019123","10/27/2011","Potassium_Chloride_ERtabs_19123_RC10-11.pdf"
"Potassium Chloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Potassium_Chloride_ERtabs_19439_RC9-11.pdf","Draft","Oral","Tablet, Extended Release","019439","09/29/2011","Potassium_Chloride_ERtabs_19439_RC9-11.pdf"
"Potassium Chloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Potassium_Chloride_ERcaps_77419_RC08-11.pdf","Draft","Oral","Capsule, Extended Release","018238","08/31/2011","Potassium_Chloride_ERcaps_77419_RC08-11.pdf"
"Potassium Citrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Potassium citrate_oral ER tablet_NDA 19071_RV11-17.pdf","Draft","Oral","Tablet, Extended Release","019071","02/08/2018","Potassium citrate_oral ER tablet_NDA 19071_RV11-17.pdf"
"Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212832.pdf","Draft","Intravenous","Solution","212832","11/08/2021","PSG_212832.pdf"
"Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212121.pdf","Draft","Intravenous","Solution","212121","11/08/2021","PSG_212121.pdf"
"Pralsetinib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213721.pdf","Draft","Oral","Capsule","213721","05/19/2022","PSG_213721.pdf"
"Pramipexole Dihydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020667.pdf","Draft","Oral","Tablet","020667","10/30/2024","PSG_020667.pdf"
"Pramipexole Dihydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022421.pdf","Draft","Oral","Tablet, Extended Release","022421","08/22/2024","PSG_022421.pdf"
"Prasterone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Prasterone_vaginal insert_NDA 208470_RC11-17.pdf","Draft","Vaginal","Insert","208470","02/08/2018","Prasterone_vaginal insert_NDA 208470_RC11-17.pdf"
"Prasugrel Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022307.pdf","Draft","Oral","Tablet","022307","10/30/2024","PSG_022307.pdf"
"Pravastatin Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019898.pdf","Draft","Oral","Tablet","019898","10/30/2024","PSG_019898.pdf"
"Praziquantel","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018714.pdf","Draft","Oral","Tablet","018714","10/30/2024","PSG_018714.pdf"
"Prazosin Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017442.pdf","Draft","Oral","Capsule","017442","10/30/2024","PSG_017442.pdf"
"Prednicarbate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Prednicarbate_topical ointment_RLD 19568_RC06-16.pdf","Draft","Topical","Ointment","019568","06/16/2016","Prednicarbate_topical ointment_RLD 19568_RC06-16.pdf"
"Prednisolone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_009987.pdf","Draft","Oral","Tablet","080354","10/30/2024","PSG_009987.pdf"
"Prednisolone Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Prednisolone acetate Ophthalmic suspension RLD 017011 PSG Page RV May 2019.pdf","Draft","Ophthalmic","Suspension/Drops","017011","05/15/2019","Prednisolone acetate Ophthalmic suspension RLD 017011 PSG Page RV May 2019.pdf"
"Prednisolone Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022067.pdf","Draft","Oral","Suspension","022067","10/30/2024","PSG_022067.pdf"
"Prednisolone Sodium Phosphate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021959.pdf","Draft","Oral","Tablet, Orally Disintegrating","021959","10/30/2024","PSG_021959.pdf"
"Prednisone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202020.pdf","Draft","Oral","Tablet, Delayed Release","202020","08/02/2022","PSG_202020.pdf"
"Prednisone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Prednisone_oral tablet_RLD084283_84122_87800_87801_87342_80352 RC01-16.pdf","Draft","Oral","Tablet","009766                                                       009986","01/27/2016","Prednisone_oral tablet_RLD084283_84122_87800_87801_87342_80352 RC01-16.pdf"
"Pregabalin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021446.pdf","Draft","Oral","Capsule","021446","10/30/2024","PSG_021446.pdf"
"Pregabalin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Pregabalin oral extended release tablet NDA 209501 RC 09-2018.pdf","Draft","Oral","Tablet, Extended Release","209501","09/13/2018","Pregabalin oral extended release tablet NDA 209501 RC 09-2018.pdf"
"Pretomanid","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212862.pdf","Draft","Oral","Tablet","212862","11/18/2020","PSG_212862.pdf"
"Primaquine Phosphate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_008316.pdf","Draft","Oral","Tablet","008316","10/30/2024","PSG_008316.pdf"
"Primidone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_009170.pdf","Draft","Oral","Tablet","009170","11/19/2024","PSG_009170.pdf"
"Procarbazine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Procarbazine_cap_16785_RC03-12.pdf","Draft","Oral","Capsule","016785","03/28/2012","Procarbazine_cap_16785_RC03-12.pdf"
"Prochlorperazine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Prochlorperazine_Rectal Suppository_RLD 040058_RC09-16.pdf","Draft","Rectal","Suppository","040058","10/04/2016","Prochlorperazine_Rectal Suppository_RLD 040058_RC09-16.pdf"
"Prochlorperazine Maleate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_010571.pdf","Draft","Oral","Tablet","010571","10/30/2024","PSG_010571.pdf"
"Progesterone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_201110.pdf","Draft","Vaginal","System","201110","02/17/2022","PSG_201110.pdf"
"Progesterone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020701.pdf","Draft","Vaginal","Gel","020701","11/17/2022","PSG_020701.pdf"
"Progesterone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022057.pdf","Draft","Vaginal","Insert","022057","08/22/2024","PSG_022057.pdf"
"Progesterone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Progesterone_caps_19781_RC02-11.pdf","Draft","Oral","Capsule","019781","02/23/2011","Progesterone_caps_19781_RC02-11.pdf"
"Promethazine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_010926.pdf","Draft","Rectal","Suppository","010926","08/22/2024","PSG_010926.pdf"
"Promethazine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Promethazine_Rec_Sup_087165_RC07-14.pdf","Draft","Rectal","Suppository","011689","07/22/2014","Promethazine_Rec_Sup_087165_RC07-14.pdf"
"Promethazine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_007935.pdf","Draft","Oral","Tablet","007935","10/30/2024","PSG_007935.pdf"
"Propafenone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Propafenone HCL_oral ER capsule_NDA 21416_RV03-17.pdf","Draft","Oral","Capsule, Extended Release","021416","05/16/2017","Propafenone HCL_oral ER capsule_NDA 21416_RV03-17.pdf"
"Propafenone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019151.pdf","Draft","Oral","Tablet","019151","10/30/2024","PSG_019151.pdf"
"Propofol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Propofol_injectable injection_RLD 19627_RC06-16.pdf","Draft","Injectable","Injection","019627","06/16/2016","Propofol_injectable injection_RLD 19627_RC06-16.pdf"
"Propranolol Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021438.pdf","Draft","Oral","Capsule, Extended Release","021438","11/18/2020","PSG_021438.pdf"
"Propranolol Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_016418.pdf","Draft","Oral","Tablet","016418","10/30/2024","PSG_016418.pdf"
"Propranolol Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018553.pdf","Draft","Oral","Capsule, Extended Release","018553","11/18/2020","PSG_018553.pdf"
"Propylthiouracil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_006188.pdf","Draft","Oral","Tablet","006188","10/30/2024","PSG_006188.pdf"
"Protriptyline Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_016012.pdf","Draft","Oral","Tablet","073645","10/30/2024","PSG_016012.pdf"
"Prucalopride Succinate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210166.pdf","Draft","Oral","Tablet","210166","10/30/2024","PSG_210166.pdf"
"Pseudoephedrine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Pseudoephedrine HCl_Oral_ER Tab_RLD 073585_RC06-16.pdf","Draft","Oral","Tablet, Extended Release","073585","06/16/2016","Pseudoephedrine HCl_Oral_ER Tab_RLD 073585_RC06-16.pdf"
"Pseudoephedrine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Pseudoephedrine_HCl_ERtabs_20021_OTC_RC08-10.pdf","Draft","Oral","Tablet, Extended Release","020021","08/30/2010","Pseudoephedrine_HCl_ERtabs_20021_OTC_RC08-10.pdf"
"Pyrazinamide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_080157.pdf","Draft","Oral","Tablet","080157","10/30/2024","PSG_080157.pdf"
"Pyridostigmine Bromide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Pyridostigmine_ERTabs_11665_RC08-11.pdf","Draft","Oral","Tablet, Extended Release","011665","08/31/2011","Pyridostigmine_ERTabs_11665_RC08-11.pdf"
"Pyridostigmine Bromide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_009829.pdf","Draft","Oral","Tablet","009829","10/30/2024","PSG_009829.pdf"
"Pyrimethamine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_008578.pdf","Draft","Oral","Tablet","008578","10/30/2024","PSG_008578.pdf"
"Quetiapine Fumarate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022047.pdf","Draft","Oral","Tablet, Extended Release","22047","08/22/2024","PSG_022047.pdf"
"Quetiapine Fumarate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020639.pdf","Draft","Oral","Tablet","20639","10/30/2024","PSG_020639.pdf"
"Quinapril Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019885.pdf","Draft","Oral","Tablet","19885","10/30/2024","PSG_019885.pdf"
"Quinidine Gluconate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_016647.pdf","Draft","Oral","Tablet, Extended Release","16647","05/19/2021","PSG_016647.pdf"
"Quinine Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Quinine_Sulfate_cap_21799_RV12-12.pdf","Draft","Oral","Capsule","21799","12/14/2012","Quinine_Sulfate_cap_21799_RV12-12.pdf"
"Quizartinib Dihydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_216993.pdf","Draft","Oral","Tablet","216993","11/19/2024","PSG_216993.pdf"
"Rabeprazole Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Rabeprazole sodium_DRcap_204736_RC02-14.pdf","Draft","Oral","Capsule, Delayed Release","204736","04/01/2014","Rabeprazole sodium_DRcap_204736_RC02-14.pdf"
"Rabeprazole Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Rabeprazole_Sodium_DRTab_20973_RC12-10.pdf","Draft","Oral","Tablet, Delayed Release","020973","12/23/2010","Rabeprazole_Sodium_DRTab_20973_RC12-10.pdf"
"Raloxifene Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020815.pdf","Draft","Oral","Tablet","020815","10/30/2024","PSG_020815.pdf"
"Raltegravir Potassium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Raltegravir_potassium_chewtab_203045_RC12-14.pdf","Draft","Oral","Tablet, Chewable","203045","12/29/2014","Raltegravir_potassium_chewtab_203045_RC12-14.pdf"
"Raltegravir Potassium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Raltgravir Potassium Oral Tablets NDA 022145 RV 09-2018.pdf","Draft","Oral","Tablet","022145","09/13/2018","Raltgravir Potassium Oral Tablets NDA 022145 RV 09-2018.pdf"
"Ramelteon","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021782.pdf","Draft","Oral","Tablet","021782","10/30/2024","PSG_021782.pdf"
"Ramipril","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022021.pdf","Draft","Oral","Tablet","022021","10/30/2024","PSG_022021.pdf"
"Ramipril","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019901.pdf","Draft","Oral","Capsule","019901","10/30/2024","PSG_019901.pdf"
"Ranitidine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020520.pdf","Draft","Oral","Tablet","020520                                                       021698","10/30/2024","PSG_020520.pdf"
"Ranitidine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018703.pdf","Draft","Oral","Tablet","018703","10/30/2024","PSG_018703.pdf"
"Ranitidine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020095.pdf","Draft","Oral","Capsule","020095","10/30/2024","PSG_020095.pdf"
"Ranitidine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020251.pdf","Draft","Oral","Tablet, Effervescent","020745                                                       020251","10/30/2024","PSG_020251.pdf"
"Ranolazine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021526.pdf","Draft","Oral","Tablet, Extended Release","021526","11/17/2022","PSG_021526.pdf"
"Ranolazine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_216018.pdf","Draft","Oral","Granules, Extended Release","216018","11/17/2022","PSG_216018.pdf"
"Rasagiline Mesylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021641.pdf","Draft","Oral","Tablet","021641","11/19/2024","PSG_021641.pdf"
"Regorafenib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_203085.pdf","Draft","Oral","Tablet","203085","03/24/2021","PSG_203085.pdf"
"Relugolix","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214621.pdf","Draft","Oral","Tablet","214621","10/30/2024","PSG_214621.pdf"
"Remdesivir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214787-Pow.pdf","Draft","Intravenous","Powder","214787","02/17/2022","PSG_214787-Pow.pdf"
"Remdesivir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214787-Sol.pdf","Draft","Intravenous","Solution","214787","02/17/2022","PSG_214787-Sol.pdf"
"Remimazolam Besylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212295.pdf","Draft","Intravenous","Powder","212295","11/08/2021","PSG_212295.pdf"
"Repaglinide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020741.pdf","Draft","Oral","Tablet","020741","10/30/2024","PSG_020741.pdf"
"Reserpine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_009838.pdf","Draft","Oral","Tablet","009838","10/30/2024","PSG_009838.pdf"
"Revefenacin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210598.pdf","Draft","Inhalation","Solution","210598","06/03/2020","PSG_210598.pdf"
"Rezafungin Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_217417.pdf","Draft","Intravenous","Powder","217417","05/16/2024","PSG_217417.pdf"
"Ribavirin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020903.pdf","Draft","Oral","Capsule","020903","10/30/2024","PSG_020903.pdf"
"Ribavirin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021511.pdf","Draft","Oral","Tablet","077456                                                       021511","10/30/2024","PSG_021511.pdf"
"Ribociclib succinate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209092.pdf","Draft","Oral","Tablet","209092","10/30/2024","PSG_209092.pdf"
"Rifabutin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Rifabutin_cap_50689_RC2-10.pdf","Draft","Oral","Capsule","050689","02/25/2010","Rifabutin_cap_50689_RC2-10.pdf"
"Rifampin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Rifampin_cap_50420_ RC6-05.pdf","Final","Oral","Capsule","050420","05/12/2008","Rifampin_cap_50420_ RC6-05.pdf"
"Rifamycin Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210910.pdf","Draft","Oral","Tablet, Delayed Release","210910","03/02/2020","PSG_210910.pdf"
"Rifapentine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021024.pdf","Draft","Oral","Tablet","021024","10/30/2024","PSG_021024.pdf"
"Rifaximin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021361.pdf","Draft","Oral","Tablet","021361","11/17/2022","PSG_021361.pdf"
"Rilpivirine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202022.pdf","Draft","Oral","Tablet","202022","10/30/2024","PSG_202022.pdf"
"Riluzole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Riluzole_tab_20599_RC11-04.pdf","Final","Oral","Tablet","020599","05/12/2008","Riluzole_tab_20599_RC11-04.pdf"
"Riluzole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209080.pdf","Draft","Oral","Suspension","209080","11/08/2021","PSG_209080.pdf"
"Rimegepant Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212728.pdf","Draft","Oral","Tablet, Orally Disintegrating","212728","10/30/2024","PSG_212728.pdf"
"Rimexolone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Rimexolone_ophthalmic suspension_RLD 020474_RV06-16.pdf","Draft","Ophthalmic","Suspension/Drops","020474","06/16/2016","Rimexolone_ophthalmic suspension_RLD 020474_RV06-16.pdf"
"Riociguat","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_204819.pdf","Draft","Oral","Tablet","204819","10/30/2024","PSG_204819.pdf"
"Ripretinib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213973.pdf","Draft","Oral","Tablet","213973","02/17/2022","PSG_213973.pdf"
"Risdiplam","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213535.pdf","Draft","Oral","For Solution","213535","05/19/2022","PSG_213535.pdf"
"Risedronate Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Risedronate_Na_DR_tabs_22560_RV12-12.pdf","Draft","Oral","Tablet, Delayed Release","022560","12/14/2012","Risedronate_Na_DR_tabs_22560_RV12-12.pdf"
"Risedronate Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Risedronate_Sodium_tab_20835_RC8-05.pdf","Draft","Oral","Tablet","020835","12/20/2008","Risedronate_Sodium_tab_20835_RC8-05.pdf"
"Risperidone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Risperidone_intramuscular injection_RLD 21346_RV08-16 separate post.pdf","Draft","Intramuscular","Injection","021346","08/29/2016","Risperidone_intramuscular injection_RLD 21346_RV08-16 separate post.pdf"
"Risperidone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020272.pdf","Draft","Oral","Tablet","020272","10/30/2024","PSG_020272.pdf"
"Risperidone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213586.pdf","Draft","Subcutaneous","Suspension, Extended Release","213586","11/19/2024","PSG_213586.pdf"
"Risperidone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021444.pdf","Draft","Oral","Tablet, Orally Disintegrating","021444","10/30/2024","PSG_021444.pdf"
"Risperidone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210655.pdf","Draft","Subcutaneous","For Suspension, Extended Release","210655","11/16/2023","PSG_210655.pdf"
"Risperidone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212849.pdf","Draft","Intramuscular","For Suspension, Extended Release","212849","08/22/2024","PSG_212849.pdf"
"Ritlecitinib Tosylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215830.pdf","Draft","Oral","Capsule","215830","11/19/2024","PSG_215830.pdf"
"Ritonavir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Ritonavir_oral powder_NDA 209512_RC07-18.pdf","Draft","Oral","Powder","209512","07/20/2018","Ritonavir_oral powder_NDA 209512_RC07-18.pdf"
"Ritonavir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Ritonavir_tab_22417_RC06-11.pdf","Draft","Oral","Tablet","022417","06/30/2011","Ritonavir_tab_22417_RC06-11.pdf"
"Ritonavir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Ritonavir_cap_20945_RC5-05.pdf","Final","Oral","Capsule","020945","05/12/2008","Ritonavir_cap_20945_RC5-05.pdf"
"Rivaroxaban","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215859.pdf","Draft","Oral","For Suspension","215859","02/15/2024","PSG_215859.pdf"
"Rivaroxaban","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022406.pdf","Draft","Oral","Tablet","022406","08/28/2020","PSG_022406.pdf"
"Rivastigmine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022083.pdf","Draft","Transdermal","Film, Extended Release","022083","11/21/2019","PSG_022083.pdf"
"Rivastigmine Tartrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020823.pdf","Draft","Oral","Capsule","020823","10/30/2024","PSG_020823.pdf"
"Rizatriptan Benzoate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020864.pdf","Draft","Oral","Tablet","020864","10/30/2024","PSG_020864.pdf"
"Rizatriptan Benzoate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020865.pdf","Draft","Oral","Tablet, Orally Disintegrating","020865","10/30/2024","PSG_020865.pdf"
"Roflumilast","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022522.pdf","Draft","Oral","Tablet","022522","10/30/2024","PSG_022522.pdf"
"Rolapitant Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_206500.pdf","Draft","Oral","Tablet","206500","10/30/2024","PSG_206500.pdf"
"Ropinirole Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Ropinirole HCL_oral ER tablet_NDA 022008_RV08-17.pdf","Draft","Oral","Tablet, Extended Release","022008","10/19/2017","Ropinirole HCL_oral ER tablet_NDA 022008_RV08-17.pdf"
"Ropinirole Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020658.pdf","Draft","Oral","Tablet","020658","10/30/2024","PSG_020658.pdf"
"Rosiglitazone Maleate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021071.pdf","Draft","Oral","Tablet","021071","10/30/2024","PSG_021071.pdf"
"Rosuvastatin Calcium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021366.pdf","Draft","Oral","Tablet","021366","10/30/2024","PSG_021366.pdf"
"Rotigotine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021829.pdf","Draft","Transdermal","Film, Extended Release","021829","11/21/2019","PSG_021829.pdf"
"Rucaparib Camsylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209115.pdf","Draft","Oral","Tablet","209115","03/24/2021","PSG_209115.pdf"
"Rufinamide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_201367.pdf","Draft","Oral","Suspension","201367","10/30/2024","PSG_201367.pdf"
"Rufinamide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021911.pdf","Draft","Oral","Tablet","021911","10/30/2024","PSG_021911.pdf"
"Ruxolitinib Phosphate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202192.pdf","Draft","Oral","Tablet","202192","10/30/2024","PSG_202192.pdf"
"Ruxolitinib Phosphate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215309.pdf","Draft","Topical","Cream","215309","11/19/2024","PSG_215309.pdf"
"Sacubitril; Valsartan","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_207620.pdf","Draft","Oral","Tablet","207620","10/30/2024","PSG_207620.pdf"
"Safinamide Mesylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_207145.pdf","Draft","Oral","Tablet","207145","10/30/2024","PSG_207145.pdf"
"Salmeterol Xinafoate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020692.pdf","Draft","Inhalation","Powder","020692","11/19/2024","PSG_020692.pdf"
"Sapropterin Dihydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022181.pdf","Draft","Oral","Tablet","022181","10/30/2024","PSG_022181.pdf"
"Saquinavir Mesylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Saquinavir_Mesylate_cap_20628_RC11-07.pdf","Draft","Oral","Capsule","020628","11/01/2007","Saquinavir_Mesylate_cap_20628_RC11-07.pdf"
"Saquinavir Mesylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Saquinavir_Mesylate_tab_21785_RC4-06.pdf","Draft","Oral","Tablet","021785","11/01/2007","Saquinavir_Mesylate_tab_21785_RC4-06.pdf"
"Sarecycline Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209521.pdf","Draft","Oral","Tablet","209521","10/30/2024","PSG_209521.pdf"
"Saxagliptin Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022350.pdf","Draft","Oral","Tablet","022350","10/30/2024","PSG_022350.pdf"
"Scopolamine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017874.pdf","Draft","Transdermal","Film, Extended Release","017874","11/21/2019","PSG_017874.pdf"
"Secnidazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Secnidazole Oral Granules NDA 209363 RC 09-2018.pdf","Draft","Oral","Granule","209363","09/13/2018","Secnidazole Oral Granules NDA 209363 RC 09-2018.pdf"
"Secretin Synthetic Human","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021256.pdf","Draft","Intravenous","For Solution","021256","05/19/2022","PSG_021256.pdf"
"Selegiline","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021336.pdf","Draft","Transdermal","Film, Extended Release","021336","11/21/2019","PSG_021336.pdf"
"Selegiline Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021479.pdf","Draft","Oral","Tablet, Orally Disintegrating","021479","10/30/2024","PSG_021479.pdf"
"Selegiline Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020647.pdf","Draft","Oral","Capsule","020647","10/30/2024","PSG_020647.pdf"
"Selenious Acid","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209379.pdf","Draft","Intravenous","Solution","209379","03/02/2020","PSG_209379.pdf"
"Selexipag","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_207947.pdf","Draft","Oral","Tablet","207947","10/30/2024","PSG_207947.pdf"
"Selinexor","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212306.pdf","Draft","Oral","Tablet","212306","05/19/2022","PSG_212306.pdf"
"Selpercatinib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213246.pdf","Draft","Oral","Capsule","213246","10/30/2024","PSG_213246.pdf"
"Selumetinib Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213756.pdf","Draft","Oral","Capsule","213756","02/17/2022","PSG_213756.pdf"
"Semaglutide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209637.pdf","Draft","Subcutaneous","Solution","209637","11/16/2023","PSG_209637.pdf"
"Semaglutide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213051.pdf","Draft","Oral","Tablet","213051","08/20/2021","PSG_213051.pdf"
"Semaglutide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215256.pdf","Draft","Subcutaneous","Solution","215256","11/16/2023","PSG_215256.pdf"
"Sertraline Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215133.pdf","Draft","Oral","Capsule","215133","10/30/2024","PSG_215133.pdf"
"Sertraline Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019839.pdf","Draft","Oral","Tablet","019839","10/30/2024","PSG_019839.pdf"
"Setmelanotide Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213793.pdf","Draft","Subcutaneous","Solution","213793","08/02/2022","PSG_213793.pdf"
"Sevelamer Carbonate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Sevelamer_carbonate_oralsusp_022318_RV12-14.pdf","Draft","Oral","Suspension","022318","12/29/2014","Sevelamer_carbonate_oralsusp_022318_RV12-14.pdf"
"Sevelamer Carbonate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Sevelamer carbonate_oral tablet_022127_RV09-15.pdf","Draft","Oral","Tablet","022127","09/18/2015","Sevelamer carbonate_oral tablet_022127_RV09-15.pdf"
"Sevelamer Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Sevelamer_HCl_tab_021179_RV12-14.pdf","Draft","Oral","Tablet","021179","12/29/2014","Sevelamer_HCl_tab_021179_RV12-14.pdf"
"Sibutramine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020632.pdf","Draft","Oral","Capsule","020632","10/30/2024","PSG_020632.pdf"
"Sildenafil Citrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_203109.pdf","Draft","Oral","For Suspension","203109","10/30/2024","PSG_203109.pdf"
"Sildenafil Citrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020895.pdf","Draft","Oral","Tablet","020895                                                       021845","10/30/2024","PSG_020895.pdf"
"Silodosin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022206.pdf","Draft","Oral","Capsule","022206","10/30/2024","PSG_022206.pdf"
"Silver Sulfadiazine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017381.pdf","Draft","Topical","Cream","017381","10/21/2022","PSG_017381.pdf"
"Simeprevir Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Simeprevir sodium_Oral capsule_205123_RC06-15.pdf","Draft","Oral","Capsule","205123","06/24/2015","Simeprevir sodium_Oral capsule_205123_RC06-15.pdf"
"Simvastatin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Simvastatin_oral suspension_RLD 206679_RC12-16.pdf","Draft","Oral","Suspension","206679","12/22/2016","Simvastatin_oral suspension_RLD 206679_RC12-16.pdf"
"Simvastatin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019766.pdf","Draft","Oral","Tablet","019766","10/30/2024","PSG_019766.pdf"
"Simvastatin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021961.pdf","Draft","Oral","Tablet, Orally Disintegrating","021961","10/30/2024","PSG_021961.pdf"
"Simvastatin; Sitagliptin Phosphate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202343.pdf","Draft","Oral","Tablet","202343","10/30/2024","PSG_202343.pdf"
"Siponimod Fumaric Acid","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209884.pdf","Draft","Oral","Tablet","209884","10/30/2024","PSG_209884.pdf"
"Sirolimus","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213478.pdf","Draft","Topical","Gel","213478","02/16/2023","PSG_213478.pdf"
"Sirolimus","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213312.pdf","Draft","Intravenous","Powder","213312","05/18/2023","PSG_213312.pdf"
"Sirolimus","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Sirolimus_oral tablet_021110_RV09-15.pdf","Draft","Oral","Tablet","021110","09/18/2015","Sirolimus_oral tablet_021110_RV09-15.pdf"
"Sitagliptin Phosphate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021995.pdf","Draft","Oral","Tablet","021995","10/30/2024","PSG_021995.pdf"
"Sodium Chloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019912.pdf","Draft","Inhalation","Aerosol, Metered","019912","02/17/2022","PSG_019912.pdf"
"Sodium Iodide I-131","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_016517.pdf","Draft","Oral","Capsule","016517","11/08/2021","PSG_016517.pdf"
"Sodium Iodide I123","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Sodium_Iodide_cap_18671_RC7-08.pdf","Draft","Oral","Capsule","018671","07/01/2008","Sodium_Iodide_cap_18671_RC7-08.pdf"
"Sodium Oxybate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214755.pdf","Draft","Oral","Suspension, Extended Release","214755","05/16/2024","PSG_214755.pdf"
"Sodium Phenylbutyrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214860.pdf","Draft","Oral","For Suspension","214860","02/15/2024","PSG_214860.pdf"
"Sodium Phenylbutyrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_216513.pdf","Draft","Oral","Pellets","216513","02/15/2024","PSG_216513.pdf"
"Sodium Phenylbutyrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020573.pdf","Draft","Oral","Powder","020573","10/30/2024","PSG_020573.pdf"
"Sodium Phenylbutyrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020572.pdf","Draft","Oral","Tablet","020572","10/30/2024","PSG_020572.pdf"
"Sodium Phenylbutyrate; Taurursodiol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_216660.pdf","Draft","Oral","For Suspension","216660","10/30/2024","PSG_216660.pdf"
"Sodium Phosphate, Dibasic, Anhydrous; Sodium Phosphate, Monobasic, Monohydrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021892.pdf","Draft","Oral","Tablet","021892","11/17/2022","PSG_021892.pdf"
"Sodium Polystyrene Sulfonate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/SodiumPolystyreneSulfonatepowderoralrectal011287_RC03-15.pdf","Draft","Oral/Rectal","Powder","011287","03/06/2015","SodiumPolystyreneSulfonatepowderoralrectal011287_RC03-15.pdf"
"Sodium Polystyrene Sulfonate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_087859.pdf","Draft","Oral, Rectal","Suspension","087859","08/28/2020","PSG_087859.pdf"
"Sodium Zirconium Cyclosilicate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_207078.pdf","Draft","Oral","For Suspension","207078","08/20/2021","PSG_207078.pdf"
"Sofosbuvir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_204671.pdf","Draft","Oral","Tablet","204671","10/30/2024","PSG_204671.pdf"
"Sofosbuvir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212480.pdf","Draft","Oral","Pellets","212480","03/24/2021","PSG_212480.pdf"
"Sofosbuvir; Velpatasvir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Sofosbuvir; velpatasir_oral tablet_RLD 208341_RC03-17.pdf","Draft","Oral","Tablet","208341","05/16/2017","Sofosbuvir; velpatasir_oral tablet_RLD 208341_RC03-17.pdf"
"Sofosbuvir; Velpatasvir; Voxilaprevir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Sofosbuvir Velpatasvir Voxilaprevir Oral Tablets NDA 209195 RC 09-2018.pdf","Draft","Oral","Tablet","209195","09/13/2018","Sofosbuvir Velpatasvir Voxilaprevir Oral Tablets NDA 209195 RC 09-2018.pdf"
"Solifenacin Succinate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209529.pdf","Draft","Oral","Suspension","209529","05/19/2022","PSG_209529.pdf"
"Solifenacin Succinate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021518.pdf","Draft","Oral","Tablet","021518","10/30/2024","PSG_021518.pdf"
"Solriamfetol Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211230.pdf","Draft","Oral","Tablet","211230","10/30/2024","PSG_211230.pdf"
"Sonidegib Phosphate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Sonidegib phosphate_oral capsule_RLD 205266_RC04-16.pdf","Draft","Oral","Capsule","205266","04/14/2016","Sonidegib phosphate_oral capsule_RLD 205266_RC04-16.pdf"
"Sorafenib Tosylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Sorafenib_Tabs_21923_RC10-11.pdf","Draft","Oral","Tablet","021923","06/14/2012","Sorafenib_Tabs_21923_RC10-11.pdf"
"Sotagliflozin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_216203.pdf","Draft","Oral","Tablet","216203","08/22/2024","PSG_216203.pdf"
"Sotalol Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019865.pdf","Draft","Oral","Tablet","019865","10/30/2024","PSG_019865.pdf"
"Sotalol Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021151.pdf","Draft","Oral","Tablet","021151","10/30/2024","PSG_021151.pdf"
"Sotorasib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214665.pdf","Draft","Oral","Tablet","214665","10/30/2024","PSG_214665.pdf"
"Soybean Oil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017643.pdf","Draft","Injection","Injectable","017643                                                       018449                                                       020248                                                       019531                                                       019942","11/16/2023","PSG_017643.pdf"
"Sparsentan","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_216403.pdf","Draft","Oral","Tablet","216403","10/30/2024","PSG_216403.pdf"
"Spinosad","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022408.pdf","Draft","Topical","Suspension","022408","10/21/2022","PSG_022408.pdf"
"Spironolactone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_012151.pdf","Draft","Oral","Tablet","012151","10/30/2024","PSG_012151.pdf"
"Spironolactone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209478.pdf","Draft","Oral","Suspension","209478","10/30/2024","PSG_209478.pdf"
"Stavudine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020412.pdf","Draft","Oral","Capsule","020412","10/30/2024","PSG_020412.pdf"
"Stiripentol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_206709.pdf","Draft","Oral","Capsule","206709","10/30/2024","PSG_206709.pdf"
"Stiripentol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_207223.pdf","Draft","Oral","For Suspension","207223","10/30/2024","PSG_207223.pdf"
"Succimer","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019998.pdf","Draft","Oral","Capsule","019998","10/30/2024","PSG_019998.pdf"
"Sucralfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019183.pdf","Draft","Oral","Suspension","019183","02/16/2023","PSG_019183.pdf"
"Sucralfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018333.pdf","Draft","Oral","Tablet","018333","02/16/2023","PSG_018333.pdf"
"Sufentanil Citrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209128.pdf","Draft","Sublingual","Tablet","209128","08/20/2021","PSG_209128.pdf"
"Sulfacetamide Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019931.pdf","Draft","Topical","Lotion","019931","11/21/2019","PSG_019931.pdf"
"Sulfadiazine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_004122.pdf","Draft","Oral","Tablet","040091                                                       004122","10/30/2024","PSG_004122.pdf"
"Sulfamethoxazole; Trimethoprim","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017377.pdf","Draft","Oral","Tablet","017377","10/30/2024","PSG_017377.pdf"
"Sulfamethoxazole;Trimethoprim","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017560.pdf","Draft","Oral","Suspension","077612                                                       017560","10/30/2024","PSG_017560.pdf"
"Sulfasalazine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Sulfasalazine_DRtab_07073_RC2-10.pdf","Draft","Oral","Tablet, Delayed Release","007073","02/25/2010","Sulfasalazine_DRtab_07073_RC2-10.pdf"
"Sulfasalazine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Sulfasalazine_tab_07073_RC2-10.pdf","Draft","Oral","Tablet","007073","02/25/2010","Sulfasalazine_tab_07073_RC2-10.pdf"
"Sulfur Hexafluoride Lipid Type A Microspheres","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Sulfur hexafluoridelipid Type-A microspheresuspension 203684RC 09-2018.pdf","Draft","Intravenous","Suspension","203684","09/13/2018","Sulfur hexafluoridelipid Type-A microspheresuspension 203684RC 09-2018.pdf"
"Sumatriptan","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210884.pdf","Draft","Nasal","Spray","210884","08/28/2020","PSG_210884.pdf"
"Sumatriptan","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Sumatriptan_Nasal spray_NDA 020626_RV Nov 2018.pdf","Draft","Nasal","Spray","020626","11/28/2018","Sumatriptan_Nasal spray_NDA 020626_RV Nov 2018.pdf"
"Sumatriptan Succinate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020132.pdf","Draft","Oral","Tablet","020132","10/30/2024","PSG_020132.pdf"
"Sumatriptan Succinate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020080-Autoinj.pdf","Draft","Subcutaneous","Injectable, Autoinjector","020080","11/17/2022","PSG_020080-Autoinj.pdf"
"Sumatriptan Succinate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020080-Vial.pdf","Draft","Subcutaneous","Injectable, Vial","020080","11/17/2022","PSG_020080-Vial.pdf"
"Sumatriptan Succinate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_206099.pdf","Draft","Nasal","Powder","206099","03/02/2020","PSG_206099.pdf"
"Sunitinib Malate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Sunitinib_Malate_caps_21938_RC04-10.pdf","Draft","Oral","Capsule","021938","04/20/2010","Sunitinib_Malate_caps_21938_RC04-10.pdf"
"Suvorexant","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Suvorexant_oral tablet_204569_RC09-15.pdf","Draft","Oral","Tablet","204569","09/18/2015","Suvorexant_oral tablet_204569_RC09-15.pdf"
"Tacrolimus","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_206406.pdf","Draft","Oral","Tablet, Extended Release","206406","08/22/2024","PSG_206406.pdf"
"Tacrolimus","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050777.pdf","Draft","Topical","Ointment","050777","11/19/2024","PSG_050777.pdf"
"Tacrolimus","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Tacrolimus_ERcap_204096_RC07-14.pdf","Draft","Oral","Capsule, Extended Release","204096","07/22/2014","Tacrolimus_ERcap_204096_RC07-14.pdf"
"Tacrolimus","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Tacrolimus_cap_50708_RV12-12.pdf","Draft","Oral","Capsule","050708","12/14/2012","Tacrolimus_cap_50708_RV12-12.pdf"
"Tacrolimus","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210115.pdf","Draft","Oral","For Suspension","210115","08/02/2022","PSG_210115.pdf"
"Tadalafil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021368.pdf","Draft","Oral","Tablet","021368                                                       022332","10/30/2024","PSG_021368.pdf"
"Tafamidis","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212161.pdf","Draft","Oral","Capsule","212161","11/18/2020","PSG_212161.pdf"
"Tafamidis Meglumine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211996.pdf","Draft","Oral","Capsule","211996","11/18/2020","PSG_211996.pdf"
"Tafenoquine Succinate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210795.pdf","Draft","Oral","Tablet","210795","10/30/2024","PSG_210795.pdf"
"Tafenoquine Succinate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210607.pdf","Draft","Oral","Tablet","210607","10/30/2024","PSG_210607.pdf"
"Tafluprost","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202514.pdf","Draft","Ophthalmic","Solution, Drops","202514","08/22/2024","PSG_202514.pdf"
"Talazoparib Tosylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211651.pdf","Draft","Oral","Capsule","211651","06/03/2020","PSG_211651.pdf"
"Talc","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_205555.pdf","Draft","Intrapleural","Powder","205555","08/28/2020","PSG_205555.pdf"
"Talc","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Talc intrapleural aerosol NDA 020587 RC 09-2018.pdf","Draft","Inhalation","Aerosol, Metered","020587","09/13/2018","Talc intrapleural aerosol NDA 020587 RC 09-2018.pdf"
"Tamoxifen Citrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017970.pdf","Draft","Oral","Tablet","017970","10/30/2024","PSG_017970.pdf"
"Tamsulosin Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/ucm090564.pdf","Final","Oral","Capsule","020579","05/12/2008","ucm090564.pdf"
"Tapentadol Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_200533.pdf","Draft","Oral","Tablet, Extended Release","200533","08/22/2024","PSG_200533.pdf"
"Tapentadol Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022304.pdf","Draft","Oral","Tablet","022304","10/30/2024","PSG_022304.pdf"
"Tapinarof","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215272.pdf","Draft","Topical","Cream","215272","11/16/2023","PSG_215272.pdf"
"Tasimelteon","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Tasimelteon_oral capsule_205677_RC09-15.pdf","Draft","Oral","Capsule","205677","09/18/2015","Tasimelteon_oral capsule_205677_RC09-15.pdf"
"Tasimelteon","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214517.pdf","Draft","Oral","Suspension","214517","10/30/2024","PSG_214517.pdf"
"Tavaborole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Tavaborole topical solution NDA 204427 RC 09-2018.pdf","Draft","Topical","Solution","204427","09/13/2018","Tavaborole topical solution NDA 204427 RC 09-2018.pdf"
"Tazarotene","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202428.pdf","Draft","Topical","Aerosol, Foam","202428","11/21/2019","PSG_202428.pdf"
"Tazarotene","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020600-Gel-0.05P.pdf","Draft","Topical","Gel  0.05%","020600","10/21/2022","PSG_020600-Gel-0.05P.pdf"
"Tazarotene","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021184-Cre-0.1P.pdf","Draft","Topical","Cream  0.1%","021184","10/21/2022","PSG_021184-Cre-0.1P.pdf"
"Tazarotene","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020600-Gel-0.1P.pdf","Draft","Topical","Gel  0.1%","020600","10/21/2022","PSG_020600-Gel-0.1P.pdf"
"Tazarotene","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211882.pdf","Draft","Topical","Lotion","211882","10/21/2022","PSG_211882.pdf"
"Tazarotene","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021184-Cre-0.05P.pdf","Draft","Topical","Cream  0.05%","021184","11/19/2024","PSG_021184-Cre-0.05P.pdf"
"Tazemetostat Hydrobromide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211723.pdf","Draft","Oral","Tablet","211723","08/20/2021","PSG_211723.pdf"
"Technetium Tc-99m Sodium Pertechnetate Generator","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202158.pdf","Draft","Intravenous, Intravesicular, Ophthalmic","Solution","202158","08/02/2022","PSG_202158.pdf"
"Tecovirimat","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208627.pdf","Draft","Oral","Capsule","208627","10/30/2024","PSG_208627.pdf"
"Tedizolid Phosphate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_205435.pdf","Draft","Oral","Tablet","205435","10/30/2024","PSG_205435.pdf"
"Tegaserod Maleate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021200.pdf","Draft","Oral","Tablet","021200","05/19/2022","PSG_021200.pdf"
"Telaprevir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Telaprevir_tab_201917_RC09-12.pdf","Draft","Oral","Tablet","201917","09/19/2012","Telaprevir_tab_201917_RC09-12.pdf"
"Telbivudine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022011.pdf","Draft","Oral","Tablet","022011","10/30/2024","PSG_022011.pdf"
"Telithromycin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021144.pdf","Draft","Oral","Tablet","021144","10/30/2024","PSG_021144.pdf"
"Telmisartan","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Telmisartan_tabs_20850_RC5-08.pdf","Draft","Oral","Tablet","020850","10/22/2010","Telmisartan_tabs_20850_RC5-08.pdf"
"Telotristat Etiprate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208794.pdf","Draft","Oral","Tablet","208794","10/30/2024","PSG_208794.pdf"
"Temazepam","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018163.pdf","Draft","Oral","Capsule","018163","10/30/2024","PSG_018163.pdf"
"Temozolomide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Temozolomide_cap_21029_RC12-08.pdf","Draft","Oral","Capsule","021029","07/01/2009","Temozolomide_cap_21029_RC12-08.pdf"
"Tenapanor Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211801.pdf","Draft","Oral","Tablet","211801","11/08/2021","PSG_211801.pdf"
"Tenofovir Alafenamide Fumarate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208464.pdf","Draft","Oral","Tablet","208464","10/30/2024","PSG_208464.pdf"
"Tenofovir Disoproxil Fumarate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022577.pdf","Draft","Oral","Powder","022577","10/30/2024","PSG_022577.pdf"
"Tenofovir Disoproxil Fumarate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021356.pdf","Draft","Oral","Tablet","021356","10/30/2024","PSG_021356.pdf"
"Tepotinib Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214096.pdf","Draft","Oral","Tablet","214096","10/30/2024","PSG_214096.pdf"
"Terazosin Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020347.pdf","Draft","Oral","Capsule","020347","10/30/2024","PSG_020347.pdf"
"Terbinafine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Terbinafine Hydrochloride Topical Cream NDA 020980 RV Feb 2019.pdf","Draft","Topical","Cream","020980","02/22/2019","Terbinafine Hydrochloride Topical Cream NDA 020980 RV Feb 2019.pdf"
"Terbinafine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022071.pdf","Draft","Oral","Granule","022071","10/30/2024","PSG_022071.pdf"
"Terbinafine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020539.pdf","Draft","Oral","Tablet","020539","10/30/2024","PSG_020539.pdf"
"Terbutaline Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017849.pdf","Draft","Oral","Tablet","017849","10/30/2024","PSG_017849.pdf"
"Terconazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Terconazole_VagCrm_19579_RC2-10.pdf","Draft","Vaginal","Cream","019579","02/25/2010","Terconazole_VagCrm_19579_RC2-10.pdf"
"Terconazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Terconazole_VagCrm_19964_RC2-10.pdf","Draft","Vaginal","Cream","019964","02/25/2010","Terconazole_VagCrm_19964_RC2-10.pdf"
"Terconazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Terconazole_VagSupp_19641_RC2-10.pdf","Draft","Vaginal","Suppository","019641","02/25/2010","Terconazole_VagSupp_19641_RC2-10.pdf"
"Teriflunomide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202992.pdf","Draft","Oral","Tablet","202992","10/30/2024","PSG_202992.pdf"
"Teriparatide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021318.pdf","Draft","Subcutaneous","Solution","021318","08/22/2024","PSG_021318.pdf"
"Terlipressin Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022231.pdf","Draft","Intravenous","Powder","022231","02/15/2024","PSG_022231.pdf"
"Testosterone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_205488.pdf","Draft","Nasal","Gel, Metered","205488","02/16/2023","PSG_205488.pdf"
"Testosterone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_080911.pdf","Draft","Implantation","Pellet","080911","05/05/2022","PSG_080911.pdf"
"Testosterone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Testosterone_gel_metered_transdermal_1_21015_RV11-13.pdf","Draft","Transdermal","Gel, Metered  1%","021015","11/05/2013","Testosterone_gel_metered_transdermal_1_21015_RV11-13.pdf"
"Testosterone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Testosterone_gel_metered_transdermal_1.62_22309_RV11-13.pdf","Draft","Transdermal","Gel, Metered","022309","11/05/2013","Testosterone_gel_metered_transdermal_1.62_22309_RV11-13.pdf"
"Testosterone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Testosterone_gel_metered_transdermal_10 mg 0.5 gm gel_21463_RC04-13.pdf","Draft","Transdermal","Gel, Metered","021463","04/05/2013","Testosterone_gel_metered_transdermal_10 mg 0.5 gm gel_21463_RC04-13.pdf"
"Testosterone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Testosterone_gel_transdermal_1_21015_RV11-13.pdf","Draft","Transdermal","Gel","021015","11/05/2013","Testosterone_gel_transdermal_1_21015_RV11-13.pdf"
"Testosterone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Testosterone_gel_transdermal_1_21454_RC04-13.pdf","Draft","Transdermal","Gel","021454","04/05/2013","Testosterone_gel_transdermal_1_21454_RC04-13.pdf"
"Testosterone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Testosterone_gel_transdermal_1.62_22309_RV11-13.pdf","Draft","Transdermal","Gel","022309","11/05/2013","Testosterone_gel_transdermal_1.62_22309_RV11-13.pdf"
"Testosterone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Testosterone_solution_22504_RC04-13.pdf","Draft","Transdermal","Solution, Metered","022504","04/05/2013","Testosterone_solution_22504_RC04-13.pdf"
"Testosterone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020489.pdf","Draft","Transdermal","Film, Extended Release","020489","11/21/2019","PSG_020489.pdf"
"Testosterone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Testosterone_ERbuccal_21543_RC10-06.pdf","Final","Buccal","Tablet, Extended Release","021543","05/12/2008","Testosterone_ERbuccal_21543_RC10-06.pdf"
"Testosterone Undecanoate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213953.pdf","Draft","Oral","Capsule","213953","10/30/2024","PSG_213953.pdf"
"Testosterone Undecanoate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_206089.pdf","Draft","Oral","Capsule","206089","03/24/2021","PSG_206089.pdf"
"Tetrabenazine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021894.pdf","Draft","Oral","Tablet","021894","10/30/2024","PSG_021894.pdf"
"Tetracaine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208135.pdf","Draft","Ophthalmic","Solution","208135","11/21/2019","PSG_208135.pdf"
"Tetracycline Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050278.pdf","Draft","Oral","Capsule","050278","10/30/2024","PSG_050278.pdf"
"Thalidomide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Thalidomide_cap_20785_21430_RV12-12.pdf","Draft","Oral","Capsule","020785","12/14/2012","Thalidomide_cap_20785_21430_RV12-12.pdf"
"Theophylline","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_085328.pdf","Draft","Oral","Tablet, Extended Release","090430                                                       086998                                                       085328","05/19/2022","PSG_085328.pdf"
"Theophylline","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_085328-TabER-600MG.pdf","Draft","Oral","Tablet, Extended Release  600 MG","040560","08/28/2020","PSG_085328-TabER-600MG.pdf"
"Theophylline","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_087942.pdf","Draft","Oral","Capsule, Extended Release","081034","08/28/2020","PSG_087942.pdf"
"Thioguanine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Thioguanine_Tabs_012429_RC09-12.pdf","Draft","Oral","Tablet","012429","09/19/2012","Thioguanine_Tabs_012429_RC09-12.pdf"
"Thioridazine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_011808.pdf","Draft","Oral","Tablet","011808","10/30/2024","PSG_011808.pdf"
"Thiothixene","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_016584.pdf","Draft","Oral","Capsule","016584","10/30/2024","PSG_016584.pdf"
"Tiagabine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020646.pdf","Draft","Oral","Tablet","020646","10/30/2024","PSG_020646.pdf"
"Ticagrelor","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022433.pdf","Draft","Oral","Tablet","022433","10/30/2024","PSG_022433.pdf"
"Ticlopidine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019979.pdf","Draft","Oral","Tablet","019979","10/30/2024","PSG_019979.pdf"
"Timolol Maleate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018017.pdf","Draft","Oral","Tablet","072668                                                       018017","10/30/2024","PSG_018017.pdf"
"Timolol Maleate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Timolol Maleate Ophthalmic Solution NDA 018086 PSG Page RC May 2019.pdf","Draft","Ophthalmic","Solution/Drops","018086","05/15/2019","Timolol Maleate Ophthalmic Solution NDA 018086 PSG Page RC May 2019.pdf"
"Timolol Maleate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020330.pdf","Draft","Ophthalmic","Solution, Gel Forming/Drops","020330","11/21/2019","PSG_020330.pdf"
"Tinidazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021618.pdf","Draft","Oral","Tablet","021618","11/21/2019","PSG_021618.pdf"
"Tioconazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Tioconazole_vagcrm_20676_RC03-11.pdf","Draft","Vaginal","Ointment","020676","03/31/2011","Tioconazole_vagcrm_20676_RC03-11.pdf"
"Tiopronin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Tiopronin_oral tablet_NDA 19569_RC05-17.pdf","Draft","Oral","Tablet","019569","07/13/2017","Tiopronin_oral tablet_NDA 19569_RC05-17.pdf"
"Tiopronin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211843.pdf","Draft","Oral","Tablet, Delayed Release","211843","05/19/2022","PSG_211843.pdf"
"Tiotropium Bromide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021936.pdf","Draft","Inhalation","Spray, Metered","021936","08/22/2024","PSG_021936.pdf"
"Tiotropium Bromide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021395.pdf","Draft","Inhalation","Powder","021395","11/19/2024","PSG_021395.pdf"
"Tipiracil Hydrochloride; Trifluridine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_207981.pdf","Draft","Oral","Tablet","207981","11/21/2019","PSG_207981.pdf"
"Tipranavir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Tipranavir_cap_21814_RC11-07.pdf","Draft","Oral","Capsule","021814","11/01/2007","Tipranavir_cap_21814_RC11-07.pdf"
"Tirbanibulin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213189.pdf","Draft","Topical","Ointment","213189","10/21/2022","PSG_213189.pdf"
"Tirzepatide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215866.pdf","Draft","Subcutaneous","Solution","215866","08/21/2023","PSG_215866.pdf"
"Tivozanib Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212904.pdf","Draft","Oral","Capsule","212904","10/30/2024","PSG_212904.pdf"
"Tizanidine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020397.pdf","Draft","Oral","Tablet","020397","10/30/2024","PSG_020397.pdf"
"Tizanidine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Tizanidine_HCl_cap_21447_RC2-06.pdf","Final","Oral","Capsule","021447","05/12/2008","Tizanidine_HCl_cap_21447_RC2-06.pdf"
"Tobramycin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Tobramycin ophthalmic ointment 0.3 NDA 050555 PSG Page RC May 2019.pdf","Draft","Ophthalmic","Ointment","050555","05/15/2019","Tobramycin ophthalmic ointment 0.3 NDA 050555 PSG Page RC May 2019.pdf"
"Tobramycin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_201688.pdf","Draft","Inhalation","Powder","201688","05/16/2024","PSG_201688.pdf"
"Tofacitinib Citrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208246.pdf","Draft","Oral","Tablet, Extended Release","208246","05/19/2021","PSG_208246.pdf"
"Tofacitinib Citrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_203214.pdf","Draft","Oral","Tablet","203214","10/30/2024","PSG_203214.pdf"
"Tofersen","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215887.pdf","Draft","Intrathecal","Solution","215887","08/22/2024","PSG_215887.pdf"
"Tolcapone","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020697.pdf","Draft","Oral","Tablet","020697","10/30/2024","PSG_020697.pdf"
"Tolterodine Tartrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020771.pdf","Draft","Oral","Tablet","020771","10/30/2024","PSG_020771.pdf"
"Tolterodine Tartrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Tolterodine_ER_Capsules_021228_RC09-12.pdf","Draft","Oral","Capsule, Extended Release","021228","09/19/2012","Tolterodine_ER_Capsules_021228_RC09-12.pdf"
"Tolvaptan","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Tolvaptan_tab_22275_RC03-12.pdf","Draft","Oral","Tablet","022275","03/28/2012","Tolvaptan_tab_22275_RC03-12.pdf"
"Tolvaptan","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_204441.pdf","Draft","Oral","Tablet","204441","03/02/2020","PSG_204441.pdf"
"Topiramate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Topiramate_ ER Cap_205122_RC03-15.pdf","Draft","Oral","Capsule, Extended Release","205122","03/06/2015","Topiramate_ ER Cap_205122_RC03-15.pdf"
"Topiramate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Topiramate_ERcap_201635_RC03-15.pdf","Draft","Oral","Capsule, Extended Release","201635","03/06/2015","Topiramate_ERcap_201635_RC03-15.pdf"
"Topiramate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020505.pdf","Draft","Oral","Tablet","020505","10/30/2024","PSG_020505.pdf"
"Topiramate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020844.pdf","Draft","Oral","Capsule","020844","10/30/2024","PSG_020844.pdf"
"Topotecan Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Topotecan_caps_20981_RC03-11.pdf","Draft","Oral","Capsule","020981","03/31/2011","Topotecan_caps_20981_RC03-11.pdf"
"Toremifene Citrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020497.pdf","Draft","Oral","Tablet","020497","10/30/2024","PSG_020497.pdf"
"Torsemide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020136.pdf","Draft","Oral","Tablet","020136","10/30/2024","PSG_020136.pdf"
"Torsemide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213218.pdf","Draft","Oral","Tablet","213218","10/30/2024","PSG_213218.pdf"
"Tramadol Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Tramadol hydrochloride_Oral ER capsule_22370_RC09-15.pdf","Draft","Oral","Capsule, Extended Release","022370","09/18/2015","Tramadol hydrochloride_Oral ER capsule_22370_RC09-15.pdf"
"Tramadol Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020281.pdf","Draft","Oral","Tablet","020281","11/19/2024","PSG_020281.pdf"
"Tramadol Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021692.pdf","Draft","Oral","Tablet, Extended Release","021692","08/22/2024","PSG_021692.pdf"
"Trametinib Dimethyl Sulfoxide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_204114.pdf","Draft","Oral","Tablet","204114","05/19/2022","PSG_204114.pdf"
"Trandolapril","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020528.pdf","Draft","Oral","Tablet","020528","10/30/2024","PSG_020528.pdf"
"Trandolapril; Verapamil Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Trandolapril;_Verapamil_ERtab_20591_RC12-08.pdf","Draft","Oral","Tablet, Extended Release","020591","12/20/2008","Trandolapril;_Verapamil_ERtab_20591_RC12-08.pdf"
"Tranexamic Acid","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Tranexamic_Acid_22430_RC12-10.pdf","Draft","Oral","Tablet","022430","03/31/2011","Tranexamic_Acid_22430_RC12-10.pdf"
"Tranylcypromine Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_012342.pdf","Draft","Oral","Tablet","012342","10/30/2024","PSG_012342.pdf"
"Trazodone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Trazodone_HCl_ERtab_22411_RC09-12.pdf","Draft","Oral","Tablet, Extended Release","022411","09/19/2012","Trazodone_HCl_ERtab_22411_RC09-12.pdf"
"Trazodone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018207.pdf","Draft","Oral","Tablet","018207","10/30/2024","PSG_018207.pdf"
"Treprostinil","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214324.pdf","Draft","Inhalation","Powder","214324","11/19/2024","PSG_214324.pdf"
"Treprostinil Diolamine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Treprostinil diolamine oral extended release tablet NDA 203496 RV Feb 2019.pdf","Draft","Oral","Tablet, Extended Release","203496","02/22/2019","Treprostinil diolamine oral extended release tablet NDA 203496 RV Feb 2019.pdf"
"Tretinoin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Tretinoin Topical Cream ANDA 090098 RV Feb 2019.pdf","Draft","Topical","Cream","090098","02/22/2019","Tretinoin Topical Cream ANDA 090098 RV Feb 2019.pdf"
"Tretinoin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Tretinoin_Caps_77684_RC09-10.pdf","Draft","Oral","Capsule","020438","09/30/2010","Tretinoin_Caps_77684_RC09-10.pdf"
"Tretinoin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209353.pdf","Draft","Topical","Lotion","209353","06/03/2020","PSG_209353.pdf"
"Tretinoin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017579.pdf","Draft","Topical","Gel","017579","10/21/2022","PSG_017579.pdf"
"Tretinoin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022070.pdf","Draft","Topical","Gel","022070","10/21/2022","PSG_022070.pdf"
"Tretinoin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017955.pdf","Draft","Topical","Gel","017955","10/21/2022","PSG_017955.pdf"
"Tretinoin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021108.pdf","Draft","Topical","Cream","021108","06/03/2020","PSG_021108.pdf"
"Tretinoin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020475.pdf","Draft","Topical","Gel","020475","05/16/2024","PSG_020475.pdf"
"Tretinoin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019963.pdf","Draft","Topical","Cream","019963","06/03/2020","PSG_019963.pdf"
"Tretinoin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019049.pdf","Draft","Topical","Cream","019049","06/03/2020","PSG_019049.pdf"
"Tretinoin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017522.pdf","Draft","Topical","Cream","017522","06/03/2020","PSG_017522.pdf"
"Tretinoin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017340.pdf","Draft","Topical","Cream","017340","06/03/2020","PSG_017340.pdf"
"Tretinoin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_016921.pdf","Draft","Topical","Solution","016921","09/16/2019","PSG_016921.pdf"
"Triamcinolone Acetonide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_012041.pdf","Draft","Injection","Injectable","012041                                                       014901","11/08/2021","PSG_012041.pdf"
"Triamcinolone Acetonide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020468.pdf","Draft","Nasal","Spray, Metered","020468","08/21/2023","PSG_020468.pdf"
"Triamcinolone Acetonide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Triamcinolone acetonide_dental paste_NDA 012097_RV11-17.pdf","Draft","Dental","Paste","012097","02/08/2018","Triamcinolone acetonide_dental paste_NDA 012097_RV11-17.pdf"
"Triamcinolone Acetonide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208845.pdf","Draft","Intra-Articular","For Suspension, Extended Release","208845","11/17/2022","PSG_208845.pdf"
"Triamcinolone Acetonide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211950.pdf","Draft","Injection","Suspension","211950","02/16/2023","PSG_211950.pdf"
"Triamcinolone acetonide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Triamcinolone acetonide_intravitreal injectable_NDA 022048_RC07-18.pdf","Draft","Intravitreal","Injectable","022048","07/20/2018","Triamcinolone acetonide_intravitreal injectable_NDA 022048_RC07-18.pdf"
"Triamcinolone Acetonide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_011602.pdf","Draft","Topical","Lotion","011602","10/21/2022","PSG_011602.pdf"
"Triamcinolone Acetonide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_011600.pdf","Draft","Topical","Ointment","087385","10/21/2022","PSG_011600.pdf"
"Triamcinolone Acetonide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_011601.pdf","Draft","Topical","Cream","011601","10/21/2022","PSG_011601.pdf"
"Triamcinolone Acetonide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_011600-Oin-0.05P.pdf","Draft","Topical","Ointment  0.05%","089595","10/21/2022","PSG_011600-Oin-0.05P.pdf"
"Triamterene","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_013174.pdf","Draft","Oral","Capsule","013174","10/30/2024","PSG_013174.pdf"
"Triazolam","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017892.pdf","Draft","Oral","Tablet","017892","10/30/2024","PSG_017892.pdf"
"Triclabendazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208711.pdf","Draft","Oral","Tablet","208711","10/30/2024","PSG_208711.pdf"
"Trientine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Trientine_HCl_caps_019194_RC06-13.pdf","Draft","Oral","Capsule","019194","06/19/2013","Trientine_HCl_caps_019194_RC06-13.pdf"
"Trifarotene","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211527.pdf","Draft","Topical","Cream","211527","05/19/2021","PSG_211527.pdf"
"Triheptanoin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213687.pdf","Draft","Oral","Liquid","213687","05/19/2022","PSG_213687.pdf"
"Trilaciclib Dihydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214200.pdf","Draft","Intravenous","Powder","214200","11/17/2022","PSG_214200.pdf"
"Trimethoprim","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018679.pdf","Draft","Oral","Tablet","018679","10/30/2024","PSG_018679.pdf"
"Trimipramine Maleate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_016792.pdf","Draft","Oral","Capsule","016792","10/30/2024","PSG_016792.pdf"
"Triptorelin Pamoate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Triptorelin pamoate_IMinj_20715_21288_22437_RV02-14.pdf","Draft","Intramuscular","Injectable","020715                                                       021288                                                       022437                                                       208956","02/01/2014","Triptorelin pamoate_IMinj_20715_21288_22437_RV02-14.pdf"
"Trofinetide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_217026.pdf","Draft","Oral","Solution","217026","08/22/2024","PSG_217026.pdf"
"Trospium Chloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022103.pdf","Draft","Oral","Capsule, Extended Release","022103","08/22/2024","PSG_022103.pdf"
"Trospium Chloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Trospium chloride_oral tablet_RLD (21595) and 91575_RV03-17.pdf","Draft","Oral","Tablet","021595","05/16/2017","Trospium chloride_oral tablet_RLD (21595) and 91575_RV03-17.pdf"
"Tucatinib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213411.pdf","Draft","Oral","Tablet","213411","11/08/2021","PSG_213411.pdf"
"Ubrogepant","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211765.pdf","Draft","Oral","Tablet","211765","10/30/2024","PSG_211765.pdf"
"Ulipristal Acetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022474.pdf","Draft","Oral","Tablet","022474","10/30/2024","PSG_022474.pdf"
"Umeclidinium Bromide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_205382.pdf","Draft","Inhalation","Powder","205382","02/15/2024","PSG_205382.pdf"
"Umeclidinium Bromide; Vilanterol Trifenatate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_203975.pdf","Draft","Inhalation","Powder","203975","02/15/2024","PSG_203975.pdf"
"Upadacitinib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211675.pdf","Draft","Oral","Tablet, Extended Release","211675","08/02/2022","PSG_211675.pdf"
"Uridine Triacetate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208159.pdf","Draft","Oral","Granule","208159                                                       208169","10/30/2024","PSG_208159.pdf"
"Ursodiol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019594.pdf","Draft","Oral","Capsule","019594","10/30/2024","PSG_019594.pdf"
"Ursodiol","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020675.pdf","Draft","Oral","Tablet","020675","10/30/2024","PSG_020675.pdf"
"Valacyclovir Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020487.pdf","Draft","Oral","Tablet","20487","10/30/2024","PSG_020487.pdf"
"Valbenazine Tosylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209241.pdf","Draft","Oral","Capsule","209241","10/30/2024","PSG_209241.pdf"
"Valganciclovir Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021304.pdf","Draft","Oral","Tablet","21304","10/30/2024","PSG_021304.pdf"
"Valproic Acid","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Valproic acid_oral capsule_RLD 018081_Final 08-17.pdf","Final","Oral","Capsule","18081","08/04/2017","Valproic acid_oral capsule_RLD 018081_Final 08-17.pdf"
"Valsartan","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021283.pdf","Draft","Oral","Tablet","21283","10/30/2024","PSG_021283.pdf"
"Vancomycin Hydrochloride:","https://www.accessdata.fda.gov/drugsatfda_docs/psg/8510dft2_Yu_Dec152008.pdf:","Draft","Oral","Capsule","50606","12/20/2008","8510dft2_Yu_Dec152008.pdf:"
"Vancomycin Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208910.pdf","Draft","Oral","For Solution","208910","11/18/2020","PSG_208910.pdf"
"Vandetanib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022405.pdf","Draft","Oral","Tablet","22405","10/30/2024","PSG_022405.pdf"
"Vardenafil Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_200179.pdf","Draft","Oral","Tablet, Orally Disintegrating","200179","10/30/2024","PSG_200179.pdf"
"Vardenafil Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021400.pdf","Draft","Oral","Tablet","21400","10/30/2024","PSG_021400.pdf"
"Varenicline Tartrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021928.pdf","Draft","Oral","Tablet","21928","10/30/2024","PSG_021928.pdf"
"Varenicline Tartrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213978.pdf","Draft","Nasal","Spray","213978","11/17/2022","PSG_213978.pdf"
"Vasopressin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_204485.pdf","Draft","Intravenous","Solution","204485","02/17/2022","PSG_204485.pdf"
"Vemurafenib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Vemurafenib_oral tablet_RLD 202429_RC06-15.pdf","Draft","Oral","Tablet","202429","06/24/2015","Vemurafenib_oral tablet_RLD 202429_RC06-15.pdf"
"Venetoclax","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Venetoclax_oral tablet_RLD 208573_RC03-17.pdf","Draft","Oral","Tablet","208573","05/16/2017","Venetoclax_oral tablet_RLD 208573_RC03-17.pdf"
"Venlafaxine Besylate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215429.pdf","Draft","Oral","Tablet, Extended Release","215429","02/16/2023","PSG_215429.pdf"
"Venlafaxine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Venlafaxine HCl_oral tablet_RLD (20151) and 76690_RV12-16.pdf","Draft","Oral","Tablet","20151","12/22/2016","Venlafaxine HCl_oral tablet_RLD (20151) and 76690_RV12-16.pdf"
"Venlafaxine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022104.pdf","Draft","Oral","Tablet, Extended Release","22104","08/22/2024","PSG_022104.pdf"
"Venlafaxine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Venlafaxine_HCl_ERcap_20699_RC2-06.pdf","Draft","Oral","Capsule, Extended Release","20699","12/20/2008","Venlafaxine_HCl_ERcap_20699_RC2-06.pdf"
"Verapamil Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Verapamil_HCl_ERtab_19152_RC07-10.pdf","Draft","Oral","Tablet, Extended Release","19152","07/28/2010","Verapamil_HCl_ERtab_19152_RC07-10.pdf"
"Verapamil Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Verapamil_HCl_ERtab_20552_RC07-10.pdf","Draft","Oral","Tablet, Extended Release","20552","07/28/2010","Verapamil_HCl_ERtab_20552_RC07-10.pdf"
"Verapamil Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Verapamil_HCl_ERcap_19614_RC12-06.pdf","Final","Oral","Capsule, Extended Release","19614","05/12/2008","Verapamil_HCl_ERcap_19614_RC12-06.pdf"
"Verapamil Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Verapamil_HCl_ERcap_20943_RC12-06.pdf","Final","Oral","Capsule, Extended Release","20943","05/12/2008","Verapamil_HCl_ERcap_20943_RC12-06.pdf"
"Verapamil Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Verapamil HCl_oral tablet_ RLD 18817_Final 08-17.pdf","Final","Oral","Tablet","18817","08/04/2017","Verapamil HCl_oral tablet_ RLD 18817_Final 08-17.pdf"
"Vericiguat","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214377.pdf","Draft","Oral","Tablet","214377","10/30/2024","PSG_214377.pdf"
"Verteporfin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021119.pdf","Draft","Injection","Injectable","21119","08/22/2024","PSG_021119.pdf"
"Vibegron","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213006.pdf","Draft","Oral","Tablet","213006","10/30/2024","PSG_213006.pdf"
"Vigabatrin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Vigabatrin_tablet_20427_RC03-15.pdf","Draft","Oral","Tablet","20427","03/06/2015","Vigabatrin_tablet_20427_RC03-15.pdf"
"Vilazodone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022567.pdf","Draft","Oral","Tablet","22567","10/30/2024","PSG_022567.pdf"
"Viloxazine Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211964.pdf","Draft","Oral","Capsule, Extended Release","211964","02/17/2022","PSG_211964.pdf"
"Viltolarsen","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212154.pdf","Draft","Intravenous","Solution","212154","02/16/2023","PSG_212154.pdf"
"Vismodegib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_203388.pdf","Draft","Oral","Capsule","203388","10/30/2024","PSG_203388.pdf"
"Voclosporin","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213716.pdf","Draft","Oral","Capsule","213716","11/17/2022","PSG_213716.pdf"
"Vorapaxar Sulfate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_204886.pdf","Draft","Oral","Tablet","204886","10/30/2024","PSG_204886.pdf"
"Voriconazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Voriconazole_tab_21266_RC4-09.pdf","Final","Oral","Tablet","21266","10/28/2011","Voriconazole_tab_21266_RC4-09.pdf"
"Voriconazole","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Voriconazole_susp_21630_RC8-06.pdf","Final","Oral","Suspension","21630","05/12/2008","Voriconazole_susp_21630_RC8-06.pdf"
"Vorinostat","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Vorinostat_cap_21991_RC8-08.pdf","Draft","Oral","Capsule","21991","08/01/2008","Vorinostat_cap_21991_RC8-08.pdf"
"Vortioxetine Hydrobromide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_204447.pdf","Draft","Oral","Tablet","204447","10/30/2024","PSG_204447.pdf"
"Vosoritide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214938.pdf","Draft","Subcutaneous","Powder","214938","02/16/2023","PSG_214938.pdf"
"Voxelotor","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_216157.pdf","Draft","Oral","Tablet, For Suspension","216157","10/30/2024","PSG_216157.pdf"
"Voxelotor","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213137.pdf","Draft","Oral","Tablet","213137","10/30/2024","PSG_213137.pdf"
"Vutrisiran Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215515.pdf","Draft","Subcutaneous","Solution","215515","08/21/2023","PSG_215515.pdf"
"Warfarin Sodium","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Warfarin_Sodium_tab_09218_RC12-12.pdf","Draft","Oral","Tablet","9218","12/14/2012","Warfarin_Sodium_tab_09218_RC12-12.pdf"
"Xenon Xe-129 Hyperpolarized","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214375.pdf","Draft","Inhalation","Gas","214375","02/15/2024","PSG_214375.pdf"
"Zafirlukast","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Zafirlukast_tab_20547_RC2-08.pdf","Draft","Oral","Tablet","20547","04/06/2008","Zafirlukast_tab_20547_RC2-08.pdf"
"Zalcitabine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020199.pdf","Draft","Oral","Tablet","20199","10/30/2024","PSG_020199.pdf"
"Zaleplon","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020859.pdf","Draft","Oral","Capsule","20859","10/30/2024","PSG_020859.pdf"
"Zanamivir","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021036.pdf","Draft","Inhalation","Powder","21036","02/15/2024","PSG_021036.pdf"
"Zanubrutinib","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213217.pdf","Draft","Oral","Capsule","213217","05/19/2021","PSG_213217.pdf"
"Zavegepant Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_216386.pdf","Draft","Nasal","Spray, Metered","216386","05/16/2024","PSG_216386.pdf"
"Zidovudine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019655.pdf","Draft","Oral","Capsule","19655","10/30/2024","PSG_019655.pdf"
"Zidovudine","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020518.pdf","Draft","Oral","Tablet","20518","10/30/2024","PSG_020518.pdf"
"Zileuton","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Zileuton_tab_22052_RC7-08.pdf","Draft","Oral","Tablet, Extended Release","22052","07/01/2008","Zileuton_tab_22052_RC7-08.pdf"
"Zileuton","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020471.pdf","Draft","Oral","Tablet","20471","10/30/2024","PSG_020471.pdf"
"Ziprasidone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021483.pdf","Draft","Oral","Suspension","21483","10/30/2024","PSG_021483.pdf"
"Ziprasidone Hydrochloride","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020825.pdf","Draft","Oral","Capsule","20825","10/30/2024","PSG_020825.pdf"
"Zolmitriptan","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020768.pdf","Draft","Oral","Tablet","20768","10/30/2024","PSG_020768.pdf"
"Zolmitriptan","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Zolmitriptan_Nasal spray_NDA 021450_RV Oct 2018.pdf","Draft","Nasal","Spray","21450","11/28/2018","Zolmitriptan_Nasal spray_NDA 021450_RV Oct 2018.pdf"
"Zolmitriptan","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021231.pdf","Draft","Oral","Tablet, Orally Disintegrating","21231","10/30/2024","PSG_021231.pdf"
"Zolpidem Tartrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Zolpidem_subtabs_21997_RC09-10.pdf","Draft","Sublingual","Tablet","21997","09/30/2010","Zolpidem_subtabs_21997_RC09-10.pdf"
"Zolpidem Tartrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Zolpidem_ERtab_21774_RC8-09.pdf","Final","Oral","Tablet, Extended Release","21774","10/28/2011","Zolpidem_ERtab_21774_RC8-09.pdf"
"Zolpidem Tartrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Zolpidem_Oral_Spray_022196_RC04-13.pdf","Draft","Oral","Spray, Metered","22196","04/05/2013","Zolpidem_Oral_Spray_022196_RC04-13.pdf"
"Zolpidem Tartrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/Zolpidem_SLtabs_22328_RC06-12.pdf","Draft","Sublingual","Tablet","22328","06/14/2012","Zolpidem_SLtabs_22328_RC06-12.pdf"
"Zolpidem Tartrate","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019908.pdf","Draft","Oral","Tablet","19908","10/30/2024","PSG_019908.pdf"
"Zonisamide","https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020789.pdf","Draft","Oral","Capsule","20789","10/30/2024","PSG_020789.pdf"
